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Abstract 
It has become increasingly apparent that mechanical force plays an important 
role in biology. Biophysical techniques such as optical tweezers and atomic 
force microscopy (AFM) have allowed the investigation of mechanical stability 
at the level of a single protein molecule.  However, despite the increasing 
sensitivity of these techniques, it is still difficult to mimic precisely the geometry 
of extension, forces and loading rates applied in vivo.  
Here we have developed a technique using a bacterial proteasome, ClpXP, 
which allowed the investigation of the mechanical stability of proteins at more 
biologically relevant forces and loading rates. It was demonstrated that various 
degradation signals can be used to target the proteins under investigation to 
ClpXP where they were unfolded, translocated and degraded. Several ClpX 
variants were investigated and an assay developed using  a pseudohexameric 
ClpX variant that allowed robust degradation of several proteins.  
This assay was used to investigate the properties of a protein containing a 30 
polyglutamine repeat sequence. Previous studies of polyglutamine repeats,  
using AFM,  have shown that it may have interesting mechanical properties: it 
has either extreme mechanical strength, or access to a conformation which 
has a high mechanical strength.  
It was shown that this protein can be completely degraded using ClpXP 
without any intermediate product, and without reducing the degradation rate 
compared to a control protein without a polyglutamine repeat. This 
demonstrates that this assay can be used to investigate proteins whose 
mechanical properties are of interest and that the loading rates and application 
v 
of force applied by this assay differ enough from those of AFM that different 
and more biologically relevant results can be obtained.   
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1 Introduction 
 Forces in biology 
We are beginning to understand that mechanical forces play an important role 
in biological function. For example, it is becoming apparent that in addition to 
chemical processes such as phosphorylation1 and calcium-sensing2 cellular 
events that are controlled by or produce mechanical force are also important. 
These occur on a wide range of scales, they can vary from subnanometer 
movements in the ear which we can sense and which allow us to hear3,  
interactions such as the hydrolysis of ATP, which in ClpX produces a 
mechanical force with a step-size of 1nm 4, or ATP hydrolysis in skeletal 
muscle which leads to a force being applied with a stroke size of approximately 
10nm 5 up to the whole organism level where many such events can combine 
to produce large macroscopic mechanical forces that can be applied for 
movement or the alteration of the organism’s environment on a scale of 
metres6. Until recently it has been difficult or even impossible to study these 
forces on a microscopic scale and to understand how they are generated or 
sensed. However, since the first mechanical protein unfolding experiments 
were carried out in 1997 techniques have been refined and new techniques 
developed to allow us to study these events down to the single molecule level7.  
Force is known to make a vital contribution to processes such as cell motility8–
10, DNA replication11 and protein unfolding12. In some forms of cell motility, 
blebs are formed in the cell membrane by the contraction of cortical acto-
myosin, which detaches the membrane from the underlying cytoskeleton. This 
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bleb is expanded by the flow of cytoplasm into it and a mesh of actin and 
myosin II assembles in the bleb forming a contractile cortex attached to the 
cell membrane. This mesh then contracts forcing the cytosol back into the 
body of the cell and causing the cell to move13.  DNA helicases are essential 
enzymes; they are molecular motors which hydrolyse nucleotide triphosphates 
in order to generate forces which they use to move along a DNA track. They 
are capable of generating enough force to not only move themselves but also 
to unwind the DNA while managing interactions between the DNA and other 
proteins such as transcription factors, histones and other repair and replication 
machinery14. Protein unfolding (which is the main focus of this thesis) is 
achieved by mechanical motor proteins of the AAA+ superfamily, one of which 
is ClpX which I will talk about in detail later in this chapter. In addition to these 
“obvious” uses of forces there are many other events in cells which require the 
use of mechanical force to unfold a protein, such as the translocation of 
proteins across membranes that is necessary during import into 
mitochondria15 of proteins synthesised in the cytosol16.  
The relevance and importance of force in nature has been suspected for some 
time, but as we have only recently been able to measure the levels of force 
that can act at the level of a cell or even a single protein it has been difficult or 
even impossible to study. Using biophysical techniques such as atomic force 
microscopy (AFM) and optical tweezers (OT) it is possible to apply and 
measure forces that are applied to a single protein molecule17 in vitro. 
Previous studies using these methods have shown interesting and counter-
intuitive results such as the observation that protein complexes with very high 
affinity interactions, such as avidin/biotin18 and colicin/immunity protein19, are 
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easily dissociated by low levels (<18 pN) of mechanical force. Other 
complexes such as that between bacterial adhesins and mannose, (which 
decorates the cells of the urinary tract for example20) to which they bind have 
evolved a more complex reaction to force, whereby they operate as “catch 
bonds” which, under force, undergo an allosteric rearrangement into a 
conformation with higher affinity binding which allows them to remain attached 
under the forces they are exposed to21,22. 
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  Dynamic force spectroscopy 
A small protein is able to fold reversibly because its final state is a 
thermodynamically stable state which has a lower free energy than other 
possible states23. As the number of amino acids in a polypeptide increases the 
number of possible conformations increases, soon reaching the point that the 
length of time required to randomly sample them all would be longer than the 
lifetime of the protein, the organism or even the universe itself. It is therefore 
apparent that proteins do not fold by randomly sampling all of the 
conformations available to them and have evolved to fold quickly into their 
native state. In its simplest form this means that we can imagine a system in 
which there is an unfolded polypeptide (U) which can move through some sort 
of transition state (TS) to reach it’s folded state (F) where it will remain until 
conditions are changed in such a way that the energy barrier keeping it in its 
folded state is lowered sufficiently that the folded peptide can overcome it and 
become unfolded as illustrated in Figure 1.1. However, proteins are not static 
entities and the protein will transiently visit the unfolded state due to thermal 
fluctuations.  
It is usual to study protein unfolding by the application of denaturants, which 
disrupt the protein-protein, protein-solvent and solvent-solvent  interactions 
reducing the energy required to reach the transition state and unfold, or by 
increasing the temperature, which destabilises the folded state by reducing 
the entropic cost of unfolding. The application of a stretching mechanical force 
can be thought of as tilting the energy landscape lowering the energy of the 
transition state and making the unfolded state more energetically favourable, 
this is in contrast to an enzyme-catalysed reaction which would lower the 
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energy of the transition state without affecting the energy levels of the folded 
or unfolded states.  
Importantly the ability to resist force-induced unfolding is governed by the 
protein’s structure local to the points of application. The mechanical behaviour 
of a protein is thus distinct to the thermodynamic or kinetic properties 
measured when unfolded by global denaturants24. 
Several manipulation techniques exist which can give information on forces in 
biochemical systems such as protein unfolding, DNA elasticity, protein-protein 
interactions and molecular motors. These techniques can be used to either 
apply forces to these systems in order to investigate their properties, or to 
directly measure the forces applied by these systems26. Of the major 
techniques for force spectroscopy each has its optimal length and force 
scales. Optical tweezers (OT) and magnetic tweezers (MT) use a technique 
of tethering a molecule between two beads and applying forces to the beads 
in order to manipulate the molecule. OT use radiation pressure from a laser to 
manipulate the sample, it has excellent force resolution and time resolution, 
but the forces applied are relatively low (<300 pN). MT use magnetic fields to 
manipulate the sample, it can apply forces between 10-100 pN27, the spatial 
resolution is excellent and can detect the unwinding of as little as 3 base pairs 
(~15nm) however a compromise must be reached between spatial and 
temporal resolution28. However, as in each assay only a single molecule is 
addressed, the experimental throughput is low, though this is improving. 
Particularly useful with MT is the ability to apply torque, or twisting forces,  as 
well as linear forces27. While MT have the potential to be a powerful technique 
with applications in a variety of biophysical systems, they have been most 
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used for the study of nucleic acids and enzymes associated with them as they 
are particularly suited for this application.  Atomic force microscopy (AFM) can 
apply a large range of forces (10-10,000pN) over large distances 
(1-10,000nm) but has a lower force resolution due to the thermal noise 
generated by the large cantilever (≈10pN) 29. AFM was chosen as the 
technique to be used for this work as it is the most suitable for the system 
under investigation since it is capable of measuring forces in the same range 
as ClpX generates, around 20 pN 4,30, it has been used extensively for the 
study of proteins17,24,31, and would allow direct comparisons with previous work 
on polyglutamine repeats32,33.  
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Figure 1.1: The effect of mechanical force on the free energy landscape of a polypeptide. The free energy landscape shows a simple two state model of polypeptide folding. Black line: the normal situation in which the polypeptide is “trapped” in its native folded state. Blue line: the situation after a mechanical force is applied which has tilted the energy landscape making the unfolded state more energetically favourable (U*) and reducing the free energy required to reach this unfolded state (ΔG*TS*-F) and increasing the unfolding rate kU. Taken from Hoffman et al30. 
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 Atomic force microscopy 
AFM uses a flexible cantilever onto the tip of which a laser can be focused. 
The laser is reflected by the tip, onto a photoelectric sensor. If the laser is 
spatially fixed, a small movement in the tip will cause an amplified movement 
in the reflected laser on the sensor (sometimes called an optical lever effect). 
This movement of the laser spot can be used to quantify the amount of 
movement at the tip. If the spring constant (measured in N/m) is known, the 
force applied at the tip can be calculated. When a force is applied to the tip its 
deflection is recorded by the sensor as described in Figure 1.2. 
Experiments investigating the mechanical unfolding of proteins use 
multi-domain protein constructs, also known as a polyproteins, in order to be 
able to detect the events of interest and to separate these from noise in the 
system due to non-specific protein-tip and tip-substrate interactions. These 
polyproteins are proteins in which a single domain with a well characterised 
force response is repeated several times with a short linker sequence inserted 
between the repeated. Polyproteins do exist in nature but these contain a 
heterogeneous mixture of similar, but not identical, domains. As each domain 
in the polyprotein needs to be identical to provide a clearly identifiable force 
profile in AFM experiments it is necessary to produce bespoke polyproteins 
by protein engineering24. There are two approaches we can take when 
designing the polyprotein, we can construct a homopolymer of the domain we 
are interested in so that each event we observe will relate to that domain, or 
we can use one or more copies of our domain of interest inserted at alternating 
positions in a larger polyprotein made up of a domains which has already been 
well-characterised by AFM and so are easily separated from the events 
9 
relating to the domain of interest24. The approach taken will depend on several 
factors that include, ease of protein expression and the type of data to be 
acquired. Several proteins have been used for AFM experiments, probably the 
most used is the I27 domain from the I-band of the muscle protein Titin 
(Human cardiac titin I band module 27). It is an immunoglobulin like domain 
(Figure 1.3). It is ideal for force experiments due to its known structure and 
high stability to chemical, thermal and force denaturation34. 
Force mode AFM uses a sample immobilised onto a surface. The AFM tip is 
lowered towards the surface and when the cantilever contacts the surface it is 
deflected. When this deflection reaches a certain threshold the AFM tip is 
retracted away from the surface. If a molecule has attached to the tip it will 
begin to exert a force on the cantilever as it resists extension. As the tip 
continues to be retracted, the forces acting on the tip will change allowing a 
force profile of the event to be generated26. 
For protein mechanical unfolding experiments a gold surface is usually used 
to which a solution containing the protein of interest containing a single or two 
consecutive cysteines at one end of the protein can be attached by a strong 
covalent Au-S bond to the surface. Protein-tip attachment can vary dependent 
on the system being investigated, it is possible to tether a protein using 
functionalization of the tip35, or by the non-specific interactions the silicon-
nitride tip makes with the protein (as long as the interaction is stronger than 
the unfolding force to be measured). The concentration of the protein is varied 
to find a balance between an acceptable number of interactions and the 
number of interactions involving a single molecule36. 
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Constant velocity experiments can be carried out, where the retraction of the 
tip occurs at a constant rate and the forces applied to the cantilever vary. This 
is the most common form of AFM mechanical unfolding due to its ease of use. 
It produces a saw-tooth force profile showing the unfolding of the multiple 
domains. From this profile it is possible to directly extract the forces at which 
unfolding events occur (Figure 1.4), and by fitting the length of polypeptide 
chain released upon unfolding to a worm like chain (WLC) model of polymer 
elasticity (Equation 1.1). The WLC model is a polymer physics model to 
explain the behaviour of semi-flexible polymers. In contrast to a freely-jointed 
chain model which models inflexible regions connected by joints which have 
free rotation, a WLC model describes a continuously flexible isotropic rod. This 
has been shown experimentally to be a better model for biological polymers 
at the levels of force we will be using to investigate them (>10pN)37,38. 
The WLC relates the contour length, (the theoretical length at maximum 
extension of an unfolded domain) to the entropic resting force generated: 
F =  ݇஻ × Tܮ௣ × ൤(0.25 × (1 −
x
ܮ௖))ିଶ − 0.25 + (
x
ܮ௖)൨ 
Equation 1.1: WLC model. Where F is force, T is the temperature, kB is the Boltzman constant, Lc is the contour length, Lp is the persistance length (which quantifies the stiffness of the polymer) and x is the measured extension37.   
Fitting WLCs to the successive unfolding events thus allows the difference in 
length between folded and unfolded states (ΔLc) to be calculated. These 
results for unfolding distance and length are taken from many unfolding events 
and histograms generated which, by means of a Gaussian fit to the data, can 
be used to obtain the most probable value for ΔLc and for unfolding force. The 
expected ΔLc is easy to calculate if we know the number of amino acids in the 
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folded polypeptide and the structure is known.  This value is compared to the 
measured value to satisfy ourselves that the events we are recording are the 
unfolding of the domains themselves and not spurious tip-protein artefacts. 
The more interesting value we can extract is the peak unfolding force (FUN), 
which gives us a measure of the mechanical stability of the domain in question.  
Constant force or force-clamp experiments can also be carried out. In this case 
a feedback system is employed to keep the force applied to the cantilever at 
a constant level. The protein unfolds when random thermal fluctuations allow 
the protein to traverse the barrier to unfolding (G*TS*-F, Figure 1.1). This 
reduces the force applied to the cantilever, and the piezo controller moves the 
tip away from the surface (shown as extension in Figure 1.5) until the force is 
restored, whereupon after a certain time thermal fluctuations will cause 
another domain to unfold. In this case, instead of the saw-tooth pattern seen 
in constant velocity experiments, a step pattern is seen by plotting extension 
against time (Figure 1.5). LS is the increase in contour length at the applied 
force upon the unfolding of a single domain, which is distinct for each domain 
and the time taken for each unfolding event is recorded. If such traces are 
overlaid, a rate constant can be obtained by fitting directly to the data.    
In terms of experimental design both constant force and constant velocity 
experiments are very similar. Both require the use of a polyprotein in order to 
both increase the number of events analysed and to ensure that each event 
is part of a single molecule interaction, both require the selection of a protein 
concentration that gives a balance between the rate of data acquisition and 
the likelihood that each event is a single molecule event and both are generally 
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done in a simple buffer with a pH and ionic strength close to “physiological” 
values such as phosphate-buffered saline39.  
In terms of the data obtained from each type of experiment, constant force 
experiments directly measure the extension of the protein over time. Many 
repetitions of this data collection are repeated and this allows the direct 
measurement of unfolding rate. Performing the experiment at various forces 
enables the calculation of ku(0F) and xu by fitting to Equation 1.2. 
݇௨(ி) = ݇௨(଴ி)݁ி௫ೠ௞ಳ் 
Equation 1.2: Where ku(F) is the observed unfolding rate, ku(0F) is the unfolding rate at zero applied force, F is the applied force, xu is the distance between the native well and the unfolding transition state, kB is Boltzmann’s constant and T is the temperature39.  
Constant velocity experiments allow direct measurement of unfolding force, 
they also allow direct measurement of the distance from the surface at which 
unfolding occurs but this is less useful than the contour length which is 
obtained by fitting to the raw data using Equation 1.1. Taking multiple 
measurements at various loading rates and plotting the most likely unfolding 
force against the logarithm of the loading rate then allows the calculation of 
ku(0F) and xu39.  
Data must be chosen carefully for analysis as not every event produces a 
perfect force profile. Sometimes more than one protein can become attached, 
resulting in a profile with more peaks than expected or unusual peaks resulting 
from tip-surface interactions or failure of a protein to cleanly detach from the 
tip. Ideally only “perfect” traces would be analysed, in reality few such traces 
exist and some analysis must be undertaken on shorter, less ideal traces to 
facilitate the acquisition of a statistically relevant data set in the available time. 
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It is important to choose the analysed traces in a consistent manner in order 
to minimize systematic bias36.  
There are several parameters we can obtain from mechanical unfolding 
experiments. As well as a simple measurement of unfolding force. It is possible 
to probe the energy barriers of unfolding. Plotting unfolding force against the 
log of loading rate allows us to calculate xu, the distance between the unfolding 
barrier and the native energy well and ku(0F), the unfolding rate constant in the 
absence of applied force, which is related to the height of the unfolding barrier. 
xu and ku(0F) remain the same while the same unfolding transition is being 
probed, but if mechanical unfolding covers a sufficiently wide range of forces, 
then deviations from these parameters can be detected giving us insight into 
“hidden” unfolding transition states40. 
These hidden transition states are not visible by other techniques such as 
chemical denaturation. They can be identified by examining a plot of unfolding 
force against the logarithm of loading rate. If a single barrier to unfolding is 
traversed then the plot produces a straight line. However, when one of these 
hidden transition states is present then more than one force regime (i.e. lines 
with different gradients) will be evident in the data. This is because upon the 
application of force, the “tilting” of the energy landscape results in  a previously 
hidden barrier (close to the native well) becoming the new rate-limiting step41. 
One example of this is the dissociation under force of the colicin E9:Im9 
complex which is understood to take place under the same theoretical 
framework. Figure 1.6 shows that there are two different force regimes in the 
data. At low, biologically accessible, loading rates the unbinding force is low, 
and has a small dependence on the loading rate. At higher loading rates the 
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unbinding forces are higher and have a stronger dependence on the loading 
rate. This indicates that the dissociation follows a three state mechanism 
involving a previously unknown “hidden” transition state35.  
A similar result is found when using AFM to investigate streptavidin-biotin 
binding, the data shows a similar result where two force regimes are evident 
in the data. Analysis of the data and comparison to a molecular dynamics 
simulation identified the different force regimes observed were due to the 
presence of a previously hidden transition state that was only visible due to 
the tilting of the energy landscape41.   
Although force spectroscopy using AFM is a powerful technique for the study 
of protein unfolding it is not always a good model for the events which take 
place in a cell. It applies forces only with a fixed directionality, since the 
polyprotein is anchored to the surface at a set point (the exposed cysteine 
residues) and the force will be applied at the N and C-termini of the protein. 
Figure 1.7 illustrates the situation with a hypothetical three  β-stranded-protein. 
In Figure 1.7A the forces are applied to the termini of the protein, if the initial 
unfolding event is the separation of the blue and green strands it is necessary 
to rupture all of the interactions between the two strands simultaneously which 
may require a large amount of force and is not how the protein would be 
expected to be unfolded in the cell. Figure 1.7B shows a situation where the 
protein is being pulled by the C-terminus into a biological unfoldase; as the 
protein is pulled though the pore into the unfoldase the opposing forces can 
act more locally and the strands can be gradually peeled apart negating the 
need for a large force to separate the entire strand. In addition the forces 
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applied loading rates applied by AFM may not represent those applied in the 
cell.  
It seems that in order to obtain a more complete understanding of how real 
forces are applied in a real system we may have to consider using a 
complementary technique. While this method may not be able to provide data 
at the resolution that is possible with AFM, it would better represent the way 
forces are applied in vivo. We can do this through use of an enzymic system 
which applies force in the cell.   
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Figure 1.2: An illustration of the basic principle of atomic force microscopy. A laser is focussed onto the tip of the cantilever. Adjustments are made with the cantilever in an unloaded state so that the reflection of the laser is in the centre of a position-sensitive detector. Any deflection of the cantilever will cause the laser to move on the detector. Quantifying the distance moved allows the deflection of the cantilever to be calculated, if the spring constant of the cantilever is known this allows the force applied to the cantilever to be calculated. Adapted from Bustamante et al25.  
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Figure 1.3: Titin, immunoglobulin repeat 27, NMR, minimized average structure. (I27) From PDB structure 1TIT42  
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Figure 1.4: A force extension profile and diagram showing the interpretation of the profile for a constant velocity experiment. At point 1 the tip has adsorbed to the protein and is being withdrawn. As the tip is withdrawn the stretched protein exerts a force upon it until, at point 2, the force is sufficient to cause unfolding of one of the domains (F1) at point 2, at point 3 one domain of the protein has unfolded and the force acting on the cantilever is reduced, the process is then repeated as the protein is stretched until a second (point 4) and third unfolding event occurs (F2 and F3). The distance between points 2 and 4 gives the difference in length between the folded and unfolded states of the domain. At point 5 no domains remain to be unfolded and the force acting on the tip increases until the protein is pulled off the tip. Adapted from Bustamante et al.26 
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Figure 1.5: Plot of extension versus time for a polyprotein with 6 domains unfolded in a force-clamp experiment. From Dougan et al32.  
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Figure 1.6: A: The dynamic force spectrum (a plot of the unbinding force versus the natural logarithm of the loading rate) of E9:Im9. Error bars are based on the standard deviation of measurements from triplicate datasets taken at each retraction velocity. Forces below the detection limit of the instrument and filtering software (18 pN, dashed line) are coloured grey. B: Postulated mechanism (top) and energy landscape (bottom) for the (un)binding of E9 from immunity proteins. The encounter complex (E9:Im*) is formed followed by the bound complex (E9:Im). Application of force causes the energy landscape to tilt (by –Fx) and the previously rate limiting step for unbinding (peak III, blue trace) is replaced by the previously hidden peak II on the red trace. Taken from Farrance et al35. 
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Figure 1.7: An illustration of force applied to a protein . A: by AFM. B: by a biological unfoldase. Black arrows indicate the locations at which forces are applied. 
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 ClpXP 
ClpXP is a member of the ATPase Associated with cellular Activity (AAA+) 
superfamily. These proteins contain a P-loop NTPase domain and have 
diverse functions such as molecular chaperones, helicases and ATPase 
subunits of proteases43,44. The ClpXP protease is a prokaryotic molecular 
machine found in several bacteria which has a similar structure and function 
to the eukaryotic 26S proteasome, with an ATPase subunit (ClpX) guarding 
the entrance to the chambered protease (ClpP)45. Its function is protein quality 
control and the degradation of a diverse array of unwanted proteins, it is 
responsible for degrading incomplete proteins on stalled ribosomes, 
degradation of secreted proteins which have failed to be secreted and can 
even function to degrade foreign proteins such as those from invading 
viruses46,47.  
ClpX is active as a hexameric ring with each of the 6 subunits containing an 
ATP binding site adjacent to the next subunit. ClpXP is made up of two stacked 
rings of heptameric ClpP oligomers to which a hexameric ring of ClpX is 
attached at one or both ends as shown in Figure 1.8.  
ClpXP is a large complex; with the central ClpP protease and two ClpX rings, 
it is approximately 870kDa. ClpX is an unfoldase which recognizes a target 
protein by means of a peptide tag and unfolds it by means of pulling it through 
a small pore49. In the absence of ClpP, ClpX is able to remodel target proteins 
and their complexes, and to disaggregate and unfold aggregated proteins, 
allowing their refolding.  It is more commonly associated with the chambered 
protease ClpP which degrades the protein as it is fed into the proteolysis 
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chamber by ClpX and releases it as short peptide fragments50. The action of 
ClpXP is summarized below (Figure 1.9). 
It has been shown experimentally that ClpX is capable of translocating and 
degrading a large variety of substrates. For example, synthetic peptides with 
D-amino acids, altered peptide bond spacing, low complexity sequences 
consisting of polyglycine, polyproline sequences, sequences consisting of all 
positively or negatively charged residues, sequences with large aromatic side 
chains or up to 10 polyglutamine residues have been successfully 
translocated51. 
Unfolding and translocation by ClpX is powered by ATP hydrolysis, each 
power stroke is generated by the hydrolysis of a single ATP within one of the 
subunits, it is a robust system in that ATP hydrolysis does not proceed in a 
sequential manner and hydrolysis in any of the subunits in contact with the 
substrate peptide can drive translocation, preventing the stalling of the 
complex by any subunit being unable to hydrolyse ATP53. The hydrolysis of 
ATP causes a conformational change in the ClpX which is transmitted to the 
substrate as mechanical work by a tyrosine residue in the pore loop54. Once 
the ssrA tag and any unstructured regions have been translocated into the 
ClpXP pore any folded domains must be unfolded before further translocation 
can take place. Unfolding can be an energy intensive process. A previous 
study investigated the kinetics of ClpXP degradation of ssrA-tagged I27 and 
compared the amount of ATP used for unfolding to that required for 
translocation of the degraded substrate. Wild-type protein required up to 550 
molecules of ATP for unfolding, whereas the same protein containing a 
destabilising V13P mutation required only 18 55. As ClpX has no way to store 
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energy from one unfolding attempt to another, each cycle of ATP hydrolysis 
represents a new attempt to unfold the protein. As each ATP hydrolysis event 
produces the same amount of force to unfold the protein, each unfolding 
attempt has the same probability of causing unfolding. Despite this, more 
thermodynamically stable proteins can still be unfolded by repeated 
application of this same force, suggesting that some change must occur in the 
substrate to allow it to unfold. If each unfolding attempt caused some slight 
change in the substrate’s structure, perhaps some sort of partial unfolding, 
then the likelihood of unfolding with each ATP hydrolysis event would increase 
over time. As this is not the case, the most likely explanation is that the more 
stable substrate is unfolded only when an ATP hydrolysis event that lowers 
the barrier to unfolding coincides with a random thermal fluctuation that allows 
traversal of the lowered barrier50,55,56.  
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Figure 1.8: A diagrammatic representation of the ClpXP macromolecule showing the ClpP subunit in grey and the ClpX in brown. From Alexopoulos et al55. 
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Figure 1.9: Cartoon model of substrate recognition and degradation by a AAA+ protease. The recognition step is mediated by binding of a peptide tag on the protein substrate to the AAA+ ATPase. The protein is unfolded, translocated into the compartmental peptidase and degraded. Peptide fragments are shown diffusing out of the peptidase, but active participation of the ATPase may be required for exit of large fragments. This figure is taken from Nyquist and Martin 201456. 
 
 
27 
1.4.1 ClpX 
ClpX is a functional hexamer. It forms a ring structure in which each of its 
ATPase active sites is situated between two of the subunits. The central pore 
is lined with loops which, by conformational changes between the small and 
large domains of each monomer brought about by the hydrolysis of ATP, can 
apply a mechanical force to a peptide. The crystal  structure of ClpX was 
solved to 2.8 Å resolution in 2003 by Kim and Kim57 (Figure 1.10). 
The wild type ClpX monomer is made up of three domains (Figure 1.11). There 
is an N-terminal domain (NTD) which is not necessary for degradation of all 
substrates as it folds independently of the other domains and is attached by a 
flexible linker. Each pair of adjacent NTDs form a dimer stabilised by the 
coordination of a zinc ion58. These are unnecessary for the degradation of all 
substrates and are instead thought to be involved in the recognition of some 
substrates and adaptor proteins and to contribute to the stability of the 
hexameric ring59. Deletion of the NTD (ΔNClpX) still allows  hexamer 
formation, binding to ClpP and the degradation of certain substrates with near 
wild-type efficiency60.  
On formation of the hexamer each small subunit is adjacent to the large 
subunit of its neighbouring monomer. These interactions are stable and each 
small and large pair can be thought of as a single rigid body which is 
connected to its adjacent rigid body by a flexible hinge region which is also 
where the ATP binding and hydrolysis occurs61.  The ring conformation is 
determined by the angles between these rigid-body units and the 
conformational changes in the hinge region47. Because of the stability of the 
ring, the arrangement of subunits relative to their topology interact and ability 
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to delete the NTD it is possible to construct ClpX variants in which the six 
monomers making up the hexamers are joined by a peptide linker, as 
pseudodimers, pseudotrimers and pseudohexamers  to form a ring that is 
made up of three, two or a single covalently linked subunit47 (Figure 1.12).   
These constructs allow the structure and function of ClpX to be studied in new 
ways. The effects of mutations in a single subunit at a known position or 
several known positions can be studied without the uncertainty that mixing 
more than one variant of the monomer entails61. 
Previous crystal structures of ClpX have been obtained by determining the 
crystal structure of a single ClpX monomer and using the electron density 
obtained from cryo-EM to fit the monomers into a plausible hexameric 
structure57. More recently, the development of the covalently linked variants 
described above have been used to determine crystal structures of ClpX ring 
hexamers  which showed that each rigid-body unit could exist in one of two 
different conformations: a “loadable” subunit orientated in a manner that 
allowed ATP binding and an “unloadable” conformation where rotation of the 
domains had removed the nucleotide binding site62, resulting in an asymmetric 
structure in the ring as shown in Figure 1.10.  
While it is still not known whether ClpX normally hydrolyses ATP in a 
sequential or a stochastic manner in relation to the level of co-ordination 
between the individual subunits of the hexamer during ATP hydrolysis, it is 
known that subunits have to be able to convert between the loadable and 
unloadable conformations for robust activity and that binding of ATP to one of 
the subunits causes allosteric changes in the ring that make binding of further 
ATP more favourable61. 
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The pseudohexamer (ΔNClpX6) is also useful because it makes the process of 
using ClpX as a tool to study the mechanical unfolding of other proteins a 
simpler proposition, both because it can be tethered at a single anchor point 
for experiments using AFM or optical tweezers30, and because it eliminates 
some of the issues that can arise when using wild type ClpX for in vitro 
experiments as shown in Chapter 3.  
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Figure 1.10: ClpX hexamer structures (3HWS). A: Face view (substrate side) showing loadable (L) and unloadable (U) subunits. B: Side View coloured by subunit. C: Face view (substrate side) coloured by rigid-body unit. D: Side view coloured by rigid-body unit. Adapted from Baker and Sauer47 The atomic-resolution structure is for a pseudo-hexamer. 
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Figure 1.11: The domain structure of E.coli ClpX. A: Arrangement of the domains showing the functional motifs. B: Structure of the NTD dimer (1OVX) showing zinc ions (orange spheres). C: Structure of a single ClpX subunit, taken from a hexameric structure (3HWS) showing the nucleotide binding site.  Colours represent: blue - ssrA tag binding region. Orange: ATP binding and hydrolysis. Purple: ClpP binding. Taken from Baker and Sauer47. 
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Figure 1.12: A schematic demonstrating A: pseudo-dimer. B: pseudo-trimer. C: pseudo-hexamer. 
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1.4.2 Substrate targeting 
ClpX can be considered a promiscuous enzyme as it has the ability to unfold 
and translocate a wide range of substrates as long as they have a short, 
unstructured, peptide sequence known as a degradation tag to which the ClpX 
can bind. This reflects its main function, protein quality control. The best 
studied of the degradation tags is the ssrA tag which is responsible for the 
targeting of polypeptides from stalled ribosomes to ClpX where they can be 
unfolded and translocated into ClpP for degradation releasing both the 
ribosome and the amino acids for re-use by the cell. As shown in Figure 1.13, 
SsrA is an RNA molecule which functions as both a transfer and messenger 
RNA. In this molecule, the tRNA-like domain is charged with an alanine which 
is added to the end of the peptide in the stalled ribosome by transpeptidation. 
The mRNA in the stalled ribosome is then released and a short open reading 
frame encoded by the SsrA is used to add a decapeptide degradation 
sequence (ANDENYALAA), known as an ssrA tag which targets the peptide 
for degradation by ClpXP63. Studies have shown that it is the final three amino 
acids (LAA) of the peptide and the negatively charged C-terminus that is 
important for recognition and binding to ClpX and that the other residues are 
involved in interaction with the SspB adaptor protein55,64.  
In addition to the degradation of truncated peptides from stalled ribosomes, 
ClpXP carries out several other functions including the regulation of cell stress 
proteins, such as RecN synthesised in response to DNA damage. Under this 
condition RecN is expressed at a sufficient level to allow an increase in its 
intracellular level despite them being targeted for constitutive degradation by 
ClpXP66. This means that they can carry out their functions while the stress is 
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on-going but are rapidly degraded once their synthesis is stopped. 
Degradation tags have also been discovered in large macromolecular 
complexes, such as ribosomes,  which are buried within the structure when 
the complex is properly assembled but exposed if the complex is misfolded or 
damaged64. 
In addition to ssrA-tagged proteins, at least five other signal motifs located at 
both the N and C termini of peptides target proteins to ClpX50,64. The  λO tag 
A Type 1 (polar-T/φ-φ-basic-φ) N-terminal motif64 (TNTAKILNFGR) is used in 
this thesis.  This tag originates from the enterobacteria phage λ where it is 
found at the N-terminus of the replication protein O. λO-tagged substrates are 
not well degraded by ClpXWT or ClpXΔN. However, it is possible to introduce 
mutations onto the pore-loops of ClpX that will change its substrate preference 
from a ssrA-tagged substrate to a λO-tagged substrate by reducing the 
positive charge of the RKH loop making interactions with the positively 
charged N-terminus more favourable67. ClpX contains three different sets of 
pore loops (Figure 1.14). The RKH loops closest to the substrate side of the 
ring are involved in recognising the negatively charged carboxylate group. 
Pore 1 or GVYG loops and pore 2 loops have also been shown to be important 
for substrate recognition both by cross linking of the ssrA tag to both of these 
loops (showing an interaction can take place68) and by mutagenesis of the 
loops which alter the KM and affinity for the ssrA tag54,69,70. It is also possible 
to take the human ClpX, which does not recognise ssrA-tagged substrates, 
and alter its specificity to recognise the ssrA tag by transplanting the E.coli 
loops into the human ClpX68.  
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In addition to the pore-loops it has been shown that other elements of ClpX 
are important for substrate recognition, particularly for the less well studied 
degradation tags such as λO, which requires the NTD for recognition71.    
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Figure 1.13: Upon stalling of the ribosome, SsrA is recruited to the A site of the ribosome. The nascent chain is transferred to the alanine-charged tRNA domain of the SsrA. The faulty mRNA is then exchanged for the SsrA open reading frame (magenta) by a message-switching event. Translation then continues until a stop codon is reached when the protein is released from the ribosome and can be degraded. Adapted from Karzai et al71. 
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Figure 1.14: The pore loops of ClpX. A: Cartoon of the 3 types of ClpX pore loop involved in substrate recognition. B: Cartoon showing the assembled ClpXP complex. Adapted from Baker and Sauer47.  
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1.4.2.1 Adaptor-mediated recognition 
There are two adaptor proteins (RssB and SspB) known which can modulate 
the activity of ClpX by altering substrate delivery.  RssB is a two component 
regulator of E.coli transcription initiation factor σs 64. The better understood 
SspB binds to the NTD of ClpX and to the ssrA-tagged substrate, increasing 
the rate at which the substrate is degraded by preventing the substrate from 
diffusing away after an unsuccessful degradation attempt. It is not required for 
degradation to occur and does not affect the mechanism of degradation or 
change the substrate specificity but alters the overall rate of ClpXP mediated 
degradation. As it does not alter the mechanism it does not alter the kinetics 
of the individual steps in the unfolding and degradation of a substrate, but it 
does increase the overall rate of degradation in a bulk solution experiment by 
raising the effective substrate concentration72. It is interesting that SspB is 
capable of mediating the degradation of various substrates which have little 
sequence similarity and bind the adaptor differently73.  
1.4.2.2 Substrate translocation by ClpX 
The exact mechanism of ClpX translocation is not known. However, as ATP 
binding and hydrolysis cause conformational changes in the ClpX ring it is 
likely that this conformational change drives translocation47,61,74. It has been 
demonstrated that, in addition to disrupting adaptor recognition, mutations in 
the GYVG loops can have an effect on ClpX translocation. In particular the 
Y153A mutation (which removes the tyrosine from the GYVG loop)  completely 
prevents ClpX translocating its substrate54. Figure 1.15 shows a hypothesised 
situation in which movement of the loop tyrosine residue drives substrate 
39 
translocation. This GYVG loop is also thought to be responsible for preventing 
backtracking and loss of the substrate from the pore54, although there is no 
conclusive evidence of this since mutations in this loop also affect the 
translocation of the substrate.  
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Figure 1.15: Cartoon representation of a possible mechanism of translocation by ClpX cycling between ATP bound (ATP), hydrolysing (Hydrol.), and empty states during substrate translocation. When ClpX is in the ATP-bound state the tyrosine residue is oriented towards the open side of the ClpX (blue) during ATP hydrolysis the tyrosine moves from being oriented towards the open side to being oriented towards the ClpP (white/orange) when there is no ATP bound the tyrosine is at the maximum orientation to the ClpP side of the ClpX (red). Adapted from Martin et al54.  
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1.4.3 ClpP 
ClpP is active as a 14-mer, its 14 subunits each have one serine protease 
active site and are arranged as two symmetric rings each of 7 subunits stacked 
face to face, producing a chambered peptidase with the active sites 
sequestered in a proteolytic chamber. Entry to the proteolytic chamber is 
through a narrow axial pore wide enough to accept only an unfolded peptide 
chain75. The crystal structure of ClpP was solved to 2.3 Å in 1997 by Wang et 
al75. The structure is shown in Figure 1.16 below.  
In isolation ClpP does not degrade folded proteins, it is reliant on delivery of 
its substrates by an associated AAA+50. This lack of activity of free ClpP is 
important for cell viability: acyldepsipeptide antibiotics kill bacteria by allowing 
ClpP to degrade unfolded peptides without regulation76. This control of 
degradation is achieved by the first 21 residues of each ClpP subunit which 
form a stem-loop structure effectively blocking the channel by which proteins 
enter the degradation chamber unless it is interacting with ClpX. The pore into 
the proteolytic site of ClpP has a diameter of only 9 Å at its narrowest point. 
Binding of the aforementioned acyldepsipeptide antibiotics or an AAA+ ring to 
ClpP can allow entry of larger substrates allowing ClpP to degrade unfolded 
peptides including those containing disulphide bonds77,78.  
There is also a much reduced activity by single ClpP subunits and single ring 
heptamers which in theory have exposed active sites.   The cleavage of 
peptides by ClpP does not seem to be sequence specific although cleavage 
after non-polar residues is preferred79,80. 
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The inner chamber of ClpP is approximately spherical and had a diameter of 
around 50 Å, the 14 active sites it contains have an equivalent concentration 
of about 350 mM which allows it to degrade even sub-optimal substrates very 
efficiently. The sites are located such that each one is about 25Å from three 
other sites, a distance spanned by around eight residues in an unfolded 
substrate allowing multiple binding and cleavage events to occur 
simultaneously. This helps prevent stalling of the ClpXP as the ClpP can 
degrade a peptide chain much faster than ClpX can translocate it47.   
43 
 
Figure 1.16: Structural views of the ClpP peptidase. Top: each of the 14 identical subunits is shown, the colouring is from red (C terminus) to blue (N terminus) for each subunit. Bottom: cutaway views showing the location of the protease active site residues within the chamber. Taken from Sauer et al50.  
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1.4.4 ClpX and ClpP interactions 
EM images have shown that ClpX can bind to either one or both sides of a 
ClpP 14-mer (Figure 1.17). The axial pores of ClpX align with the pores in 
ClpP providing a route for substrate translocation into the proteolytic chamber. 
Interestingly even in ClpXP complexes with two ClpX caps, only one of them 
will actively translocate a substrate at any given time, indicating some 
communication must occur through the ClpP81,82.     
As ClpX is a hexamer and each ClpP ring a heptamer there is inevitably a 
symmetry mismatch between the two different components. As no high 
resolution structures of complete ClpXP exist (only EM reconstructions) it is 
not known exactly how this mismatch is resolved, as can be seen in Figure 
1.17 the resolution of the available EM images is too low to resolve this 
mismatch. It is known from mutagenesis studies that the pore-2 loops of ClpX 
and the N-terminal stem-loop residues of ClpP are involved, as is the binding 
of ATP but it is not known exactly how 69,83.   
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Figure 1.17: Cryo EM image showing the assembled ClpXP complex. Left :ClpXP with two ClpX rings, right: ClpXP with one ClpX ring. Adapted from Ortega et al82. 
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1.4.5 Forces applied by ClpX 
Two studies have been undertaken using optical tweezers to manipulate 
beads to which ClpX and a substrate have been tethered (Figure 1.18) in order 
to investigate the forces applied by ClpX4,29. While both studies used optical 
tweezers the precise experimental design differed. While both used one 
polystyrene bead to which ClpX had been tethered, and a second bead to 
which the substrate protein was attached at the N-terminus by a DNA linker, 
the substrate proteins were different. Maillard et al. used a fusion protein with 
an ssrA tag and either one or two copies of green fluorescent protein, 
Aubin-Tam et al. used an ssrA tag fused to 8 filamin A domains. The findings 
of these studies showed good agreement regarding the main detail of ClpX 
unfolding and translocation detailed in Table 1.1. They were successful in 
determining the force applied by the ClpX and to measure the translocation 
rates which show good agreement with earlier bulk solution studies84.   
The force applied by ClpX was measured up to 20 pN with a translation rate 
(approximately analogous to a loading rate) of 4.5 nm s-1 4,30 which means that 
both the applied force and loading rate are at the lower end of what can be 
achieved by biophysical methods such as AFM or optical tweezers. Both sets 
of results supported the expected power stroke unfolding mechanism where 
ATP hydrolysis supplies the energy for a conformational change that provides 
a method of doing work on the substrate protein rather than some Brownian 
ratchet mechanism where the ClpX just provides a mechanism by which 
random Brownian motions of the substrate can only move in one direction. 
The studies also supported the hypothesis that ClpX will repeatedly pull on the 
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substrate and that unfolding will occur when this pulling coincides with random 
thermal fluctuations in the substrate protein. In this way substrates can be 
unfolded with a wide range of thermodynamic and mechanical properties.  
The main disagreement between the two studies was the different level of 
unfolding intermediate seen in the unfolding events, but as each was using a 
different substrate protein this in unsurprising. 
Table 1.1: Summary of the results of Maillard et al. and Aubin-Tam et al. regarding the mechanical unfolding of a substrate by ClpX investagated by optical tweezers. 
Finding  Maillard et al4.   Aubin-Tam et al29.  
20 pN stall force Yes Yes 
Slower translocation at 
higher foces 
Yes Yes 
1 nm minimum 
translocation step size  
Yes Yes 
Pauses before 
unfolding 
Yes Yes 
Unfolding intermediates 
detected  
70% of events 15% of events 
Peak work applied by 
ClpX 
5 kT 5 kT  
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Figure 1.18: A: experimental setup of an optical tweezer experiment for measuring the force applied by ClpXP. Two polystyrene beads are held in an optical double trap with a passive force-clamp geometry. The multidomain substrate is attached to one bead by a DNA linker, ClpXP is tethered to the other bead and contact between the two beads is maintained by the contacts between the substrate and ClpXP. B: an idealised trace showing the typical data obtained from such an experiment. Increases in the distance (between the beads) represents an unfolding event, decreases in the distance represent substrate translocation and the dwell is the time required for unfolding of the next domain.  Adapted from Aubin-Tam et al30. 
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1.4.6  ClpXP as a tool to study mechanical forces 
The degradation of substrates by ClpXP has several steps: 
1. Productive binding of substrate by ClpX 
2. Mechanical unfolding of the substrate by ClpX 
3. Translocation of the substrate by ClpX  
4. Degradation of the substrate by ClpP 
It has been shown that mechanical unfolding of the substrate by ClpX is the 
rate-limiting step in a degradation reaction and that the rate of degradation 
depends on the mechanical stability of the substrate49. While it is not possible 
with the system I have used to directly measure the unfolding of a substrate, 
subsequent degradation of the substrate by ClpP provides an all-in-one linked 
assay as we can assume that as unfolding is the rate-limiting step then the 
rate of unfolding is proportional to the rate of degradation. 
Consequently care must be taken when using the data from degradation 
experiments to infer the mechanical unfolding rate of a substrate. What we 
can measure using the assay developed here is the degradation rate of the 
protein and while these should be linked (as described above) it is important 
to realise that we are not measuring unfolding directly.  
Most studies involving ClpXP have concentrated on understanding the 
mechanism of ClpXP itself. My project involves the use of ClpXP as a model 
system to study how different proteins react to the mechanical forces which 
ClpX can apply. The lack of substrate specificity (except for the requirement 
for a degradation tag) and the ability of ClpXP to degrade a wide variety of 
substrates make it an ideal model system for this study which investigates the 
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mechanical strength of proteins containing long stretches of polyglutamine 
repeats.  
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 Polyglutamine Repeats 
Polyglutamine (polyQ) expansion in proteins is caused by the genetic 
expansion of a CAG nucleotide repeat. It causes several hereditary, 
progressive neurodegenerative diseases. Since the identification and 
sequencing of the Huntington’s disease (HD) gene in 199385 much research 
has been carried out to determine the mechanisms of these diseases. Briefly, 
polyQ disease proteins contain a polyQ region coded for by repeated CAG 
codons which become expanded in one of the genes of diseased individuals. 
While it is possible to inherit a gene with an already expanded CAG region, 
expansion can also occur during meiosis and mitosis. While the mechanisms 
of CAG expansion are understood, the pathogenic consequences of 
polyglutamine expansion are not, and neither is the structure of polyglutamine 
regions of proteins. The polyglutamine repeat disorders share several 
similarities in their pathogenicity and are thought to be caused by similar 
mechanisms, involving a toxic gain-of-function in the disease protein. Current 
therapeutic strategies have concentrated on relief of the symptoms of these 
disorders rather than treating the underlying condition. Gene therapy has 
gained popularity as a possible treatment; if the underlying genetic defect can 
be corrected or expression of the disease protein reduced, the condition can 
be treated without having to fully understand the mechanisms by which the 
toxic effect is produced. More traditional therapies such as small molecule 
inhibitors of toxicity or aggregation do not yet exist, but further study of 
polyglutamine structure and aggregation may allow their development.  
Recent studies have started to shed some light on the structure of 
polyglutamine repeats (see section 1.5.6) which may in time lead to the 
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effective development of more traditional therapies for polyglutamine 
expansion disorders. This project will attempt to elucidate more details about 
the mechanical properties of polyglutamine repeats using a traditional 
biochemical method of enzyme assays, exploiting the ability of ClpXP to apply 
forces to degrade proteins, and the biophysical technique of dynamic force 
spectroscopy, using an AFM to directly apply and measure the force required 
for the unfolding of polyglutamine and to investigate its unfolding resistance.  
1.5.1 Polyglutamine function 
Analysis of the human genome suggests polyQ-containing proteins are 
enriched in transcriptional co-activator and transcription factor binding 
proteins86. This leads to two major biological functions for polyQ containing 
genes; DNA dependent transcriptional regulation and neurogenesis. 
Interestingly, most eukaryotic proteins containing homo-peptide repeats are 
involved in nucleic acid interactions in some way; transcription, translation or 
direct binding to nucleic acids or chromatin87.  
1.5.2 Polyglutamine diseases 
Polyglutamine expansion diseases, also known as CAG repeat diseases are 
hereditary neurodegenerative diseases caused by the expansion of a CAG 
repeat in the gene for a cellular protein leading to the expansion of a polyQ 
tract in the protein which causes a toxic gain-of-function88. To date there are 
nine known polyQ expansion diseases, Huntington’s disease (HD), 
dentatorubropallidoluysian atrophy (DRPLA), spinal bulbar muscular atrophy 
(SBMA) and six types of spinocerebrellar ataxia (SCA1, 2, 3, 6, 7, and 17)85 
(see Table 1.2). The diseases, of which HD and SCA3 are the most common, 
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share some features indicating a common toxicity related to the expanded 
polyQ. They are autosomal dominant diseases and the toxic protein is 
normally expressed at the same level and alongside the normal length protein.  
Most of the proteins involved are expressed systematically but the toxic effects 
are seen only in neuronal cells, perhaps due to increased expression in these 
cells89. The accumulation of these proteins in neuronal cells seems to lead to 
their dysfunction and death. The diseases are progressive in nature, both in 
the symptoms presented and the accumulation of the protein. The specific 
pathogenic mechanism of polyQ diseases is complex and not fully understood 
and several models have been devised to explain it. None, however, have 
been conclusively proven, but an inverse correlation between repeat length 
and the age of onset of clinical symptoms has been observed, and the risk of 
suffering from a polyglutamine disease is increased in individuals with a long 
uninterrupted polyglutamine tract89.  
1.5.3 Length 
As shown in Table 1.2, repeat lengths in both normal and disease proteins can 
vary considerably. Polyglutamine repeats in disease proteins are generally 
longer than 35 Q; however in SCA6 it can be as low as 21 or, in SCA3, as 
high as 62. This indicates that length of the polyQ repeat alone cannot be 
responsible for the disease, as polyQ lengths that would be considered normal 
in one protein can cause disease in another, so the protein context of the 
polyQ repeat must be important90. 
Despite disease proteins being expressed throughout an individual’s life, 
polyQ diseases are typically considered to have an adult onset, although 
increased length of polyQ repeat is associated with both earlier age of onset 
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and disease severity92 thus childhood onset is possible yet uncommon. For 
example, onset of HD in juveniles (defined as before age 20) occurs in 
approximately 10% of cases, the majority of these having a repeat length of 
60 or greater93. While infantile onset (before 1 year) occurs in 1% of cases 
with typical repeat lengths of 80-9094 and repeat lengths of up to 250 have 
been recorded95.  
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Table 1.2: List of polyglutamine expansion diseases, with protein names and functions, showing the variation of polyQ length in normal and disease proteins85,95. 
Disease Protein Protein Function polyQ length 
Normal Disease 
SBMA Androgen receptor Testosterone-activated steroid receptor 6-36 38-62 
DRPLA Atrophin-1 Possible transcriptional repressor 3-38 49-88 
HD Huntingtin Possible scaffolding protein linked to diverse cellular pathways 
6-35 36-121 
SCA1 Ataxin-1 Transcriptional repressor involved in transcription regulation, cell specification and synaptic activity 
6-39 41-83 
SCA2 Ataxin-2 Component of RNA processing and translational regulation pathways 
14-32 34-77 
SCA3 Ataxin-3 Deubiquitinating enzyme involved in protein quality control 
12-40 62-86 
SCA6 P/Q-type calcium channel subunit 1A 
Voltage-dependent P/Q-type calcium-channel subunit  4-18 21-30 
SCA7 Ataxin-7 Component of histone acetyltransferase complex and transcriptional regulation pathways 
7-18 38-200 
SCA17 TATA-binding protein 
Component of core transcriptional complex TFIID 25-43 45-63 
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1.5.4 Pathogenicity 
Studies have concluded that the expansion that occurs in polyglutamine 
disorders is responsible for a toxic gain-of-function rather than loss of the 
normal protein function89. However, the specific pathogenic mechanisms of 
each disease seem to be unrelated and it is unlikely that a common pathway 
will emerge92. The most likely candidate for a shared mechanism was the 
ability of expanded polyglutamine peptides to form aggregates and inclusions, 
since inclusions containing the relevant protein are found in the regions of the 
brain subject to neurodegeneration96. However it has been questioned 
whether these aggregates and inclusions are directly pathogenic86,97. It seems 
that the polyQ expansion causes a pathogenic mechanism related to a change 
in conformation of the normal protein resulting in a change in function86,97. This 
idea is supported by reports that overexpression of molecular chaperones can 
reduce polyQ toxicity in model systems92.  
There are many proposed models to explain polyQ toxicity and it is unlikely 
that any one will be sufficient to fully explain the diverse observations. Instead 
several of the proposed mechanisms are likely acting together in each of the 
diseases91. Table 1.3 summarises several of the proposed mechanisms.  
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Table 1.3: Proposed mechanisms of polyglutamine toxicity86–88. 
Proposed mechanisms of polyglutamine toxicity 
Protein misfolding causing a toxic gain-of-function 
Adverse protein interactions between the disease protein and the proteome 
Formation of toxic oligomers 
Transcriptional dysregulation 
Mitochondrial misfunction impairing bioenergetics and causing oxidative stress 
Impaired axonal transport 
Abnormal neuronal signalling and excitotoxicity 
RNA toxicity  
Ubiquitin-proteosome system impairment 
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1.5.5 Therapy 
Although current treatments for polyglutamine diseases in clinical use can 
treat only the symptoms, the hereditary nature of the diseases and the ease 
of identifying at-risk individuals through genetic screening make it a good 
target for therapy. As most current therapies concentrate on symptomatic 
relief88 there is therefore a need to develop our understanding of the diseases 
at a molecular level in order to design effective treatments. 
One therapeutic target may be the gene itself, turning off, or down-regulating 
expression of the mutant gene. RNA interference using siRNA would, in 
theory, provide a cure98,99, however this approach is not without its challenges 
and a clinical application may be some years away.  
If expression of the protein cannot be prevented another strategy is to enhance 
its clearance. Improving degradation by either autophagy or the ubiquitin 
proteasome system (UPS) may be effective, although as discussed later the 
UPS itself may be impaired by polyQ. A final strategy is to prevent polyQ 
forming toxic structures; however without a greater understanding of the 
structure of polyQ and its aggregation this will not be possible. 
1.5.6 Polyglutamine structure  
Polyglutamine peptides are examples of intrinsically disordered proteins (IDP), 
sequences that under non-denaturing conditions do not form an ordered 
tertiary structure. Polyglutamine is a typical IDP in that it has a low sequence 
complexity and a lack of hydrophobic residues100. It has been shown by 
several different methods that polyglutamine peptides form a random coil 
conformation in water. Circular dichroism spectroscopy (CD) indicates a high 
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degree of random coil conformation over several polyQ lengths, indicating no 
significant structural change that could account for the difference in toxicity of 
the different length polyQ tracts100–102. Nuclear magnetic resonance (NMR) 
also shows that polyglutamine adopts a random coil conformation103.  
Structural information about polyQ at an atomic level is very difficult to obtain: 
until recently the database of protein structures contained no structures for 
polyQ repeats greater than 3 104.  Only one crystal structure at atomic 
resolution exists for a repeat greater than Q10 and this does not give a single 
definitive structure. This crystal structure, obtained by Kim et al105, is of the 
first exon of huntingtin which containined 17 glutamine repeats located 
between the 17 amino acid N-terminal region and a polyproline rich region. 
Data was collected from 30 crystals, and a partial structure for the polyQ 
region was achieved for 7 of them. The N terminal region was shown to be 
α-helical, with the α-helix continuing into the polyQ region for between 1 and 
12 glutamines before becoming a random coil. The 4 glutamine residues 
immediately before the polyproline region adopted an extended loop 
conformation105.  
Water is a poor solvent for polyglutamine peptides longer than 16Q106 and 
they form a compact collapsed globular structure in water stabilized by 
extensive intra-chain hydrogen bonding100,107.  Indeed, polyQ longer than 16Q 
does not remain in solution and quickly forms aggregates, but when in the 
context of a soluble protein or a peptide with sufficient charged residues, it can 
maintain solubility. The poor solubility of polyQ is counterintuitive given the 
hydrophilic nature of glutamine and the high solubility of small amides in water. 
Some change must occur between the small amides and the polyamide and it 
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seems that the polyglutamine backbone is more favourably solvated by 
interacting with itself than with the solvent water causing a collapse of the 
chain to minimize its exposure to the solvent100,107. This is thought to be due 
to the increased probability of the formation of intermolecular hydrogen bonds, 
which can be backbone-backbone, side chain-side chain or side chain-
backbone, as the peptide length increases. Once several intermolecular 
hydrogen bonds have formed the peptide becomes trapped in a collapsed 
conformation and further interchain hydrogen bonds can form106. The disorder 
of the structure may lie in the fact that there are many potential hydrogen bond 
donors and acceptors in a polyglutamine sequence. Exploration of a polyQ 
sequence by use of molecular dynamics simulations (MD) shows there are a 
large number of hydrogen bonds able to form because they can form almost 
anywhere along the chain, in any of the accessible conformations. For 
example, a Q15 peptide in a compact or semi-compact globule can form an 
average of 4-5 sidechain-backbone hydrogen bonds108. To date, it has not 
been possible to obtain a definitive structure for expanded polyQ regions in 
context as a part of a native protein. A study using a polyQ/glutathione 
S-transferase (GST) fusion protein in order to look at the structure of polyQ 
tracts in a more native-like environment by both CD and NMR indicated a 
random coil conformation104. Most studies of polyQ structure, if they have 
considered the structure of the individual polyQ tract, have concentrated on 
how its structure facilitates its aggregation.  
1.5.7 Polyglutamine aggregation  
From both in vitro studies of peptides and in vivo observations it has been 
observed that polyQ can aggregate to form amyloid-like fibrils. Given that the 
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majority of polyglutamine expansion disorders are characterised by the 
formation of both cytoplasmic and intranuclear inclusions within neurons it 
seems clear that this aggregation is important to the pathogenesis of polyQ 
diseases. However, it is unclear whether these aggregates are directly 
responsible for toxicity, merely represent the end point of a toxic mechanism 
involving an aggregation intermediate, or even have a protective role85. It 
seems reasonable to assume that the proposed conformational change 
brought about by an increase in polyQ length which allows aggregation to 
occur has other effects which may cause toxicity.  
It has been known for some time that aggregated polyQ has a β-sheet 
structure, which may be stabilized by a polar zipper of hydrogen bonds formed 
between the main chain and side chain amides; other suggested structures 
include parallel β-sheets and β-hairpins109–111 these structures are 
summarised in Figure 1.19.  
Aggregation appears to follow a nucleation-dependent mechanism. When fibril 
growth is observed in vitro there is a lag phase, representing the formation of 
a nucleus, followed by a rapid increase in aggregation; the lag phase can be 
eliminated by the seeding of a solution with pre-formed aggregate.  
The length of the lag phase and the critical concentration for aggregation (the 
concentration at which it becomes more thermodynamically favourable for the 
peptide to form aggregate) was found to be inversely correlated with the length 
of the polyQ112.  This likely explains the correlation of polyQ length with 
severity of disease and the inverse correlation with age of onset. Interestingly 
it has been suggested that in addition to aggregation of expanded polyQ 
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peptides, normal length polyQ peptides also play a role in enhancing 
aggregation kinetics113.  
Since polyQ is inherently disordered without a stable structure, we can 
assume that in solution it will sample several of the conformations available to 
it. One of these may be relatively extended and have some β-sheet character. 
This conformation, however briefly occupied, may form the nucleus for 
subsequent aggregation101. It may be that as polyQ length increases, the 
likelihood that it will occupy this conformation, or that part of it may occupy this 
conformation increases, explaining the increased aggregation of longer polyQ 
sequences. It has also been shown that the context of the polyQ expansion 
strongly affects the rate of onset of disease90.  
1.5.8 Protein context  
The physico-chemical environment of the polyQ residues will be strongly 
affected by the adjacent through-space sequence of the protein in which it 
resides. Thus, in addition to the conformation and repeat-length, the 
characteristics of adjacent domains,  posttranslational modifications, protein 
interactions, cellular location and normal function of the protein may all be 
important in the mechanisms of polyQ diseases and aggregation90. As shown 
in Figure 1.20  it may be that the flanking regions themselves form an initial 
aggregate that causes or accelerates polyQ aggregation by bringing polyQ 
regions into close proximity. 
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Figure 1.19: A summary of the possible structures for aggregated polyglutamine. A and B show only the backbone and backbone hydrogen bonding. They represent parallel β-sheets and β-hairpins respectively. C: shows a polyglutamine polar zipper formed by the hydrogen bonding between both the backbone and the side chains. Key: red: oxygen, blue: nitrogen, black: backbone carbon, grey: side-chain carbon.    
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Figure 1.20: Mechanism of aggregation for huntingtin exon 1 (HTTNT) mediated aggregation of polyQ. The HTTNT domain (green) unfolds in a polyQ repeat length–dependent fashion and, once unfolded, self-aggregates without a nucleation barrier to form oligomers with cores comprising HTTNT and not polyQ (red). The next identified aggregates involve both HTTNT and polyQ in amyloid-like structure; the proline rich domain (black) is not incorporated into the core. This drawing is schematic and is not meant to imply any details of aggregate structure, except that final aggregates are rich in β-sheet, are fibrillar and involve both HTTNT and polyQ. Taken from Thakur et al114.  
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Table 1.4 shows the polyQ region of the known polyQ disease proteins 
together with the amino-acids adjacent to their primary sequence. It is 
immediately notable from Table 1.4 that not all of the “polyglutamine regions” 
contain exclusively polyglutamine. For example, ataxin-3 contains a lysine and 
Ataxin-1 contains a central histidine-glutamine-histidine sequence. This does 
not alter the random coil conformation of the polyglutamine tract, but it does 
have an effect on the aggregation kinetics as aggregation is slowed by 
reducing the nucleation equilibrium constant, Kn*, which is calculated by fitting 
to Equation 1.3, and is approximately analogous to Ka113,115. This is thought to 
be due to the structure of His containing aggregates being more restricted due 
to the positioning of His residues in reverse turns115.   
߂ = 12 ܭ௡∗݇ାଶ ܥ௡∗ାଶݐଶ 
Equation 1.3: where Δ is the slope of a log-log plot of the initial aggregation kinetics versus concentration, Kn* is the nucleation equilibrium constant, k+ is the second order elongation rate constant (calculated seperatley from the molar concentration of viable growth points in the seed fibrils), n* is the critical nucleus (n* = slope -2), C is concentration and t is time115.  
The presence of the H-Q-H motif may explain the longer polyQ region required 
for a pathological polyQ repeat in SCA1 116. Another notable feature is that 
many of the polyQ regions are flanked by homopeptide repeats or regions rich 
in a single amino acid; in particular, polyproline or proline rich regions, but 
polyalanine, polylysine and polyhistidine are all represented. It has been found 
that the addition of a polyproline sequence of 5-6 amino acids C-terminal to 
the polyQ region can reduce the rate of aggregation117. It is proposed that this 
occurs due to the structural constraints of polyproline, it favours a PII helix that 
may influence the conformation of residues N-terminal to the polyproline, 
imposing a degree of order on the polyQ region118,119. Studies of exon 1 of 
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huntingtin (consisting of the 17 N-terminal amino acids (HTTNT), the polyQ 
repeat and the polyproline region) have shown that as well as changing the 
aggregation kinetics, sequence context can also alter the aggregation 
mechanism. Instead of a simple nucleation-aggregation mechanism, the 
presence of HTTNT causes the formation of an aggregation intermediate made 
up of aggregated unfolded HTTNT which forms without having to overcome a 
nucleation barrier, followed by aggregation of the attached polyQ, forming the 
nucleus for further polyQ aggregation (see Figure 1.20)114. Studies of polyQ 
aggregation have mostly used polyQ peptides, whereas in the disease the 
focus has been on full length proteins. However, proteasomal degradation of 
polyQ containing proteins may release shorter polyQ peptides into the 
cell114,120–122, making studies of polyQ peptides more biologically relevant than 
it first appears. 
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Table 1.4: The polyglutamine regions (in red) and surrounding amino acids of the known polyglutamine expansion disorders. 
Protein UniProt Identifier PolyQ region sequence Disease 
Huntingtin P42858 MATLEKLMKA FESLKSFQQQ QQQQQQQQQQ QQQQQQQQQQ PPPPPPPPPP PQLPQPPPQA 
Huntington’s 
Disease 
Ataxin-1 P54253 LANMGSLSQT PGHKAEQQQQ QQQQQQQQHQ HQQQQQQQQQ QQQQQHLSRA PGLITPGSPP 
SCA1 
Ataxin-2 Q99700 ACEPVYGPLT MSLKPQQQQQ QQQQQQQQQQ 
QQQQQQQQPP PAAANVRKPG 
SCA2 
Ataxin-3 P54252 LRKRREAYFE KQQQKQQQQQ QQQQQQQQQQ QQQQQQQRDL SGQSSHPCER 
SCA3 
Ataxin-7 O15265 GEPRRAAAAA GGAAAAAARQ QQQQQQQQQP PPPQPQRQQH PPPPPRRTRP 
SCA7 
TATA-box-binding protein 
P20226 ILEEQQRQQQ QQQQQQQQQQ QQQQQQQQQQ QQQQQQQQQQ QQQQQAVAAA AVQQSTSQQA 
SCA17 
Voltage-dependent P/Q-type calcium channel subunit alpha-1A 
O00555 SPVIRKAGGS GPPQQQQQQQ QQQQAVARPG RAATSGPRRY 
 
SCA6 
Androgen Receptor P10275  
GASLLLLQQQ QQQQQQQQQQ QQQQQQQQET SPRQQQQQQG 
 
SBMA 
Atrophin-1 P54259 TAHPPVSTHH HHHQQQQQQQ QQQQQQQHHG NSGPPPPGAF  DRPLA 
68 
1.5.9 Polyglutamine degradation  
Two main methods exist for eukaryotic cells to remove misfolded and toxic 
proteins: the autophagy-lysosome pathways and the ubiquitin proteasome 
system123. In autophagy, cytoplasmic proteins are bound within autophagic 
vacuoles, autophagosomes, which fuse with lysosomes to form 
autophagolysosomes, within which lysosomal enzymes degrade the enclosed 
proteins123. This pathway may be activated in cells containing aggregated 
polyQ if the ubiquitin-proteasome system (UPS) is unable to degrade the 
misfolded protein123, and evidence exists that its up-regulation may reduce 
clinical symptoms of polyQ diseases124.  
UPS degradation is carried out by the 26S proteasome which is an energy 
dependent multicatalytic protease which recognizes proteins tagged with 
ubiquitin as targets for degradation125. However, despite having 3 different 
types of catalytic sites (chymotrypsin-like, trypsin-like and caspase-like, which 
cleave peptides after hydrophobic, basic and acidic residues respectively) 
they are unable to hydrolyse polyQ tracts after the initial glutamine and must 
release the polyQ region as a polyQ peptide126. Not only is the proteasome 
unable to degrade polyQ effectively, it can also become irreversibly associated 
with it, leading to its sequestration in polyQ aggregates121. Several studies 
have found different results when examining impairment of the UPS by polyQ. 
There appears to be no global impairment of the UPS127, but several different 
assays have detected some degree of impairment123. Depleted levels of free 
proteasome are not detected in cells containing aggregates128, which may 
indicate that the proteasome is still present, but its function is impaired by the 
presence of polyQ. Recent research has shown that induction of mutant 
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huntingtin expression in a mouse model does transiently affect UPS function. 
When the mutant huntingtin is initially expressed, UPS function is reduced. On 
the formation of aggregated inclusion bodies, however, UPS function was 
restored129. This may indicate that monomeric mutant huntingtin or an 
oligomeric form free in the cytoplasm has the ability to block or otherwise 
disrupt the proteasome, but on aggregate formation the protein is no longer 
accessible to the UPS and so function is restored.    
The mechanical stability of monomeric polyglutamine may be a factor in its 
inability to be properly degraded by the proteasome107 and may explain some 
of the observed impairment before aggregation.  In a recent study, it was found 
that the polyQ domains of an engineered protein were extremely resistant to 
mechanical force. Several lengths of polyQ from 15-75 were investigated by 
dynamic force spectroscopy using a force-clamp AFM and found to resist 
unfolding at an applied force of 180 pN. By comparison, the mechanically 
strong I27 domain of the muscle protein titin was unfolded at a force between 
150-200 pN. Further experiments found a polyQ chain of 50 repeats was 
resistant to a mechanical force of up to 800 pN, demonstrating extreme 
mechanical stability; a surprisingly high figure, but not inconsistent with 
molecular dynamics simulations32. A particularly surprising result was that the 
mechanical resistance of the polyQ was length-independent, as both the 
physiological symptoms and aggregation propensity are known to increase 
with polyQ length. This may explain some of the impairment of the UPS 
observed, since the UPS uses mechanical force to unfold its substrate125, if 
the UPS is unable to unfold the polyQ it may block the proteasome preventing 
its function. 
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1.5.10 Other repeat expansion disorders 
Polyglutamine is not the only repeat expansion disorder, nine genes 
containing an alanine tract expansion are also known. Similar to polyglutamine 
diseases these can cause misfolding and aggregation, although the disease 
pathology appears more likely to be due to an accumulation of cytotoxic 
aggregates or a loss of protein function rather than the more complex and less 
well understood mechanism of polyQ diseases130. It is interesting that other 
repeat expansion disorders cause such symptoms as it is understood that 
polyQ’s aggregation properties are related to the propensity of its side chains 
to hydrogen bond to each other rather than to the surrounding solvent, with 
polyalanine this is of course not possible.  
At least another 11 disorders associated with repeat expansion are known, 
however these operate by conceptually simpler mechanisms or as yet 
unknown mechanisms.  Expansions in non-coding regions can  cause loss of 
protein function as in fragile X syndrome where a non-coding  CGG codon is 
expanded causing transcriptional silencing and loss of the protein product, 
fragile-x mental retardation protein. This protein binds RNA and its silencing 
leads to severe mental retardation. Expansions can also occur in coding but 
unexpressed regions such as in dystpophia myotonica. Here the CAG repeat 
is part of the 3’ untranslated region of the mRNA, so it is transcribed as RNA 
but the sequence comes after the stop codon. Consequently while it is not 
translated into a protein it can cause an alteration of RNA function. In this case 
RNA containing the expansion binds aberrantly to RNA-binding proteins that 
control splicing, this leads to abnormal splicing and dysregulation of protein 
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function. Others have an as yet unknown pathogenic mechanism though most 
are thought to disrupt RNA function97,130. 
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 Forces and polyglutamine 
Given the putative involvement of an energy-dependent unfoldase in its 
cytotoxic mechanism, the idea of using force to study polyglutamine is not 
new. There are two previous studies in this area which are very relevant to my 
work. Dougan et al32. looked at the collapsed, mechanically rigid 
conformations adopted by homopolypeptide chains by force-clamp AFM. 
Hervás et al33. studied common features at the start of the neurodegeneration 
cascade by investigating the mechanical properties of a range of protein 
sequences involved in amyloid-like pathology. I will briefly review both here 
and then attempt to reconcile their differing conclusions.  
1.6.1 Single homopolypeptide chains collapse into mechanically 
rigid conformations 
This study used a single-molecule force-clamp technique where a chimeric 
polyprotein containing several I27 domains combined with one or more polyQ 
segments was stretched at a constant force of 180 pN in order to investigate 
the force response of the polyQ. They used the length fingerprint of the I27, 
which extends by 24 ±0.4nm on unfolding, to ensure that they were pulling on 
a single polyprotein. They looked at the initial length (LInitial) of the polyprotein 
before any of the domains unfolded, this was in good agreement with an 
expected initial length calculated using a worm-like chain model (LWLC) when 
the length of linkers (short amino acid sequences between and at the ends of 
the construct) and an expected size for a globular polyQ region were 
accounted for. In order to demonstrate that they were able to see a difference 
in Linitial if the protein contained a domain which unfolded before the constant 
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force of 180 pN was reached, which would allow them to determine whether 
the polyglutamine region unfolded at this level of force, they used a protein 
containing the titin PEVK region which has a random-coil conformation but 
little mechanical strength. When the Linitial of a protein construct containing two 
of these PEVK regions was compared to the same construct without these 
domains the expected increase in Linitial was observed.  
In the experiments with polyQ they saw the three unfolding events they would 
expect to observe from the unfolding of I27 but they did not see any polyQ 
unfolding events and the LInitial observed corresponded to the polyQ being in a 
globular conformation. They used polyQ regions of lengths between 15 and 
75 glutamine and saw no difference in the LInitial or any unfolding events that 
indicated any unfolding of the polyQ. (Figure 1.21). 
They also used a force-ramp technique where the force applied to the 
polyprotein was increased in a linear manner up to 800 pN. This also failed to 
detect any disruption of the polyQ region and both the initial and final lengths 
were in agreement with what was expected from the extension of the linkers 
and I27 domains. Interestingly similar results were also observed for 
polyalanine.  
In order to explain these unexpected results they used molecular dynamics 
simulations to explore what might be happening in the polyQ. They took a 
polyQ region, unfolded it by heating to 800 K then allowed it to anneal at a 
temperature of 300 K before applying a mechanical unfolding force to it. They 
used this approach to probe 10,000 collapsed structures. These 
conformations were found to unfold in silico over a large range of mechanical 
forces but some were very stable and required up to 1,500 pN to unfold.  
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They theorised that this may be due to the extensive network of intra-chain 
hydrogen bonding found in these polyQ structures. It has been found in the 
unfolding of β-sheet rich proteins that those which require the rupture of a 
large number of hydrogen bonds tend to have more mechanical strength40. 
Dougan et al. thus hypothesised that the unfolding of polyQ might require the 
simultaneous rupture of a large number of hydrogen bonds and that this may 
explain the extreme mechanical strength seen in the polyQ.  Another 
explanation could be that their polyglutamine containing peptides were not 
mono-disperse and some intermolecular interaction between the 
polyglutamine domains of different proteins was lending them an appearance 
of an increase in intrinsic mechanical strength. Such an observation could be 
seen if polyQ was in a fibre or pre-fibrillar aggregated state and I27 was in a 
soluble form decorating the fibre.  
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Figure 1.21: Probing the mechanical properties of homopolypeptide chains. Chimeric proteins were constructed comprising I27 and polyglutamine chains of different length, A: Q15, B: Q25, C: Q50, D: Q75. A constant force of 180 pN was applied, resulting in a series of step increases in length. Full mechanical extension of a complete construct was identified by the presence I27 unfolding steps (24 nm). Initial extension (LInitial) were measured for each trajectory that satisfied this criterion. Histograms of LInitial are shown for each of the constructs. A Gaussian fit to the histograms (solid line) gave an average LInitial for each construct For all polyproteins, the measured LInitial was significantly shorter than that expected for full extension of the construct if the polyQ had unfolded (black shaded area). Instead LInitial was in close agreement with the expected length extension of only the folded I27 proteins and linkers (grey shaded area). From Dougan et al32. 
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1.6.2 Common features at the start of the neurodegeneration 
cascade 
This study used single molecule force spectroscopy by constant velocity AFM 
to investigate the mechanical resistance of the monomeric form of several 
amyloidogenic peptides. To maintain these aggregation-prone peptides in a 
soluble form they devised a novel method called a carrier-guest strategy 
(illustrated in Figure 1.22). This involves placing the peptide of interest (guest) 
within a loop of a ubiquitin domain (carrier). They claim that this allows a 
definitive identification of the force events corresponding to the unfolding of 
the peptide of interest as it is isolated from the application of force until the 
carrier ubiquitin is unfolded. They claim that this also eliminates any issues 
with non-specific tip or surface interaction by the guest as it unfolds far from 
the surface and guarantees that the analysed data comes from the stretching 
of a single guest protein. 
They used this system to analyse the force response of a variety of 
polyglutamine lengths (Table 1.5). They saw only a few polyQ regions which 
were very mechanically stable, although the number seen did show a positive 
correlation with polyQ length. The reason for their results not agreeing with 
the results from Dougan et al. are unclear, they say that their results are not 
directly comparable with the results by Dougan et al. because they have a 
clear marker to indicate which are the unfolding events that should be 
analysed and have better controls for inter-molecular interactions. 
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It is also possible that the results are different because they used a different 
technique (constant velocity rather than constant force) with different loading 
rates and the isolation of the polyQ by the carrier means that when the carrier 
unfolds the polyQ experiences a sudden loading of force rather than a more 
gradual loading that would be experienced if the polyQ were a normal part of 
the chain.  
Whatever the reason for these differences it is clear that polyQ reacts to the 
application of force in an interesting manner and that some mechanically 
resistant conformers are present, these could provide an explanation for polyQ 
appearing to block the proteasome. Even if the proteasome was only blocked 
by a relatively rare mechanically resistant polyQ (as suggested by Hervas 
et al. and the simulation of Dougan et al.), if it were to remain blocked it would 
prevent further degradation by that proteasome until the blockage was 
cleared. It is clear from both of these results that polyQ reacts to force in a 
remarkable manner which is worthy of further study. It will be particularly 
interesting to investigate how it reacts to force applied at only one end as 
illustrated in Figure 1.7B  and at lower loading rates. For this reason it was 
chosen to investigate it by using the bacterial proteasome ClpXP.      
78 
 
Figure 1.22: An illustration of the carrier-guest strategy. A guest neurotoxic protein (yellow) was placed in the loop of a ubiquitin carrier (grey) Adapted from Hervas et al33. 
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Table 1.5: The results of SMFS experiments performed with guest proteins consisting of several different lengths of polyQ. n is the number of events analysed. 
  Unfolding force of polyQ 
Q Length n ≤20 pN (%) 20-400 pN (%) ≥400 pN (%) 
19 111 100 0 0 
35 100 95 5 1 
62 107 92.5 7.5 2.8 
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 Other proteins used in this work 
While conducting this thesis research two other proteins were studied, which 
were used here as either a protein to calibrate an assay or as a substrate for 
ClpXP degradation.  
1.7.1 Beta-2-microglobulin 
Beta-2-microglobulin (β2m) is the non-covalently bound light chain of the 
major histocompatibility complex class 1 where it plays an important role in 
the assembly of the complex for antigen presentation. β2m contains 99 amino 
acids and adopts a classical β-sandwich fold with seven anti-parallel β-strands 
stabilised by a disulphide bridge. It has been well studied due to its 
aggregation being involved in dialysis related amyloidosis131. It was used in 
this study as an invariant standard to allow normalisation of densitometry data 
due to its availability in the laboratory.  
1.7.2 Colicin E9 
E. coli produce endonuclease colicins as a defence mechanism against 
competition by other bacteria. The endonuclease domain of the colicin 
E9 (herein called E9) is noted for its tight binding to its cognate immunity 
protein, Im9. The structure of the E9 endonuclease domain is shown in Figure 
1.23.  It was used in this study to provide a test-substrate for N-terminal 
degradation by ClpXP.  
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Figure 1.23: Cartoon rendering of colicin E9 endonuclease domain (orange) in complex with its cognate immunity protein Im9 (yellow). From PDB ID 1EMV132 
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1.7.3 Arc repressor 
The E. coli arc repressor (Arc) was chosen as a substrate to test N-terminal 
degradation of a substrate by ClpXP because the Sauer group have used it 
successfully for this purpose previously67. It is dimeric in solution and its 
structure is shown in Figure 1.24. 
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Figure 1.24: Cartoon depiction of the solution structure of Arc from 1ARQ. Determined by NMR.133. Each monomer is shown in a different colour.  
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 Aims and Objectives 
1.8.1 Aims 
The aims of this project are to develop ClpXP for use as a tool by which the 
mechanical properties of proteins can be investigated in a more biologically 
relevant manner than is available by the use of biophysical methods. This will 
then be used to investigate the mechanical properties of a polyglutamine 
repeat containing protein and to compare the results to those obtained by 
AFM.  
1.8.2 Objectives 
The initial objectives of this project are (i) to synthesise the necessary 
components of a ClpXP proteasome and find a suitable test protein; (ii) to 
develop an assay that can be used to investigate the mechanical properties of 
a substrate protein and (iii) to further develop this assay to allow investigation 
of different substrate proteins and conditions such as alternative 
unfolding/degradation directions and a non-reducing environments.  
Once these have been achieved a polyglutamine-repeat-containing protein 
will be synthesised, its suitability assessed by circular dichroism, fluorescence 
emission spectroscopy and analytical ultracentrifugation. It will then be 
subjected to the assay developed and investigated by dynamic force 
spectroscopy using AFM and the results compared.  
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2 Materials and Methods 
 Reagents and Materials  
2.1.1 General 
Dithiothreitol (DTT) was purchased from Melford Laboratories, UK. 
Ethylenediaminetetraacetic acid disodium salt (EDTA) was purchased from 
Fisher Scientific, UK.  
All other chemicals were purchased from Sigma-Aldrich, UK and were of 
analytical grade. 
All solutions were made up with 18 MΩ.cm resistivity de-ionised water.  
2.1.2 Molecular biology 
Water used for molecular biology was sterilised by autoclaving for 20 minutes 
at 120 °C. Isopropyl-β-thiogalactosidase (IPTG), and carbenicillin disodium 
salt, were purchased from Melford Laboratories, UK. Ampicillin sodium salt 
was purchased from Formedium, UK. LB bouillon was purchased from Merck, 
Germany. Restriction enzymes, Quick ligase, T4 phosphonucleotide kinase, 
Vent polymerase and Antarctic phosphatase were purchased from New 
England Biolabs (UK) Ltd. pGEM-T Vector Systems, 5-bromo-4-chloro-3-
indolyl-β-D-galactoside (X-gal) and T4 DNA ligase were purchased from 
Promega Corporation, USA. QIAprep Spin Miniprep Kit, HiSpeed Plasmid Midi 
Kit and QIAquick Gel Extraction Kit were purchased from Qiagen, UK. 
Oligonucleotides were purchased and depending on their size purified by 
HPSF or HPLC+ from MWG biotech, UK. DNA sequencing was carried out in 
house, by DBS genomics, UK or by Beckman Coulter Genomics (UK). 
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2.1.3 Protein purification and analysis  
Solutions used during protein purification were vacuum filtered using 0.45 μm 
Durapore® membrane filters purchased from Millipore, UK. 
Ammonium persulphate and 30% (w/v) acrylamide:0.8% (w/v) bis-acrylamide 
were purchased from Severn Biotech Ltd, UK. 10× Tris-Tricine SDS 
electrophoresis buffer was purchased from Fermentas, UK. Mark 12 unstained 
standard molecular mass markers were purchased from Invitrogen, USA. 
Instant Blue was purchased from Expedion Protein Solutions, UK. Ni 
Sepharose high performance affinity chromatography resin, Source 15Q, 
Resource Q, Superdex 75 and Superdex 300 columns were purchased from 
GE Healthcare, Sweden. Spectra/Por (3,500 Da MWCO) dialysis tubing was 
purchased from Spectrum Medical Industries, USA. 
2.1.4 Atomic force microscopy  
Silicon nitride contact probes, model MLCT, were purchased from Veeco 
Instruments Ltd, UK. Phosphate buffered saline (Dulbecco A) (PBS) tablets 
were purchased from Oxoid Ltd., UK. Silicon wafers covered with a 1000 Å 
surface layer of evaporated gold were purchased from Platypus Technologies, 
USA. Microscope slides were purchased from Menzel GmbH, Germany.  Epo-
Tek 377 was purchased from Epoxy Technology, Inc. USA. Viva Spin 20 
ultrafiltration spin columns (3,500 Da MCWO) were purchased from Sartorius 
Stedim Biotech GmbH, Germany. 
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 Molecular biology  
Escherichia coli strains used are described in Table 2.1. 
2.2.1 Growth media 
Bacterial strains were typically cultured in lysogeny broth (LB) prepared by 
dissolving 25 g per litre of LB bouillon in distilled water and sterilised by 
autoclaving for 20 minutes at 120 °C and 121 psi. Media were allowed to cool 
before the addition of the appropriate filter-sterilised antibiotic. 
Agar plates were prepared from media as above with the addition of 15 g 
bacto-agar per litre of medium prior to autoclaving. After cooling, 
filter-sterilised antibiotics were added and the solution thoroughly mixed 
before being poured into 100 mm diameter petri dishes, 25 ml per dish. Plates 
were allowed to set before being stored at 4 °C. 
Blue-white screening plates were prepared in the same way with the addition 
of 80 μg/ml X-gal and 0.5 mM IPTG prior to pouring.  
Antibiotics were used at the following final concentrations: ampicillin 
100 µg/ml, carbenicillin 100 µg/ml both dissolved in sterile water and 
chloramphenicol 25 µg/ml dissolved in 100% ethanol and filter-sterilised 
through a 0.22 μm filter.  
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Table 2.1: E. coli strains used; including their source, genotype and reason for their use in this project. 
Strain Source Genotype Purpose 
SURE2 Stratagene endA1 glnV44 thi-1 
gyrA96 relA1 lac recB 
recJ sbcC umuC::Tn5 
uvrC e14- Δ(mcrCB-
hsdSMR-mrr)171 F’[ 
proAB+ lacIq lacZΔM1
5 Tn10 Amy CmR] 
Cloning of DNA 
containing 
repeated 
sequences 
(I27 
concatamers, 
ΔNClpX6) 
BLR(DE3) 
pLysS 
Novagen F- ompT gal dcm lon 
hsdSB(rB- mB-) λ(DE3) 
pLysS(cmR) recA- 
Expression of 
proteins 
containing 
repeated 
sequences 
(I27 
concatamers, 
ΔNClpX6) 
BL21(DE3) Laboratory 
Stocks 
F– ompT gal dcm lon 
hsdSB(rB- mB-) λ(DE3) 
ClpX expression 
BL21(DE3) 
pLysS 
Laboratory 
Stocks 
F- ompT gal dcm lon 
hsdSB(rB- mB-) λ(DE3) 
pLysS(cmR) 
ClpP expression 
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2.2.2 Agarose gel electrophoresis 
1.5-3 g agarose was added to 100 ml of TAE buffer (200 mM Tris, 0.114% 
(v/v) glacial acetic and 1 mM EDTA) in a conical flask and the solution heated 
until the agarose was dissolved. The solution was allowed to cool until it could 
be handled comfortably before addition of 1 mg/ml ethidium bromide to a final 
concentration of 1 µg/ml. The gel was then poured into a mould containing a 
comb with the appropriate number of lanes. For most purposes 1.5% (w/v) 
agarose gels were used apart from separation of ligated polyQ fragments, 
where 3% (w/v) agarose gels were used. 
Gels were then completely covered with TAE buffer in a gel tank making sure 
no air was trapped between the tank and the casting unit. DNA samples 
(containing 100 ng-1 g DNA) and markers were added to 6×gel loading 
buffer (0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol, 40% (w/v) 
sucrose).   
Gels were electrophoresed at 10 volts per centimetre for around 1 h until the 
bottom marker reached no further than half-way through the gel. The DNA was 
then visualised by UV trans-illumination (Syngene, GVM20). If the ethidium 
bromide counter-migrated further than the lowest expected DNA band then 
the gel was re-stained for one hour in TAE buffer containing 1 µg/ml ethidium 
bromide.  
2.2.3 PCR mutagenesis 
All PCR mutagenesis of I27 was performed on single I27 cassettes in pGEM 
derived plasmids before ligation into a concatamer. Mutagenic primers were 
designed with the reverse complement of the strand to which they were to be 
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annealed with a length sufficient to provide an annealing temperature between 
55-65 °C (using the formula of Tm = 4(C+G) + 2(A+T) °C) terminating in a 3’ C 
or G. 5’ to this they contained the required mutation followed by 9 random 
bases 5’ to the annealing sequence to facilitate cutting by restriction enzymes. 
PCR mixture consisted of: 
 50-100 ng dsDNA template 
 50 pmol of each primer 
 dNTPs at a final concentration 750 μM dNTP 
 Thermo pol buffer at 1×final concentration 
 MgSO4 to a final concentration of 2, 4 or 6 mM 
 0.5 μl (1 unit) Vent DNA polymerase 
 1 μl dimethyl sulfoxide  
The solution was made up to 100 μl final volume with chilled (on ice) distilled 
water. 
Temperature cycling was performed in a PTC-100 programmable thermal 
controller (MJ Research Inc.). The thermal cycle was: 
1. 95 °C 30 seconds 
2. 95 °C 30 seconds 
3. n °C 60 seconds  
4. 72 °C 60 seconds per kb of expected product 
5. Repeat steps 2-4 24 times 
6. 72 °C 5 minutes 
n = 5 °C below primer Tm. 
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The reaction mixture was stored until use at 4 °C or frozen at -20 °C until 
required. 
See Appendix – Section 7.2 for a full list of primers used.  
2.2.4 Site directed mutagenesis 
Small additions, deletions and mutations were carried out using a QuikChange 
Site-Directed Mutagenesis Kit (Agilent Technology, USA) according to the 
manufacturer’s instructions with the exception that DpnI digests were carried 
out overnight rather than for 1 hour as instructed. Primers were designed using 
QuikChange primer design software available at: 
https://www.genomics.agilent.com/primerDesignProgram.jsp.  
2.2.5 Plasmid DNA preparation 
Small scale plasmid preparation (to obtain approximately 3 μg in 28 μl buffer) 
was carried out using a QIAprep Spin Miniprep Kit (Qiagen) according to the 
manufacturer’s instructions with the following modification. DNA was eluted 
with 30 μl elution buffer; the eluate was then added back into the column and 
eluted again. 
Large scale plasmid preparation (to obtain approximately 200 μg in 1 ml 
buffer) was carried out by use of a HiSpeed Plasmid Midi Kit (Qiagen) 
according to manufacturer’s instructions. Eluted DNA was then concentrated 
by use of a QIAquick Gel Extraction Kit (Qiagen) with the omission of the steps 
involved in dissolving the agarose gel. 
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2.2.6 Preparation of competent cells 
A 10 ml overnight culture of desired strain was grown in LB medium from a 
single colony with the appropriate antibiotics. This was inoculated (1:20) into 
100 mL LB and grown at 37 C until the OD600 was 0.40–0.45. 
Cells were harvested in sterile 50 ml FalconTM tubes (4000 rpm, 4 C for 
10min, taking care that the Beckman Coulter JS 5.3 rotor was pre-chilled) then 
the pellet gently resuspended in 10mL of sterile, pre-chilled 100 mM CaCl2. 
They were then incubated on ice for 10 min and centrifuged as before. The 
pellet was resuspended in 2 mL of 100 mM CaCl2, 30% (v/v) glycerol then 
divided into 100 L aliquots in micro-centrifuge tubes resting on dry ice and 
allowed to freeze. The aliquots were then stored at -80 °C until use.  
2.2.7 Transformation 
Transformations of commercial competent cells with plasmid DNA were 
carried out according to the manufacturer’s instructions.  
Transformation of laboratory stocks of competent cells was by addition of 2 μl 
DNA at a concentration of 1ng/μl to 50 μl competent cells freshly thawed on 
ice, in a sterile 14 ml polypopyline transformation tube (Starlab, UK). The cells 
were then incubated on ice for 30 minutes with occasional gentle mixing. The 
cells were heat shocked in a water bath at 42 °C for 30 seconds before being 
incubated on ice for a further 5 minutes. 500 μl sterile LB was then added to 
the transformation tube and incubated at 37 °C in an orbital incubator at 200 
rpm. Cells were then spread onto two selective agar plates, (100 μl on one 
plate and 450 μl on a second plate) and the agar was allowed to dry before 
inversion and incubation overnight at 37 °C. 
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2.2.8 Restriction digests 
Restriction digests were performed using NEB restriction enzymes according 
to the manufacturer’s instructions. The optimal buffer composition for double 
digests were calculated according to the NEB double digest finder.134 Typical 
digests contained 1μg of DNA.  
2.2.9 Ligation of cassettes into vector 
Vector plasmids were digested with the appropriate restriction enzymes. 
Phosphate groups were removed from 5’ overhangs by use of Antarctic 
Phosphatase according to the manufacturer’s instructions. After inactivation 
of the phosphatase (5 minutes at 70 °C) the DNA was then separated by 
electrophoresis on a 1.5% (w/v) agarose gel and the correct band was excised 
with a scalpel and the DNA purified using a QIAquick Gel Extraction Kit 
according to the manufacturer’s instructions.  
Inserts were prepared in the same way as the vector but the 
dephosphorylation step was omitted. 
Ligation was carried out by using Quick Ligase according to the 
manufacturer’s instructions (50 ng template DNA with a 3 fold molar excess of 
insert) and the ligation mixture (5 ng in a 2 μl volume) transformed into the 
appropriate competent cells. 
2.2.10 Polyglutamine preparation 
PolyQ tracts were prepared by the use of terminator and elongator DNA 
fragments as described in section 4.3.1. Each fragment was made from two 
complimentary oligomers with 5’ and 3’ overhangs that were complementary 
to upstream or downstream cassettes (Appendix – Section 7.2.1). 
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The oligomers were phosphorylated by use of T4 polynucleotide kinase 
according to the manufacturer’s instructions. Each pair of oligomers required 
to make the duplex terminators and elongators were mixed together in a 1:1 
ratio and 3 M NaCl was added to a final concentration of 100 mM. The 
terminators and elongators were then annealed by heating to 95 °C then 
cooling to 25 °C at 1 °C per minute. 
Ligation was performed by mixing terminators and elongators in a 1:10 ratio 
to a total mass of 2 μg DNA. 10 μl of 10× T4 ligase buffer and 5 μl T4 DNA 
ligase was added and the solution made up to 100 μl with distilled water. The 
mixture was incubated at 15 °C for 3 hours then 12 °C for 15 hours. A control 
was prepared in the same way but the T4 DNA ligase was replaced with 
distilled water. 
Small unligated DNA fragments and enzymes were removed from the mixture 
by use of a QIAquick Gel Extraction Kit (Qiagen) following the manufacturer’s 
instructions. 
2.2.11 Blunt-ended ligation 
The purified polyQ ligation mixture was blunt-end ligated into a pGEM-T 
plasmid by use of a pGEM-T Vector system. Briefly, the mixture was “A-tailed” 
and ligated into the plasmid as per the manufacturer’s instructions then 
transformed into E. coli SURE 2 super-competent cells. The transformed cells 
were plated onto blue-white colour screening plates (Section 2.2.1) and grown 
overnight. 
White colonies containing the insert were selected and inoculated into 5 ml LB 
with 100 μg/ml ampicillin using a sterile wire loop and grown overnight at 37 °C 
95 
with shaking at 200 rpm. The presence of an insert was confirmed by a 
restriction digest and the DNA was sequenced (Sections 2.2.5 and 2.2.8). 
2.2.12 λO-Arc  
DNA encoding λO-Arc was created synthetically using a commercial supplier 
(MWG Eurofins). To design the sequence to be ordered the E. coli arc 
repressor protein sequence [Escherichia coli P0299483.3] was obtained from 
the NCBI protein database adding the protein sequence for the λO 
degradation tag to the N-terminus and a hexahistidine tag to the C-terminus. 
The sequence was then reverse translated to optimise E. coli codon usage 
using the reverse translation tool at 
http://www.bioinformatics.org/sms2/rev_trans.html adding restriction sites to 
the obtained DNA sequence  5’ XhoI and 3’ NdeI. The sequence was then 
ordered form MWG Eurofins and a restriction digest and ligation used 
(Sections 2.2.8 and 2.2.9) to transfer the gene into a pET23a plasmid for 
expression.   
2.2.13 λO-E9 
A plasmid containing a variant of the colicin domain of E9 (TEV-(T1-16)-E9) 
was obtained (a gift from C. Kleanthous, University of York). PCR 
(Section 2.2.3) was used to add the λO sequence (MTNTAKILNFGR) to the 5’ 
end to produce λO-(T1-16)-TEV-E9. this is referred to as 
pET23λO-(T1-16)-TEV-E9. This was then ligated into a pET-derived plasmid 
for transformation and expression (Section 2.2.9), this is referred to as 
pET23λO-(T1-16)-TEV-E9..   
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 Plasmid source summary  
Table 2.2: Plasmids used in this thesis and their sources 
Plasmid Protein Source Notes 
pET23His6-ClpX ClpX with N terminal His tag Gift of J.Pullen (Brockwell Group) 
 
pET23ClpXΔRKH ClpX with N terminal His tag and R228A, K229A, and H230A mutations 
New See Appendix: Figure 7.1 for plasmid map 
pET23ClpXΔRKH-TC ClpX with a thrombin cleavable  N terminal His tag and R228A, K229A, and H230A mutations 
New See Appendix: Figure 7.2 for plasmid map 
pAYCΔNClpX6-His6 ClpX psuedohexamer with deleted N-terminal domain 
Gift of R.T.Sauer group135 
 
pET23ClpP ClpP Gift of J. Pullen (Brockwell Group) 
 
pET23-His6ClpP ClpP with N-terminal His tag Gift of J. Pullen (Brockwell Group) 
 
pET23λOARC-His6 Arc repressor with N terminal λO sequence and C-terminal His Tag 
New See Appendix: Figure 7.3 for plasmid map 
pET23λO-(T1-16)-E9 λO-(T1-16)-E9 colicin domain New See Appendix: Figure 7.4 for plasmid map 
pET23His6-I27-ssrA I273-ssrA concatamer with N-terminal His tag New See Appendix: Figure 7.5 for plasmid map 
pET23His6-Q30-ssrA I27-Q30-(I27)2-ssrA concatamer with N-terminal His tag 
New See Appendix: Figure 7.6 for plasmid map 
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 Protein preparation  
2.4.1 Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
Gel electrophoresis was routinely used to monitor over-expression and 
purification of proteins as well as protein quantification in degradation assays. 
Tris-tricine buffered SDS-PAGE gels were used for this purpose, using a two-
layered system consisting of a stacking gel and a resolving gel.   
Two glass plates (Atto mini-gel kit) separated by a 1.5 mm spacer were 
assembled, according to the manufacturer’s recommendations.   
The resolving gel mixture (Table 2.3) was made and rapidly poured to within 
2 cm of the top of the glass plates. The stacking gel mixture was then mixed 
and poured on top of the resolving gel and a comb inserted to create sample 
wells. Anode buffer (200 mM Tris-HCl pH 8.9) and cathode buffer (1×Tris-
tricine SDS electrophoresis buffer) were added to the gel tank. The samples 
were diluted two-fold in 2× loading buffer (50 mM Tris-HCl pH 6.8, 100 mM 
DTT, 2% (w/v) SDS, 0.1% (w/v) bromophenol blue, 10% (v/v) glycerol) and 
boiled for a minimum of 2 minutes before loading onto the gel. 15  µl Invitrogen 
Mark 12 unstained standard molecular mass markers were loaded into one 
lane to aid identification of protein bands. The gels were electrophoresed at a 
constant current of 30 mA until the sample entered the resolving gel when 
the current was then adjusted to 60 mA.  Gels were rinsed with distilled water 
then stained in Instant Blue (Expedeon)for one hour before being rinsed again. 
The gel was visualised using a light box and an image of the gel acquired 
using Gene Snap (Synoptics Ltd).  
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Table 2.3: Components of Tris-tricine buffered SDS-PAGE gels. The volumes indicated are 
sufficient for casting two 8 cm × 10 cm mini gels using a 1.5 mm spacer. 
Solution component Resolving gel 
Volume to add (ml) 
Stacking gel 
Volume to add (ml) 
30% (w/v) Acrylamide:0.8% (w/v) 
bis-acrylamide 
7.51 0.83 
H2O 0.44 3.72 
3 M Tris, 0.3% (w/v) SDS pH 8.45 5 1.55 
Glycerol 2 - 
10% (w/v) ammonium persulphate 0.1 0.2 
N,N,N’,N’-tetramethyl-
ethylenediamine (TEMED) 
0.01 0.01 
                                            
1 For ΔNClpX6 3.75 ml acrylamide and 4.19 ml H2O were used. 
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 Over-expression 
2.5.1 Expression trial 
After transformation E. coli with of a plasmid harbouring the appropriate gene 
each of four colonies were used to inoculate 5 ml of LB growth medium 
containing appropriate selection antibiotics. The culture was shaken overnight 
at 200 rpm and 37 C. 500 µl of these cultures were mixed with 500 μl sterile 
30% glycerol (v/v) and frozen at -20 °C. 1 ml of each overnight culture was 
used to inoculate 50 ml of LB medium under the same antibiotic selection.  
These flasks were shaken at 200 rpm and 37 C until an OD600 of ~0.6 was 
attained. Protein expression was induced for three of the four cultures with 
filter sterilised IPTG at a final concentration of 1 mM for 4 h. 1 ml of culture 
was then removed and centrifuged for 1 min at 16,300 RCF using a bench-top 
centrifuge (Spectrafuge 24D Labnet international Inc.). The supernatant was 
discarded and the cell pellets were stored at -20 C until required. For ΔNClpX6 
the same procedure was followed except that incubation was at 18 °C. 
2.5.2 Sample analysis by  SDS-PAGE 
E. coli cell pellets were resuspended in 500 μl of 15 mM Tris-HCl pH 7.0 buffer 
containing lysozyme (1 mg/ml), RNAse (0.1 mg/ml) and DNAse (0.1 mg/ml 
and left at room temperature for 20 minutes. A 50 µl sample was removed and 
added to 50 µl of 2× loading buffer (50 mM sodium phosphate pH 6.8, 100 mM 
DTT, 2% (w/v) SDS, 0.1% (w/v) bromophenol blue, 10 % (v/v) glycerol). The 
remaining sample was then centrifuged for 5 minutes, 16,300 RCF in a bench-
top centrifuge. The supernatant was then mixed with an equal volume of 2× 
loading buffer and the pellet was re-suspended in 450 µl of 15mM Tris-HCl pH 
100 
7.0 and mixed with an equal volume of 2× loading buffer. The samples were 
boiled for 5 minutes. 15μl aliquots were loaded on to an SDS-PAGE gel. 
2.5.3 Large scale over-expression 
A starter culture of 200 ml LB with appropriate selection antibiotics was 
inoculated by a sterile wire loop from the glycerol stock of the best expressing 
transformant taken during the expression trial. The culture was incubated 
overnight at 37 °C shaking at 200 rpm. 10 × 1 l LB with appropriate selection 
antibiotics was then was inoculated with 20 ml of the starter. This was 
incubated (37 °C, 200 rpm) until an OD600 ≈ 0.6 was reached, when expression 
was induced by addition of IPTG to a final concentration of 1 mm. After 4 
hours, cells were harvested in a Heraeus Contrifuge at 15,000 rpm (Rotor 
8575) at 4 °C. Cell pellets were frozen at – 20 °C until required. The procedure 
for ΔNClpX6 was the same except that cells were incubated at 18 °C.  
2.5.4 Auto-induction 
Stock solutions (Tables 2.4 - 2.7) were autoclaved separately at 120 °C and 
121 psi for 20 min. Trace elements (Table 2.7) were filter-sterilised through a 
0.22 μm filter. 2ZYM – 1×LAC expression medium was prepared by addition 
of 50× LAC, 20× NPSC and trace elements to a 2.5 l sterile baffled conical 
flask containing 2 ZY as described in Table 2.8.  
Cultures were grown in for 24 hours after inoculation with 10 ml from an 
overnight starter culture grown in LB medium.  Cells were then harvested as 
described in Section 2.5.3. 
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Table 2.4: Components of 2 ZY solution (per 465 ml) 
Yeast extract  5 g 
Bactotryptone  10 g 
 
 
Table 2.5: Components of 50× LAC solution (per 50 ml) 
Glycerol  12.5 g 
Glucose  1.25 g 
α-Lactose  5.00 g 
 
 
Table 2.6: Components of 20 × NPSC solution (per 50 ml) 
NH4Cl 2.675 g  1 M 
Na2SO4 1.61 g  0.1 M 
KH2PO4 3.4 g  0.5 M 
Na2HPO4 3.55 g  0.5 M 
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Table 2.7: Components of Trace elements 1000× (per 1 l) 
FeSO4.7H2O  1.0 g 
ZnSO4.7H2O  8.8 g 
CuSO4.7H2O  0.4 g 
MnSO4.4H2O  0.15 g 
Na2B4O7.10H2O  0.1 g 
(NH4)6Mo7O24.4H2O  0.05 g 
 
 
Table 2.8: Components of 2ZYM – 1× LAC media. 
2ZY solution  465 ml 
1M MgSO4  1 ml 
50 x LAC  10 ml 
20 x NPSC  25 ml 
Trace Elements  500 μl 
103 
 Protein extraction and purification 
2.6.1 General procedures 
Before purification, cell pellets were defrosted and then re-suspended in 10 ml 
per gram of cell pellet of the buffer to be used in the first stage of purification. 
Cells were fragmented using a cell disrupter (Constant Cell Disruption 
Systems) and the debris removed by centrifugation at 12,000 rpm, 4 °C, 30 
minutes (rotor JLA 16.250, Beckman Coulter). The cleared lysate was 
subsequently decanted and filtered through a 0.2 µm syringe filter. 
Estimated extinction coefficients for all proteins were determined using the 
online protein parameter calculator at http://web.expasy.org/protparam/. 
2.6.2 Lyophilisation 
Before lyophilisation the A280 of the protein solution was measured using a 
spectrophotometer (Ultraspec 2100 pro, Amersham Biosciences). Protein  
concentration was calculated using Equation 2.1: 
ܿ݋݊ܿ݁݊ݐݎܽݐ݅݋݊  ܾܽݏ݋ݎܾܽ݊ܿ݁݁ݔݐ݅݊ܿݐ݅݋݊ ܿ݋݂݂݁݅ܿ݅݁݊ݐ ×  ݌ܽݐ݄ ݈݁݊݃ݐ݄ 
Equation 2.1: The Beer-Lambert equation 
 
The volume of protein required in each aliquot was determined by using 
Equation 2.2. 
ݒ݋݈ݑ݉݁ = ܽ݉݋ݑ݊ݐ ݋݂ ݌ݎ݋ݐ݁݅݊ ݎ݁ݍݑ݅ݎ݁݀ܿ݋݊ܿ݁݊ݐݎܽݐ݅݋݊  
Equation 2.2: Used to determine the volume of liquid required for a given amount of protein when the concentration is known. 
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The protein was divided into aliquots (typically 10 × 0.5 or 1 mg with the 
remainder of 5 or 10 mg) and placed in either a 1.5 ml micro-centrifuge tube 
or a 50 ml FalconTM tube. The protein solution was then frozen by immersing 
the sealed container in a bath of ethanol containing dry ice. Once the solution 
was frozen the lid was replaced with one which had been pierced to allow 
evaporation and the protein placed in a lyophiliser (PowderDry PL3000, Heto). 
Once all the liquid was removed the pierced lid was replaced with the original 
lid and the protein stored at -20 °C until required. 
2.6.3 ClpP purification 
ClpP over-expression was achieved from a pET23 derived plasmid conferring 
ampicillin resistance transformed into E. coli BL21 [DE3].  
All steps were carried out on ice using chilled buffers. The cell pellet of a large 
scale culture of E. coli BL21 [DE3] pET23aClpP (Section 2.5.3) was lysed in 
Ni Sepharose wash buffer (50 mM Tris-HCl pH 7.6. 500 mM NaCl, 
10% Glycerol (v/v), 20 mM imidazole) and the lysate clarified and filtered as 
described in Section 2.6.1. The filtered lysate was made up to 100 ml with 
Ni Sepharose wash buffer. 
Beads of Ni Sepharose High Performance (GE Healthcare, Sweden) were re-
suspended by gentle shaking and 0.5 ml was added to each of 4 50 ml 
FalconTM tubes. The beads were equilibrated by adding 25 ml  Ni Sepharose 
wash buffer,  mixing thoroughly (roller mixer SRT6, Stuart) and centrifuged for 
5 minutes, 4,000 rpm, 4 °C (rotor Beckman Coulter JS 5.3). The supernatant 
was discarded and the procedure repeated. The filtered lysate was then added 
105 
to the beads and incubated for 20 minutes. 4 wash steps were carried out in 
Ni Sepharose wash buffer by sequential re-suspension and centrifugation 
steps as described above. Three further washes were carried out at increasing 
imidazole concentrations (100, 150 and 200 mM). Two elutions were carried 
out by resuspending the beads in  50 ml elution buffer (as wash buffer but with 
500 mM imidazole) and centrifuging as before. The supernatant was retained 
and the two elutions were pooled. Samples were retained from each step to 
determine purity and the eluted sample was dialysed (3,500 MWCO tubing) 
into ClpXP storage buffer (25 mM HEPES pH 7.6, 15% (v/v) glycerol, 200 mM 
KCl and 2 mM EDTA) with stirring and two buffer changes allowing a minimum 
of three hours between buffer changes. The dialysed sample was then 
concentrated using Vivaspin 20 ultrafiltration spin columns to a concentration 
between 5-20 μM of ClpP14 (tetradecameric ClpP has an estimated 
ε280 = 109,200 M-1 cm-1). ClpP was aliquoted into 50 µl samples, snap frozen 
in liquid nitrogen and stored at -80 °C until required.  
2.6.4 ClpX purification 
ClpX over-expression was achieved from a pET23 derived plasmid conferring 
ampicillin resistance transformed into E. coli BL21 [DE3] pLysS, except 
ΔNClpX6, which is in a pACYC derivative plasmid which confers 
chloramphenicol resistance (J. Davis, personal communication) and is 
transformed into E. coli BLR [DE3].  
Purification of all ClpX variants was the same as for hexahistidine tagged ClpP 
(Section 2.6.3) except that the intermediate wash steps at 100, 150 and 
200 mM imidazole were omitted. Additionally, before concentration the sample 
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was subjected to size exclusion chromatography using a Sephacryl S300 HR 
16/60 column (G.E. Healthcare, Sweden,120 ml bed volume) attached to an 
ÄKTA prime chromatography system. After equilibration of the column with 2 
column volumes of ClpXP storage buffer, 5 ml volumes of the sample were 
injected into the loading loop using a syringe and after injection onto the 
column the sample was eluted with 350 ml ClpXP storage buffer at a flow rate 
of 0.5 ml/minute. Fractions showing increased A280 values were collected and 
analysed by SDS-PAGE and fractions containing ClpX were pooled and 
concentrated by Vivaspin 20 ultrafiltration spin columns to a concentration 
between 5-20 μM (ClpX6). ClpX6 variants and ΔNClpX6 have an estimated 
ε280 = 82,700 M-1 cm-1). ClpX was aliquoted into 50 μl volumes, snap frozen in 
liquid nitrogen and stored at -80 °C until required.  
2.6.5 Thrombin cleavage 
Thrombin cleavage was carried out using a Thrombin Clean-Cleave Kit 
(Sigma). 100 μl thrombin resin was equilibrated with ClpXP storage buffer by 
first pelleting the thrombin beads by centrifugation at 4,000 rpm for 5 minutes 
at 4 °C (rotor Beckman Coulter JS 5.3). After removing the supernatant the 
resin was re-suspended by adding 10× its volume of ClpXP storage buffer. 
This procedure was then repeated. The beads were then re-suspended with 
an equal volume of ClpXP storage buffer and ClpX with a thrombin-cleavable 
His tag was then added and incubated for 4 hours at room temperature with 
shaking. A 15 μl aliquot was taken every hour for analysis by SDS-PAGE. The 
beads were chilled to 4 °C and incubated for a further 18 hours. Once the time 
taken for complete cleavage of the thrombin tag was optimised, the procedure 
was scaled up to use 1ml of thrombin beads with a larger amount of ClpX (1 ml 
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of ~10μM ClpX6). The cleaved ClpX was recovered by washing the beads 
twice with ClpXP storage buffer. This solution then had imidazole added to a 
concentration of 20 mM and was added to Ni Sepharose beads equilibrated 
with the same solution. The Ni Sepharose beads were then centrifuged as 
above and the supernatant containing the ClpX was recovered and stored as 
described above.  
Both the Thrombin and Ni Sepharose beads were washed and regenerated 
as per the manufacturer’s instructions for re-use.   
2.6.6 λO-Arc purification 
λO-Arc over-expression is achieved from a pET23 derived plasmid conferring 
ampicillin resistance transformed into E. coli BL21 [DE3] pLysS.   
λO-Arc was expressed and purified in the same way as ClpX (Sections 2.5.3 
and 2.6.4, respectively) except that the buffers used for Ni Sepharose 
purification were 25 mM Tris, 500 mM NaCl, 20 mM imidazole at pH 7.6 for 
binding and the elution buffer contained 500 mM imidazole. Gel filtration was 
carried out using 25 mM Tris, 500 mM NaCl, at pH 7.6 using a HiLoad 26/60 
Superdex 75 prep grade column (120 ml bed volume).   
2.6.7  λO-(T1-16)-TEV-E9 purification 
λO-(T1-16)-TEV-E9 over-expression is achieved from a pET23 derived 
plasmid conferring ampicillin resistance transformed into E. coli BL21 [DE3] 
pLysS. 
λO-(T1-16)-TEV-E9 is co-expressed with a hexa-histidine tagged variant of 
E9’s cognate immunity protein (Im9) to which it binds very tightly19 
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(Kd = 10-16 M). Both proteins are encoded on the same pET derived plasmid, 
conferring ampicillin resistance, from the same T7 promoter.  
As the E9:Im9 complex is extremely avid, when Im9 is purified by affinity 
chromatography, λO-(T1-16)-TEV-E9 will be co-purified with it. The complex 
is left bound to the Ni Sepharose and the proteins can then be separated by 
denaturing them with guanidine hydrochloride. This denatures and dissociates 
the λO-(T1-16)-TEV-E9:Im9 complex, eluting the λO-(T1-16)-TEV-E9 while 
leaving the Im9 bound to the resin.  
λO-(T1-16)-TEV-E9 was purified by nickel affinity using Ni Sepharose beads 
in an XK26 column (with a bed volume of 35 ml) on an ÄKTA prime purification 
system.  
Three buffers were used for the affinity chromatography:  
Binding buffer: 25 mM Tris, 200 mM NaCl, 20 mM imidazole pH 8.0. Elution 
buffer: binding buffer with the addition of 6 M guanidine hydrochloride. Wash 
buffer: binding buffer with the addition of 500 mM imidazole.   
The cells were lysed after being re-suspended in binding buffer (Section 2.6.3) 
and the cleared lysate was loaded on to the Ni Sepharose column 
pre-equilibrated with binding buffer. The column was then washed with binding 
buffer until no changes in the A280 of the eluant were detected. The 
λO-(T1-16)-TEV-E9 was dissociated from the His-tagged Im9 by addition of 
denaturing elution buffer and eluted; collecting fractions that contained 
λO-(T1-16)-TEV-E9. The Im9 was eluted from the column with wash buffer 
and discarded.  
The fractions containing λO-(T1-16)-TEV-E9 were dialysed overnight into gel 
filtration buffer (25 mM Tris, 100 mM NaCl, pH 8.0) before further purification 
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using a Superdex S75 column (G.E. Healthcare, Sweden, 120 ml bed 
volume). Fractions containing λO-(T1-16)-TEV-E9 were then dialysed (3,500 
MWCO dialysis tubing) into distilled water with stirring and two buffer changes, 
allowing a minimum of three hours between buffer changes. The protein was 
then lyophilised as described in Section 2.6.2.   
2.6.8 I273-ssrA and I27-Q30-(I27)2-ssrA purification 
I27 concatamer over-expression is achieved from a pET23 derived plasmid 
conferring ampicillin resistance transformed into E. coli BL21 [DE3] pLysS. 
Cells were re-suspended in lysis buffer (25 mM Tris-HCl pH8.0, 2 mM DTT), 
and lysed as described in Section 2.6.1. The cleared lysate was made up to 
100 ml with lysis buffer and an ammonium sulphate precipitation procedure 
was performed. Briefly, the lysate was placed in a beaker on ice and powdered 
ammonium sulphate was added stepwise with constant stirring. The mass of 
ammonium sulphate to be added at each step was determined from Table 
20.1 of Burgess, 2009136. 
Ammonium sulphate was added to 20% saturation (106 g/l), then insoluble 
material removed by centrifugation at 15,000 rpm, 0 °C for 10 minutes (rotor 
JLA 25.50 Beckman Coulter). The insoluble pellet was re-dissolved in lysis 
buffer and a sample taken for analysis by SDS-PAGE, the volume of the 
supernatant was measured and further ammonium sulphate added in intervals 
of 10% saturation until 80% saturation was achieved, with centrifugation at 
each stage as described. After analysis by SDS-PAGE, samples containing 
significant amounts of the concatamer were pooled and dialysed against 
distilled water before lyophilisation (Sections 2.6.6 and 2.6.2 respectively). 
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Lyophilised protein was then re-dissolved in buffer A (25 mM Tris-HCl pH 8.0, 
2 mM DTT, 1 mM EDTA). A 5ml Q anion exchange column on an ÄKTA prime 
purification system was equilibrated with two column volumes of buffer A 
before addition of 2 ml protein, via the injection loop and washing with a further 
two column volumes of buffer A. The concentration of buffer B (as buffer A 
with the addition of 1 M NaCl) was adjusted to 30% and the column washed 
with a further two column volumes. A gradient of 30-70% buffer B was then 
applied over ten column volumes before 100% buffer B was used for a further 
two column volumes. The fractions showing an increase in A280 were analysed 
by SDS-PAGE and fractions containing the protein were pooled, dialysed 
against distilled water and lyophilised as described above.  
Lyophilised protein was re-dissolved in gel filtration buffer (25 mM Tris-HCl pH 
8.0, 2 mM DTT, 1 mM EDTA and 200 mM NaCl). A Superdex 75 prep grade 
HiLoad 26/60 gel filtration column, 318 ml bed volume (G.E. Healthcare, 
Sweden)  attached to an ÄKTA prime purification system was equilibrated with 
1.5 column volumes of gel filtration buffer before addition of 5 ml protein via 
the injection loop and elution with gel filtration buffer. The fractions showing 
an increase in A280 were analysed by SDS-PAGE and those containing the 
pure concatamer were dialysed against distilled water and lyophilised as 
described above.  
I27 constructs with a hexahistidine affinity tag were purified in the same way 
except that the ammonium sulphate precipitation was replaced with nickel 
affinity purification as described for ClpX (section 2.6.4). 
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 Protein source summary  
Table 2.9: The proteins used in this thesis, their source and abbreviation used. 
Protein Abbreviation Source 
ClpX with N terminal His tag ClpX New protocol 
ClpX with N terminal His tag and R228A, K229A, and H230A mutations 
ClpXΔRKH New Protocol 
ClpX with a thrombin cleavable  N terminal His tag and R228A, K229A, and H230A mutations 
Thrombin cleaved ClpXΔRKH  New Protocol 
ClpX psuedohexamer with deleted N-terminal domain 
ΔNClpX6 New Protocol 
ClpP ClpP New Protocol 
ClpP with N-terminal His tag His6-ClpP New Protocol 
Im9 with N-terminal His tag and C-terminal ssrA tag Im9-ssrA Gift (J.Pullen, Brockwell group, Leeds) 
Creatine phosphokinase  Purchased (Sigma) 
Beta-2-microglobulin β2M Gift (G.N.Khan, Radford group, Leeds) 
Myoglobin  Purchased (Sigma) 
Arc repressor with N terminal λO sequence and C-terminal His tag 
λO-Arc New Protocol 
λO-(T1-16)-E9 colicin domain-His6 E9 Modified existing Protocol provided by C. Kleanthus Group 
His6-I273-ssrA (I27)3 New Protocol 
His6-I27-Q30-I27-ssrA Q30 New Protocol 
His6-(I27)5 (I27)5 Gift (O.Farrance, Brockwell group, Leeds) 
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 Degradation assay 
The degradation assay was performed at 30 °C in a reaction mixture 
containing 200 nM ClpX6, 600 nM ClpP14, 5 mM ATP, 16 mM creatine 
phosphate, 0.032 mg/ml creatine phosphokinase, 25 mM Tris-HCl pH 7.6, 
10 mM MgCl2, 200 mM KCl, 10% glycerol (v/v) and 1 mM DTT. A typical 
reaction volume was 200 μl. 
Immediately before the degradation assay, aliquots of ClpX, ClpP, ATP and 
10× reaction buffer (containing creatine phosphate, creatine phosphokinase, 
Tris-HCl pH 7.6, MgCl2, KCl, and DTT) were removed from the freezer, thawed 
on ice, added to glycerol and mixed. A control was carried out in which the 
ATP was replaced with distilled water. 
Lyophilised substrate protein was dissolved in distilled water and centrifuged 
in a bench-top centrifuge for 5 minutes at 16,300 RCF to remove insoluble 
aggregates. The reaction mixture and substrate were then pre-incubated 
separately at 30 °C for 5 minutes. The substrate protein was added 
(concentrations varied but were typically 10 mM) and a sample taken 
immediately (time = 0). ClpXP-catalysed degradation in this and subsequent  
samples were quenched immediately by addition to an equal volume of 
quenching/loading buffer (50 mM Tris-HCl pH 6.8, 100 mM DTT, 2% (w/v) 
SDS, 0.1% (w/v) bromophenol blue, 30 mM EDTA) and mixed thoroughly. 
Further samples were taken at various time points throughout the experiment. 
The samples were then analysed by SDS-PAGE running each sample in 
duplicate to reduce the impact of pipetting errors during analysis. The rate of 
degradation was quantified by densitometry as described in Section 2.8.1.  
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2.8.1 Densitometry 
Degradation assays were quantified through the use of densitometry. Images 
of the SDS-PAGE gels were taken using an IN-Genious SynGene Bio Imaging 
(Synoptics Ltd.) gel documentation system with the following settings: shutter 
speed 40 ms,  focal length 25 mm, aperture 12, with the focus set half way 
between 5 m and ∞.  
Gene Tools software (Synoptics Ltd.) was used to analyse the gels. The band 
for undigested substrate protein was selected in each lane along with a  band 
of constant intensity (usually ClpP). The software then converted these bands 
to a line graph showing each band as a peak on the graph. Care was taken to 
ensure that the area of the peak selected was applied consistently across the 
gel. Figure 2.1 illustrates how this was achieved. Both the reference band and 
band of interest were selected in each lane. The software was allowed to pick 
the bands itself to ensure consistency and they were only adjusted in cases 
where it had clearly made an error in picking the bands. Examples of errors 
encountered are: identifying two proximal bands as a single band (Figure 
2.1B) and picking only half of a band (Figure 2.1C).  Bands which had been 
badly selected by the software were manually adjusted to be consistent with 
the picking of the other bands. The picked bands were then analysed to obtain 
the total peak volume which accounts for the density and area of the band. As 
the reference band contained the same amount of protein in each sample and 
should vary only due to loading errors it was possible to obtain a corrected 
value for the peak of interest in each lane (VC) by taking the apparent peak 
area (VA) and using the ratio of the peak area of the invariant band in the first 
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lane (generally time = 0) (I0) and the peak area of the invariant band for that 
lane (IT) using Equation 2.3.  
஼ܸ = ஺ܸ × ܫ଴ܫ் 
Equation 2.3: Used to calculate the corrected values for densitometry data 
In the example in Figure 2.1 VA is the value obtained for the band of interest 
in lane 2,  I0 is the value obtained for the reference band in lane 1 and IT is the 
value obtained for the reference band in lane 2. This normalises the apparent 
peak area of the band of interest in lane 2 with respect to the band of interest 
in lane 1, correcting for any loading errors or differential staining of the gel.  
This was applied to each band of interest to obtain corrected values which 
could then be analysed.      
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Figure 2.1: Screen capture of a portion of the Gene Tools software demonstrating densitometry analysis of the bands. A: typical example of a gel with well picked bands. B: an example of a badly picked band, the lower band covers too large an area, C: an example of a badly picked band, the lower band covers too small an area.  
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 Force spectroscopy 
2.9.1 Atomic force microscopy slide preparation 
Glass microscope slides (76 × 26 mm) were cut into 10 × 10 mm squares 
using a glass cutter. The glass squares were stuck onto a gold coated (100 Å 
thickness) silicon wafer (Platypus Technologies) with a small drop of Epo-Tek 
377 2 part epoxy resin, taking care not to trap any air bubbles and leaving a 
minimum 0.5 mm border between the glass squares (Figure 2.2A). The silicon 
wafer was then heated to 120 °C for one hour to allow the glue to cure. 
Immediately before use, a glass square was removed from the wafer with a 
scalpel and attached to a larger glass microscope slide using vacuum grease 
(Figure 2.2B). 
2.9.2 Sample preparation 
The lyophilised protein prepared as described in Section 2.6.8 was dissolved 
in Phosphate Buffered Saline (Dulbecco A), to a concentration of 1 mg/ml then 
centrifuged in a bench-top centrifuge (16,300 RCF for 10 minutes) to remove 
any insoluble residue before being added to the gold microscope slide. 
2.9.3 Atomic force microscopy 
AFM was carried out on an MFP-3D-SA (Asylum Research) atomic force 
microscope using silicon nitride MLCT contact probes. Typically cantilever D 
was used with a nominal spring constant of 30 pN/nm.  
50 μl of solution containing ~1 mg/ml protein was placed on a freshly template-
stripped gold covered glass square. The tip was lowered until the meniscus of 
the protein solution covered the tip. The laser was then focussed onto the 
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cantilever and adjusted to give a good signal indicating the reflected beam 
was centred on the photodetector. The deflection sensitivity of the cantilever 
was calibrated by engaging the tip and running a single approach-retract cycle 
then setting the virtual deflection line and the inverse optical lever sensitivity. 
The spring constant was calibrated using the thermal method137; the tip was 
retracted so it was no longer in contact with the surface, but was within the 
protein solution and the MFP-3D software thermal tune function was used to 
obtain a resonance curve for the cantilever. The thermal tune function 
continually samples the resonance curve and calculates an average over time. 
This was allowed to run until the resonance curve shown was no longer 
changing. (1-2 minutes) obtaining a curve as shown in Figure 2.3. Fitting to 
the first resonance curve provided the spring constant for the cantilever. The 
tip was then re-engaged and data collection started. A pull distance of 1 μm 
was used and a balance between mostly single molecule events and a 
reasonable data collection rate was achieved by altering the contact force and 
surface dwell time. Approximately one valid event per ten approach-retract 
cycles with a total of 1,000 cycles was typically achieved. 
2.9.4 Data analysis 
The data was analysed using the MFP-3D software; a worm like chain37 fitting 
tool is used to determine the contour length of the chain at each unfolding 
event using Equation 1.1. F, T, kB and x are either constants or are known 
from the data and Lp is assumed to be 0.4 nm. The difference in Lc between 
successive events is used to calculate the unfolding length, which is related to 
the polypeptide length, and the unfolding force can be determined from the 
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heights of the peaks.  The expected unfolding length of I27 was not calculated 
but a value of 28.1 nm from the literature was used.138  
 
119 
 
 
Figure 2.2: Cartoon demonstrating the method of producing gold coated AFM slides. A: the glass squares are attached to the gold coated wafer with epoxy resin. B: The squares are removed from the wafer bringing the freshly exposed gold which was previously attached to the wafer with them, these squares are then attached to a microscope slide with vacuum grease.  
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Figure 2.3: Screen capture of thermal tune function showing an acceptable resonance curve (black) and the fit to the 1st peak (blue).  
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 Biophysical characterisation 
2.10.1 Sedimentation velocity analytical ultracentrifugation  
A 0.32 mL sample was centrifuged in a 1.2 cm path-length 2-sector epon 
centrepiece cell built with sapphire windows using an 8-place An50 Ti 
analytical rotor running in an Optima XL-I analytical ultracentrifuge (Beckman 
Instruments, Inc., Palo Alto, California 94304) at 48,000 rpm and at a 
temperature of 20.0˚C. Changes in solute concentration were detected by 
Interference optics and absorbance scans at 280nm. A total of 100 scans per 
cell were collected for ~10 hours. 
Sedimentation analysis was performed with the program Sedfit139. Buffer 
densities and viscosities were calculated using the program Sednterp140. 
All sedimentation AUC was carried out by Amy M. Barker. 
2.10.2  Fluorescence emission spectra 
Fluorescence emission spectra were measured using a Photon Technology 
International Fluorimeter (Ford, West Sussex, UK). For spectra of native and 
denatured proteins, each protein was dissolved in buffer (10 mM Tris-SO4, 
1 mM EDTA, 42 mM K2SO4, 0.5 mM TCEP pH 7.6) containing 0 M or 8 M urea 
(protein concentration ~ 5 μM) and incubated at 30 °C for one hour. Excitation 
slit widths were set to 2 nm, emission slit widths were adjusted to give a good 
signal. Each spectrum was recorded from 290 nm to 500 nm in 1 nm 
increments, using an excitation wavelength of 280 nm. Spectra of all 
denatured states were assumed to have the same maximum intensity. The 
spectra of each native protein were normalised to the intensity of their 
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respective denatured state, allowing direct comparison of the fluorescence 
intensity between proteins. 
2.10.3 Circular dichroism spectroscopy 
Circular dichroism spectroscopy (CD) was performed using a J-715 
spectrophotometer (JASCO Corp.). Measurements were taken between 190 
and 260 nm in a 1 mm path-length cuvette. The recording parameters were: 1 
nm bandwidth, 1 nm resolution, 20 nm/min scan speed, 8 second response 
time and the average of 3 scans was taken. Spectra were measured at 30 °C. 
Observed ellipticity, after subtraction of the buffer only sample was converted 
to mean residue ellipticity by use of Equation 2.4. 
[ߠ]௠௢௟௔௥,ఒ = 100 × ߠఒ݉ × ݀  
Equation 2.4: For calculation of mean residue molar ellipticity Where: [θ]molar,λ is mean residue molar ellipticity,  θλ is the observed ellipticity (degrees), d is the path length (cm) and m is the mean residue molar concentration. 
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3 Production and testing of the ClpXP system 
 Introduction 
As described in section 1, ClpXP is a bacterial proteasome capable of 
degrading diverse protein substrates if suitably tagged. Most previous work 
reported for ClpXP has focussed on ClpXP itself; determining its structure, 
function and mechanism of action. Great progress had been made in this field 
and both ClpXP structure and function are now well understood12,47.  Although 
the precise mechanism of action and processivity are still unknown, its general 
mechanism has been elucidated12,47. In summary: In the presence of ATP, 
ClpX forms a hexameric ring. These Hexamers can then bind to one or both 
ends of a cylinder composed of two heptameric rings formed from ClpP 
monomer; the pore loops of ClpX are capable of recognising and binding a 
degradation tag; ATP hydrolysis occurs causing a conformational change in 
ClpX which drives translocation of the substrate through the central pore of 
ClpX. This applies force onto the substrate accelerating its unfolding rate; the 
unfolded peptide is then moved into the central degradation chamber of ClpP 
where it is degraded in a non-sequence-specific manner by the serine 
protease sites contained in the degradation chamber, finally the degradation 
products (short peptides) are then released by the ClpP.  
For most stable globular proteins the rate-determining step of this mechanism 
is the unfolding rate of the substrate peptide. For active degradation this can 
be assumed to be dependent on the mechanical stability of the substrate (see 
introduction). Following the rate of degradation of a folded protein by ClpXP 
by analysing the disappearance of the substrate band on an SDS-PAGE gel 
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will allow investigation of the mechanical resistance of a degradation tagged 
substrate peptide at loading rates that are inaccessible by AFM but found in 
in vivo protein degradation and other processes. 
In this chapter I will describe my attempts to develop ClpXP as a biological 
applicator of mechanical force which can be used to investigate the 
mechanical strength of a range of tagged substrate peptides.  
 Aims 
The aims of this chapter are (i) to describe the expression and purification of 
a selection of ClpX variants, ClpP and suitable substrate proteins, (ii) develop 
a robust degradation assay and (iii) investigate a variety of conditions under 
which degradation can be observed.  
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 ClpXP production 
All of the ClpX and ClpP variants used were based on the published E. coli 
ClpX/P sequence (see Appendix – Section 7.1) and inserted into plasmids 
containing the T7 promoter from the T7 bacteriophage (pET23, pET14 and 
pAYC). Overexpression was subsequently achieved by transformation of 
E. coli [DE3] which are lysogenic for λ-DE3, and contain the T7 bacteriophage 
gene I, encoding T7 RNA polymerase under the control of the lac UV5 
promoter allowing inducible expression by the addition of IPTG141.   
3.3.1 ClpX 
An array of ClpX variants was used in this work. These are summarised in 
Figure 3.1 and described in detail in Appendix – Section 7.1.1. 
3.3.1.1 His6-ClpX 
The first variant produced was His6-ClpX with an N-terminal hexahistidine 
affinity tag to facilitate purification. This had been previously studied in the 
Brockwell group and the plasmid (pET23His6-ClpX) was available in the 
laboratory.  
pET23His6-ClpX was transformed into E. coli BL21 [DE3] pLysS 
(Section 2.2.7) and a test expression was performed as described in Section 
2.5.1. Figure 3.2 shows the results from the test expressions from four single 
colonies. A band with significant density was present in both the soluble and 
insoluble fraction at the expected mass for His6-ClpX. It was decided not to 
attempt to solubilise the insoluble protein as sufficient was present in the 
soluble fraction for further purification. This obviates the requirement to find 
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suitable conditions (if any) that would allow the refolding of denatured 
His6-ClpX to an active form. 
A large scale expression was then carried out using 10 l of LB (Section 2.5.3) 
and the cells lysed (Section 2.6.1) and a batch purification using nickel affinity 
followed by size-exclusion chromatography (Section 2.6.4) was carried out. 
The final product was concentrated to 1 μM and snap frozen as shown in 
Figure 3.3. 
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Figure 3.1: schematic representation of ClpX variants used in this work. His - hexahistidine tag, TCS - thrombin cleavage site, ClpX - ClpX sequence, ΔN-ClpX - ClpX with N-terminal domain removed. 
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Figure 3.2: SDS-PAGE gel of His6-ClpX test expression. After cell lysis the soluble and non-soluble proteins were separated by centrifugation then the supernatant and resuspended pellet were analysed by SDS-PAGE. Four test expressions were analysed, labelled Sample 1-4. Fractions are labelled as follows. I: re-suspended pellet, S: supernatant. The migration distance expected for His6-ClpX is shown on the right. 
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Figure 3.3: SDS-PAGE gel showing the batch purification of His6-ClpX. The lanes marked pellet and supernatant show the fractions obtained after cell lysis and centrifugation, the resuspended pellet and the supernatant containing the soluble proteins respectively. The lanes marked wash steps show the supernatant obtained after washing the Ni sepharose beads with Ni sepharose wash buffer then centrifuging the sample to pellet the beads, numbers refer to repeated washes. The lane marked elution shows the supernatant obtained after washing the beads with elution buffer (wash buffer with the addition of 500 mM imidazole). Numbers refer to repeated washes. The lane marked SEC shows the final His6-ClpX protein obtained after size-exclusion chromatography and concentration.  
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3.3.1.2 ΔNClpX6 
In the absence of ATP the ClpX homohexamer is unstable and prone to 
dissociation and inactivation. The Sauer group (MIT) have overcome this 
limitation by constructing a pseudohexameric single chain ClpX variant with a 
C-terminal (His)6 tag (Section 1.4.1). This group had worked extensively and 
successfully with this variant.30,54,61,135.The plasmid containing ΔNClpX6, a 
pAYC derivative (pAYCΔNClpX6) was, therefore obtained from the Sauer group 
and transformed into BLR (DE3) pLysS cells and a test expression performed 
(Figure 3.4). While a band was observed which was consistent with that 
expected for ΔNClpX6 (ΔNClpX6 was too large to enter the resolving gel with a 
molecular weight of 247 kDa), it was present only in the insoluble fraction.  
A further expression trial was undertaken, where the culture was incubated at 
22 °C upon addition of IPTG. It was rationalised that such a large protein was 
vulnerable to misfolding and aggregation, and expression at lower 
temperature has been shown to minimise these effects due to the temperature 
dependence of the hydrophobic interactions (which determine the rate of 
protein aggregation), the increase in expression and activity of E. coli 
chaperones, and the reduced induction of heat shock proteases142. The lower 
temperature also slows the rate of RNA translation and so protein production 
allowing the protein more time to fold successfully as it leaves the ribosome.  
Lower temperature expression did indeed improve the soluble expression of 
ΔNClpX6 and the results of a 22 °C expression trial are shown in Figure 3.5. 
Although a large amount was also present in the insoluble fraction it was felt 
that enough was present in the soluble fraction for it to be worthwhile 
continuing with a large-scale overexpression and purification. 
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A large-scale over-expression using 10 l of LB broth with chloramphenicol 
cultured at 22 °C after induction was performed and the cells harvested and 
lysed as described in Section 2.6.1 and purified using Ni sepharose followed 
by size-exclusion chromatography carried out as described in Section 2.6.4. 
This initial purification protocol resulted in a protein of low purity and the 
method was refined by using several wash steps with a variety of different 
imidazole concentrations to try and minimise non-specific binding of 
contaminant proteins in the first purification step. As can be seen from Figure 
3.6 it was not possible to find the ideal conditions that would wash off the 
contaminants while leaving the ΔNClpX6 bound to the resin. The eluate from 
the 100 and 500 mM imidazole washes was thus pooled and concentrated 
(Vivaspin 20, 30,000 MWCO (Sartorius Stedim)) to a volume of 5 ml and 
further purified by size-exclusion chromatography (Sephacryl S-300 HR, using 
ClpXP storage buffer as the elution buffer) (Figure 3.7). Fractions 15-17 were 
pooled and concentrated to 1 μM, divided into 20 μl aliquots then snap-frozen 
in liquid nitrogen before storage at -80 °C. It is noticeable in Figure 3.7 that a 
second protein band is visible at approximately 66 kDa, this band was present 
in all ΔNClpX6 purifications carried out and could not be eliminated entirely. 
Since the amount of contaminant present was low, it did not appear to affect 
the activity of the purified ΔNClpX6 and due to the sensitivity of ClpX to 
prolonged purification it was decided that the ΔNClpX6 produced was pure 
enough for use in further experiments. If it were necessary to quantify the 
exact concentration of ΔNClpX6 then densitometry could be used to estimate 
the proportion of this contaminant present.  
While it is the ClpX component of the ClpXP complex that acts as a 
mechanical unfoldase which is able to unfold substrate proteins and dissociate 
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aggregates in isolation, it is not possible to use ClpX independently in an 
ensemble assay as any unfolded protein would be able to refold after 
translocation through the ClpX ring. Monitoring this by SDS-PAGE (which is 
how the degradation was to be followed) would thus lead to no change in 
signal. It was therefore necessary to express and purify ClpP to use in 
conjunction with the ClpX. This renders the mechanical unfolding step of the 
substrate irreversible and allows the rate of unfolding (rate limiting step) to be 
measured by rate of disappearance of full-length protein by SDS-PAGE 
coupled with densitometry.    
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Figure 3.4: SDS-PAGE gel of ΔNClpX6 test expression after cell lysis. The cell lysate was centrifuged to separate the soluble and non-soluble proteins then the supernatant and re-suspended pellet were analysed by SDS-PAGE. The lane labelled Pellet shows the re-suspended pellet, the lane labelled Supernatant shows the supernatant containing the soluble proteins.  
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Figure 3.5: SDS-PAGE gel of ΔNClpX6 test expression at two different temperatures after cell lysis. The cell lysate was centrifuged to separate the soluble and non-soluble proteins then the supernatant and re-suspended pellet were analysed by SDS-PAGE. Four test expressions were analysed, two at 22 °C and two at 37 °C. Fractions are labelled as follows: I - re-suspended pellet, S - supernatant. The migration distance expected for ΔNClpX6 is shown on the right, this is at the interface of the stacking and resolving gels as the expressed protein is too large to enter the resolving gel. 
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Figure 3.6: SDS-PAGE showing the initial purification step of ΔNClpX6. The lane marked M shows the molecular weight markers. The lanes marked WCL, I and S show: the whole cell lysate before centrifufation (WCL), and after centrifugation the re-suspended pellet containing the insoluble proteins (I) and the supernatant containing the soluble proteins (S), which was used for further purification. The lanes showing imidazole concentrations are the supernatant from sequential wash-steps with the stated imidazole concentration after centrifugation to pellet the Ni sepharose beads. The migration distance expected for ΔNClpX6 is shown on the right, this is at the interface of the stacking and resolving gels as the expressed protein is too large to enter the resolving gel. 
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Figure 3.7: SDS-PAGE showing fractions which showed an increase in absorbance at 280 nm eluted from size-exclusion column during the purification of ΔNClpX6. The migration distance expected for ΔNClpX6 is shown on the right, this is at the interface of the stacking and resolving gels as the expressed protein is too large to enter the resolving gel.  
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3.3.2 ClpP 
The ClpP used throughout this study is the E. coli ClpP (Appendix 7.1.2). It is 
inserted into a pET14 derived vector conferring ampicillin resistance. 
pET14ClpP was transformed into E. coli Bl21 [DE3] (Section 2.6.3). An initial 
test expression was performed as shown in Figure 3.8. ClpP was found to 
express well and was found mostly in the soluble fraction, there was another 
prominent band present in the soluble fractions at approximately 14 kDa, no 
attempt was made to identify this as it would be expected to be removed by 
purification but it is likely to be lysozyme (Molecular mass = 14,307 Da) used 
in the cell lysis procedure. A large scale overexpression using 10 l of LB 
medium was performed and the resulting cells harvested and lysed before 
purification as described in Section 2.6.3.   
The initial attempt at purification using ammonium sulphate precipitation and 
anion exchange chromatography steps were unsuccessful and resulted in a 
poorly purified protein as shown in Figure 3.9. As this was unsuccessful a new 
strategy was devised. A ClpP variant with a C-terminal hexahistidine affinity 
tag had been constructed previously in the Brockwell group (D. Brockwell, 
personal communication) but had not been used as it was unknown whether 
the tag would interfere with ClpP complex formation. As (His)6 purification 
greatly facilitates production of high purity proteins it was decided to purify 
ClpP(His)6 as described in section 2.6.3, because if this was successful it 
would greatly reduce the amount of work required for ClpP production during 
the course of this project. A transformation and expression trial was carried 
out successfully as described above and a small scale test purification was 
carried out in order to optimise the purification strategy. A successful scheme 
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was devised using several different washes with different imidazole 
concentrations (Figure 3.10). After purification ClpP was dialysed into ClpXP 
storage buffer and snap frozen as described for ΔNClpX6. 
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Figure 3.8: SDS-PAGE of lysed and centrifuged samples from a ClpP expression trial. The lanes marked Control show an uninduced control, Samples 1 and 2 have been induced with 1 mM IPTG and grown for a further 4 hours. I and S refer to the re-suspended pellet containing the insoluble proteins and the supernatant containing the soluble proteins respectively. The migration distance expected for ClpP is shown on the right. 
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Figure 3.9: Composite of SDS-PAGE gels showing the results of the ClpP purification protocol. Whole cell lysate, Lysed supernatant and Lysed pellet show the results of the initial cell lysis and centrifugation. The section labelled AS cut refers to the ammonium sulphate precipitation step of the purification. Ammonium sulphate was added to a saturation of 30% and 60%, separating the resulting suspension at each stage by centrifugation. Shown are the supernatant containing the soluble proteins and the pellet containing precipitated proteins (after it had been redissolved). The fraction which was insoluble at 60% ammonium sulphate was selected for further purification by anion exchange (Anion exchange fractions). The fractions indicated by arrows were selected for further purification by size exclusion chromatography (Gel filtration fractions). The fractions indicated by the arrows were pooled, concentrated and frozen. A sample of this is shown labelled Purified ClpP.   
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Figure 3.10: SDS-PAGE showing purification of ClpP. Nickel resin was washed 4 times with a buffer containing 20 mM imidazole, a single wash at each of 100, 150 and 200 mM and eluted with 2 washes at 500 mM. 
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 Degradation assays 
In addition to determining its approximate mass by SDS-PAGE, an excellent 
test to verify the identity of the proteins isolated in sections 3.3.1.2 and 3.3.2 
is the ability of these proteins to assemble and carry out ATP dependent 
degradation of tagged substrates. The substrate chosen for this was Im9-ssrA. 
This is the E. coli immunity protein 9; produced as a defence against the 
bacterial E colicin, E9 which is produced as part of the SOS stress response, 
with the ssrA degradation tag added to the C-terminus. It has been used 
previously in the Brockwell group as a substrate for ClpXP and a large stock 
of lyophilised ssrA-tagged Im9 produced by James Pullen was available for 
use and has so far proven to be sufficient for all of the experiments for which 
it has been required.     
3.4.1 Initial degradation 
The reaction mixture for the degradation assay contains: ClpXP to unfold and 
degrade the substrate protein; Tris-HCl (pH 7.6), KCl, glycerol and DTT to 
provide the conditions in which ClpXP is stable and active; MgCl2 to provide 
the Mg2+ ions necessary for the hydrolysis of ATP; creatine phosphokinase 
and creatine phosphate to act as an ATP regeneration system; and ATP to 
provide the energy source for the ClpX and allow complex formation. ATP was 
omitted in the control reactions. The reaction mixture and substrate was pre-
warmed to the reaction temperature (30 °C), the substrate added and samples 
of the mixture are taken at the appropriate time-points for analysis, the results 
are shown in Figure 3.11.  
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The initial reaction conditions were based on previously successful 
experiments performed in the Brockwell group (J. Pullen, personal 
communication). Optimisation concentrated on changing the concentrations 
of ClpX and ClpP in the reaction in order to have the reaction take place in a 
time frame which made a good balance between the time taken for the 
experiments and allowed a reasonable number of samples to be taken for 
analysis. It was attempted to keep reaction times to under 1 hour while taking 
around 8 samples. An example of typical reaction components is given in 
Table 3.1. The concentration of most components remained the same, the 
ones that might typically be varied was the ClpX and ClpP concentrations in 
order to alter the rate of the reaction. The fraction of ClpXP which was active 
was not quantified. 
While it is the ClpX component of the ClpXP complex that acts as a 
mechanical unfoldase which is able to unfold substrate proteins and dissociate 
aggregates in isolation, it is not possible to use ClpX independently in an 
ensemble assay as any unfolded protein would be able to refold after 
translocation through the ClpX ring. Monitoring this by SDS-PAGE (which is 
how the degradation was to be followed) would thus lead to no change in 
signal. It was therefore necessary to express and purify ClpP to use in 
conjunction with the ClpX. This renders the mechanical unfolding step of the 
substrate irreversible and allows the rate of unfolding (rate limiting step) to be 
measured by rate of disappearance of full-length protein by SDS-PAGE 
coupled with densitometry.    
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Table 3.1: Typical concentrations of components used in ClpXP mediated degradation reactions. ClpX and ClpP concentrations sometimes varied from this, if so it is stated in the experimental description. ATP was omitted from control reactions. pH was adjusted to 8 by the addition of HCl.  
Reaction Component Concentration 
Tris base 25 mM 
KCl 200 mM 
Glycerol 10% v/v 
DTT 2 mM 
MgCl2 10 mM  
Creatine phosphokinase 0.032 mg/ml 
Creatine phosphate 16 mM 
ATP 5 mM 
ClpX (pseudohexamer or homohexamer) 200 mM  
ClpP (homo-14mer) 600 mM  
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Figure 3.11: Initial test degradation showing that ΔNClpX6P is active against an ssrA-tagged substrate. 
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3.4.2 Assay validation 
In order to determine whether it was possible to use SDS-PAGE gels in 
conjunction with densitometry to follow the progress of a degradation reaction 
accurately it was necessary to conduct an experiment where a known amount 
of protein was loaded onto a gel then densitometry used to quantify the 
resultant bands. Two proteins were chosen that were readily available: Beta-
2-microglobulin (prepared by Nasir Khan) (β2m) and myoglobin from equine 
heart (Sigma).   
β2m has a molecular weight of 11,860 Da and myoglobin 17,600 Da. The β2m 
was used as an invariant standard to correct for loading errors and 1 μg was 
loaded in each lane, myoglobin was used as the variable protein and was 
loaded in amounts varying from 0.25 μg to 3 μg which spanned the range that 
would be used in the degradation assays. To quantify the error of such an 
approach, six gels were loaded and run in identical conditions. The gels were 
stained by two methods: SYPRO red protein gel stain (Lonza, USA) (Figure 
3.12A), which is a fluorescent stain visible under UV light (λEX = 300 nm, 
λEM = 550/630 nm)) whose manufacturer claims it provides a superior staining 
with a detection limit to Coomassie of 1ng/band143 and has a linear range 
between ng/band to µg/band allowing accurate quantification over a greater 
range of protein quantity. The second method was using a Coomassie-based 
stain (sensitivity = 8ng/band)143 (Instant Blue, Expedion) (Figure 3.12B). The 
intensity of each band was determined and normalised to the reference protein 
β2M as described in Section 2.8.1. The results are shown in Figures 3.13 and 
3.14.  
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The two dyes stain by different methods and allow detection in different ways. 
Coomassie-based staining involves the binding of a coloured dye to the 
protein by a combination of electrostatic and Van der Walls interactions and is 
known to stain proteins well, particularly those containing basic residues144. 
Due to its preference for basic residues Coomassie can provide different levels 
of staining for different proteins depending on their amino acid composition 
but as we are interested in quantifying different concentrations of the same 
protein this need not concern us. SYPRO red stain is a fluorescent dye which 
binds to the SDS coat proteins acquire during SDS-PAGE143.  I feel that the 
SYPRO red staining, by virtue of being a light emitting stain in contrast to being 
an absorbing stain like Coomassie, probably did in theory provide a result that 
would give better staining over a wide range of protein concentration. This is 
due to the way that the camera records the result; with a light emitting stain it 
is possible to adjust the exposure so that the brightest band is not 
overexposed and the other bands will then be less bright. Brighter bands 
should emit more light if they contain more protein. Whereas with a Coomassie 
stain once a band is stained to its maximum darkness (where no light can be 
transmitted through that band) it cannot be determined whether it has just 
reached that level or has surpassed it, and what you are measuring becomes 
the size of the band. In practice however there is no evidence that the SYPRO 
red is either more sensitive or has a greater range of linearity and in fact as 
shown by the error bars the variation between gels was much greater than for 
Coomassie staining. This might be because the staining with SYPRO red 
tended to be very uneven across the gel with a varying intensity in the 
background staining and the occasional bright spot that did not seem to be a 
protein band. You can see this in Figure 3.12A, gel 2 shows an example of 
148 
uneven staining across the gel, gel 1 shows a “bright spot” which is in the 
middle of a protein band, gel 4 has examples of both problems. These 
problems meant that while in theory the SYPRO red had the ability to provide 
a more accurate assay; in practice Coomassie was often better because the 
staining was more likely to be even across the gel and no artefacts in the 
background staining would interfere with the densitometry. Consequently, in 
future assays, the gels were stained with SYPRO red and if the staining was 
even with few artefacts these were used; if the SYPRO red staining was poor 
the gels were re-stained with Instant Blue and these used instead for 
quantification. It should be noted that while the Beer-Lambert law says that 
the relationship between the signal and the amount of protein being measured 
is linear and so it would be expected that in Figure 3.13 and Figure 3.14 that 
the line of best fit should pass through the origin. The calibration graphs show 
that this method over-estimated the volume for small values, this is likely due 
to errors in estimating the baseline. However this problem can be overcome 
by careful selection of the concentration of protein used in degradation assays 
to ensure that the majority of the assay will take place over the linear range.   
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Figure 3.12: SDS-PAGE gels used to determine the linear range over which protein sample concentration could be accurately quantified. Each gel stained with (A) SYPRO red and (B) Instant Blue. (C) is a composite image of various screen-grabs from the Gene Tools software showing the bands picked on the gel image. Yellow lines are the maximum intensity and dashed orange lines are the boundaries of the band, shown below the gel image are the intensity profiles measured for each band with V being the upper variant band and I being the lower invariant band. The volume under each intensity profile is then calculated and the values for the variant bands normalised as described in section 2.8.1. (D) shows a comparison between the raw volumes and relative (to 1) raw volumes and corrected volumes for the data shown in C. The relative corrected volumes were then averaged and plotted as shown in Figures 3.13 and 3.14.  
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Figure 3.13: Analysis of densitometry from loading a known amount of protein when using Coomassie-based stain. Error bars represent the standard error of the mean from the 6 replicate gels. The solid black line is a best-fit to the mean values r2 = 0.99 
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Figure 3.14: Analysis of densitometry from loading a known amount of protein when using SYPRO red stain. Error bars represent the standard error of the mean from the 6 replicate gels. The solid black line is a best-fit to the mean values r2 = 0.98. 
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  DTT requirement 
One potential application of using ClpXP as a biologically relevant force 
applicator would be investigating the possibility of altering the mechanical 
strength of a protein for degradation (or a ligand for such a protein) by the 
introduction or removal of  specific disulphide bonds within the protein35. While 
it is of course possible to use protein engineering to add or remove such 
disulphide bonds by adding or removing cysteines from the protein; a simpler 
method is to simply make or break these bonds by performing the experiment 
in a reducing or non-reducing environment. However, upon searching the 
ClpXP literature it was unclear whether reducing agents are required for ClpXP 
activity. The only reference was as follows: “Because reducing agents are 
important for robust ClpXP activity but would cleave disulphides, we used the 
HaloTag domain to allow an alternative method of covalent linkage to the 
DNA.”30. However no evidence was given for this statement and some studies 
have been performed which did not mention the use of reducing agents in their 
experimental protocol. It was decided to investigate the claim that reducing 
agents were required.  
ΔNClpX6 (200 nM) was used with ClpP14 (600 nM) and 10 μM test substrate 
(Im9-ssrA, which does not contain disulphide bonds) and degradations were 
carried out in both reducing (2 mM DTT) and non-reducing conditions. Figure 
3.15 shows the raw results from a series of assays including 2 mM DTT and 
shows the same experiment without DTT.  Figure 3.16 shows the compiled 
results of the reaction, plotting the mean amount of Im9-ssrA remaining 
(calculated relative to the 10 μM Im9-ssrA present at time = 0).  
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As can be seen from Figure 3.15, degradation by ΔNClpX6P is still robust 
irrespective of the presence of a reducing agent, in this case DTT. However 
the rate of degradation is slowed in the absence of DTT (Figure 3.16, Table 
3.2). If it was desired to investigate the mechanical strength of a protein in the 
presence and absence of disulphide bonds it will be necessary to disrupt them 
by removing one of the cysteines from the protein by mutagenesis.   
The reason degradation is enhanced in reducing conditions is unclear, 
because the precise mechanism of action of ClpX is not known. It has been 
reported that the presence of DTT can have effects on protein function not 
directly related to disulphide formation which may account for this145,146. The 
mechanism by which these effects operates is unknown, and is both less 
common and less well studied than thiol-disulfide exchange but could include 
the chelation of metal ions147, or interactions between DTT and the protein due 
to DTT’s capacity to form two strong and two weak hydrogen bonds which may 
cause conformational change or steric hindrance145. 
Interestingly two single molecule studies, discussed in the introduction, 
performed a ClpXP degradation to investigate the stall force and slippage 
experienced by ClpX as it unfolded and translocated a substrate under distinct 
redox conditions4,30. This study did not investigate the effects of the reducing 
environment specifically. However, the study that did not use a reducing 
environment found that ClpX had a lower stall force and greater slippage than 
the other study which had 1 mM DTT in the reaction mixture. 
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Figure 3.15: SDS-Page showing degradation of Im9-ssrA by ΔNClpX6P in the presence (A) and absence (B) of 2mM DTT. Lanes marked +ATP contained 5 mM ATP (i) shows the complete gel. (ii-iv) show just the Im9-ssrA band from replicate experiments. Some lanes, such as those in B iii and B iv had bands which had completely degraded. If no visible band remained the amount of remaining protein was assumed to be 0.  
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Figure 3.16: Graph of the mean results of ΔNClpX6P degrading Im9-ssrA. Blue diamonds show the reaction containing 2 mM DTT; red squares represent reactions without DTT. Blue and red lines show the result of a mono-exponential fit to the data. Error bars show the standard error. n=3. 
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Table 3.2: Results of fitting a mono-exponential to the Im9-ssrA degradation data shown in Figure 3.16. 
 k /s-1 R2 for fit 
2 mM DTT 0.28±0.33 0.99 
0 mM DTT 0.15±0.02 0.95 
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 Substrate switching  
Another interesting use of the ClpXP system would be to investigate the 
importance of directionality of an applied force to protein mechanical strength 
at biologically accessible loading rates. Since the ssrA tag is fused to the 
substrate protein at the C-terminus, ClpX can only apply force to the substrate 
in one geometry. There are however,  N-terminal tags which will allow ClpX to 
apply its unfolding force at the N-terminal of a protein64. Unfortunately the 
ΔNClpX6 variant used here is unsuitable for this purpose as the N-terminal tags 
require the N-terminal zinc binding domain of the ClpX in order to be degraded 
and this is lacking in the pseudohexamer (see section 1.4.1)148,149.  
Wild type ClpX is able to degrade N-terminally tagged substrates, such as 
those with a λO degradation tag. The rate of degradation of N-terminally 
tagged substrates is, however, much slower relative to ssrA-tagged 
substrates64. It was decided to make a mutant ClpX where the positively 
charged residues of the RKH loop, which normally interact with the negatively 
charged residues and the C-terminus of the ssrA tag, were replaced with 
alanine, which has shown to increase the rate of degradation of a λO-tagged 
substrate67.  
3.6.1 ClpXΔRKH 
The wild type ClpX with an N-terminal hexahistidine affinity tag (available in 
the laboratory) was altered by site-directed mutagenesis (Quikchange, 
Stratagene) to the R228A, K229A, and H230A mutant which was named His6-
ClpXΔRKH. An expression trial was carried out showing successful expression 
in BL21 (DE3) pLysS E. coli and a large scale expression was performed. The 
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His6-ClpXΔRKH was purified as previously described and the results of the 
purification are shown in Figure 3.17.  
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Figure 3.17: Composite summarising the purification of His6-ClpXΔRKH. Lanes show the whole cell lysate, the fraction selected from the Ni Sepharose purification and the fraction selected for freezing in aliquots after gel filtration 
160 
3.6.2 λO-Arc 
It was necessary to produce a λO-tagged substrate for degradation by His6-
ClpXΔRKH; the substrate chosen was the E. coli Arc repressor protein (Arc) 
(Section 1.7.3, Figure 1.24) as this has previously been shown to be degraded 
successfully by ClpX mutants.  A fusion protein was devised in which the first 
12 residues of the λO sequence was added to the N-terminal of Arc and six 
histidine residues were added to the C-terminal to facilitate purification to 
produce λO-Arc (Appendix – Section 7.1.3.2). The sequence for this protein 
was reverse translated using a database of the most commonly used E. coli 
codons150. A 5’ NdeI and a 3’ XhoI restriction site was added to this DNA 
sequence and a synthetic gene purchased (Eurofins MWG Operon, 
Germany). The DNA was supplied in a pCR2.1 plasmid and the required 
sequence was excised by a restriction digest and ligated into a pET23a 
plasmid for expression. After expression and purification a test degradation 
was performed to ensure that His6-ClpXΔRKH was capable of degrading λO-
Arc. As can be seen from Figure 3.18 His6-ClpXΔRKH and λO-Arc were 
compatible and the degradation was robust.  
Figure 3.19 and Figure 3.20 show the results obtained when ClpX and His6-
ClpXΔRKH were each used to degrade both Im9-ssrA and λO-Arc. These results 
clearly demonstrate that ClpX had a greater activity against ssrA-tagged 
substrate and a reduced activity against the λO-tagged substrate. By contrast,  
the situation was reversed for His6-ClpXΔRKH, which had good activity against 
the λO-Arc substrate and no detectable activity against Im9-ssrA. These initial 
results were encouraging, demonstrating that it was possible to change the 
specificity of the ClpX by making changes in the RKH loop. 
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A summary of the results of these experiments are shown in Table 3.3. 
Generally these data demonstrate that the substrate specificity of ClpX has 
been switched. The data for His6-ClpXΔRKH vs Im9-ssrA reveals the expected 
error of the method as it shows an apparent 13% increase in remaining 
substrate over time. It demonstrates that the ClpX RKH mutation decreases 
the activity of ClpX against the ssrA-tagged Im9 substrate compared to WT 
and increases activity against the λO-tagged Arc substrate.  
However, several problems were identified during these experiments. Firstly it 
appeared that ClpX was degrading over the experimental time-course, which 
is most apparent in the gel of His6-ClpXΔRKH versus λO-Arc (Figure 3.19D), but 
is also detectable in the other gels shown in Figure 3.19. These figures show 
that His6-ClpXΔRKH appeared to be degrading, yielding a cleavage product. 
This may be due to the presence of an extended length of polypeptide at the 
N-terminus of His6-ClpXΔRKH (His6 tag). This unstructured sequence can then 
be engaged by ClpXPRKH leading to autodegradation151. This effect could be 
ameliorated by addition of an excess of His6-ClpXΔRKH. In terms of a 
quantitative assay, however, this is not ideal situation as the enzyme 
concentration changes in addition to the substrate.  
It is interesting to speculate on what might be happening at a molecular level. 
Previous work in the Brockwell group has shown that the conversion of ClpX 
into the cleaved product reduces the degradation activity of the ClpXP152 it is 
not known, however, whether the ClpX is degraded while part of the complex 
or as a free monomer in solution. As ClpX is not ssrA tagged the former is 
most likely. It is also not known whether the ClpXP complex will disassociate 
after degrading one of its member ClpX subunits or whether it becomes 
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inactive or even if it remains active but becomes less efficient as it is known 
that a ClpX ring containing one or more inactivated subunits will retain some 
activity74. It is not known whether the ClpXP complex can dynamically 
assemble/disassemble under the assay conditions though as proteins are not 
static entities it is likely that the complex exists in equilibrium with monomeric 
and partially assembled complexes. I believe the most likely outcome is that a 
ClpX ring which contains a partly degraded ClpX monomer will disassociate 
into its individual parts, which will become free to reassemble into a new ClpX 
ring which most likely will not include any of the partly degraded ClpX as the 
changes it undergoes will make it unlikely to maintain the required features for 
ring formation. However no compelling evidence exists to support this 
speculation.  
It would also have been possible to try the experiments omitting either the 
ClpX or ClpP component to check for possible contaminant protease activity 
that was contributing to the ClpX degradation, but this was not done.  
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Figure 3.18: SDS-PAGE gel showing the degradation of λO-Arc by His6-ClpXΔRKH P. ATP concentration was 5 mM. For lanes where the amount of remaining substrate was too small to be detected the amount was assumed to be 0.   
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Figure 3.19: Gel composite showing the degradation of λO-Arc or Im9-ssrA by either ClpXP or His6-ClpXΔRKH P. A: ClpX vs. Im9-ssrA. B: His6-ClpXΔRKH vs. Im9-ssrA. C: ClpX vs. λO-Arc. D: His6-ClpXΔRKH vs. λO-Arc. All experiments used an ATP concentration of 5 mM.  
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Figure 3.20: Graph of the densitometry results obtained from the results shown in Figure 3.19. % Substrate remaining is the amount of the initial 10 μM substrate remaining after each time interval. Each experiment was performed once.  
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Table 3.3: showing the results of fitting mono-exponentials to the data shown in Figure 3.20. 
 k /s-1 R2 for fit 
His6-ClpXΔRKH vs Im9-ssrA 0.16±0.18 0.49 
His6-ClpXΔRKH vs λO-Arc 0.28±0.027 0.99 
His6-ClpX vs Im9-ssrA 0.063±0.011 0.97 
His6-ClpX vs λO-Arc 0.056±0.024 0.89 
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3.6.3  λO-E9 
In an attempt to devise a better test substrate for His6-ClpXΔRKH it was decided 
to utilise another protein which has been used within this group: the DNAse 
domain of the E. coli defence protein colicin E9. Since E9 is toxic to E. coli it 
is co-expressed alongside the immunity protein Im9. The interaction between 
E9:Im9 is one of the tightest known (Kd = 10-16 M). In the laboratory, E9 is co-
expressed with Im9, which inhibits E9 activity by binding to the DNAse domain 
thus  preventing lethality19.   
PCR followed by restriction enzyme digestion and ligation into pET23 was 
used to add the λO tag to the N-terminus of E9 as described in Section 2.2.13. 
After confirmation of the DNA sequence (Appendix – Section 7.1.3) 
pET23λOE9 was transformed into BL21 [DE3] E. coli cells. However, no 
transformants were obtained. A subsequent attempt at transformation, 
alongside a positive control (pUC19) was attempted using a freshly prepared 
batch of competent cells along with a positive control. The bacteria 
transformed with the positive control grew but the ones transformed with 
pET23λOE9 did not. It was concluded that adding the λO tag to the E9 could 
be interfering with the E9:Im9 binding and causing toxicity to the E. coli cells. 
An E9 variant which had an extended N-terminal sequence (residues 1-16 of 
the translocation (T) domain of E9 and a TEV cleavage site), known to express 
well was obtained from the group of Colin Kleanthous at the University of York. 
The λO tag was added to the variant (Appendix – Section 7.1.3) as before and 
the resulting sequence confirmed. This new variant was known as λO-(T1-16)-
TEV-E9. pET23λO-(T1-16)-TEV-E9 was transformed into BL21 [DE3] E. coli 
and again failed to produce any colonies. However when it was transformed 
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into BL21 [DE3] pLysS, colonies were obtained. This may have been due to 
the pLysS which expresses T7 lysozyme, which further suppresses basal 
expression of T7 RNA polymerase prior to induction, stabilizing recombinants 
encoding target proteins that affect cell growth and viability153 reducing any 
toxic effects of the protein. 
After a small scale trial confirmed protein expression, a large scale (10 l) 
culture was carried out. The protein was purified via the hexahistidine tag on 
the Im9 (section 2.2.13). Briefly, cleared lysate was applied to a Ni sepharose 
column to immobilise the Im9:E9 complex. E9 was eluted by denaturing the 
protein complex with an increasing concentration of the denaturant 
guanidinium hydrochloride. The E9 was then further purified by size-exclusion 
chromatography. Results of protein purification are shown in Figure 3.21.  
The purified λO-(T1-16)-TEV-E9 was degraded by the His6-ClpXΔRKH (Figure 
3.22) but the autodegradation was found to be exacerbated with this more 
robust substrate. 
169 
 
Figure 3.21: Composite gel showing the purification of λO-(T1-16)-TEV-E9. Flow through: cleared lysate which did not bind to the column. Wash: washing column with binding buffer. [Guanidine] shows the elution of the E9 in an increasing concentration of guanidine hydrochloride. Imidazole: Elution of Im9 with wash buffer. After gel filtration: purified E9 after size-exclusion chromatography.  
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Figure 3.22: SDS-PAGE Gel showing the degradation of λO-(T1-16)-TEV-E9 by His6-ClpXΔRKH P. Lanes labelled +ATP contained 5 mM ATP, lanes labelled –ATP were the negative control containing no ATP.  
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3.6.4 Thrombin cleaved His6-ClpXΔRKH 
It was decided to use a slightly different variant of ClpXΔRKH with a thrombin 
cleavage site between the hexahistidine tag and the ClpX to try and resolve 
this problem. A his-tagged monomeric wild-type ClpX with the thrombin 
cleavage site, available in the laboratory, was mutated to R228A, K229A,  
H230A using the Quikchange site directed mutagenesis kit (Section 2.2.4). 
This was expressed and purified as described for His6-ClpX (Section 2.6.4 and 
3.3.1) A thrombin CleanCleave kit (Sigma) was used to remove the His tag as 
described in Section 2.6.5. Unfortunately as shown in Figure 3.23A, the 
protein was no longer in solution after overnight incubation. Another attempt 
was made with a shorter incubation followed immediately by purification of the 
protein by gel filtration (Superdex 75 10/300 GL). Only a very small peak was 
observed eluting from the column and when the protein in this peak was 
visualised using SDS-PAGE an insignificant amount of protein was present 
(Figure 3.23B).  
While it may have been possible to improve the situation by generating further 
variants of ClpX (each of the three mutations used in the ClpXΔRKH variant 
have been shown to improve the degradation of λO-tagged proteins when 
used separately67) it was decided not to pursue further optimisation of the 
ClpXP system. Instead it would be more useful to use the experimentally 
tractable ΔNClpX6  variant to explore the mechanical properties of 
polyglutamine containing proteins. 
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Figure 3.23: Thrombin cleaved His6-ClpXΔRKH to ClpXΔRKH after incubation with thrombin. The protein was incubated with the beads at room temperature for 4 hours then: A: incubated for a further 14 hours at 4 °C, or B: immediately purified by size-exclusion chromatography at 4 °C. Markers on the right show the expected positions for the protein before (Uncleaved) and after (Cleaved) removal of the His tag by thrombin cleavage.   
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4 Investigation of polyglutamine containing proteins 
 Introduction 
As discussed in section 1.6 there is an interesting unresolved question related 
to the mechanical stability of proteins containing polyglutamine repeats. When 
the stability of soluble protein constructs containing polyQ  is investigated by 
AFM it has been found to be either very mechanically stable32, or to have 
access to a hyperstable conformation33. How this mechanical stability is 
related to the deleterious effects of polyQ aggregation in vivo remains 
unresolved. In order to examine whether polyQ constructs were resistant to 
the actions of biological unfoldases it was decided to compare the rate of 
degradation (unfolding), using the ClpXP assay detailed in Chapter 3, with 
mechanical unfolding data obtained using AFM on the same system. 
 Aims  
The aims of this chapter are to design and produce a protein containing a 
polyglutamine repeat sequence and a control protein lacking that region. 
These will then be characterised using a variety of biochemical techniques, 
investigated using AFM to see if the earlier results can be replicated and  
finally subjected to degradation by ClpXP to determine what insights we can 
find using this more biologically relevant technique.    
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 Protein substrate production 
It was necessary to design and produce a protein that could be used in 
experiments to determine the properties of polyQ (Figure 4.1). It was decided 
to produce a trimeric I27 polyprotein with two cysteine residues at the 
N-terminus and an ssrA degradation tag at the C-terminus ((I27)3-ssrA). This 
protein would be useful for both AFM experiments (which could be compared 
to earlier experiments using I27154) and degradation assays. The N-terminal 
cysteines would allow it to be tethered to a gold surface and the multiple I27 
domains would produce a distinctive fingerprint facilitating the analysis of AFM 
force-extension data. (Section 1.3). Once characterised, a cassette would be 
inserted at the DNA level (at the SpeI site, Figure 4.1)  containing various 
polyQ repeat lengths. These constructs would then be characterised by a 
variety of techniques and compared to the I27 only control. 
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Figure 4.1: Design of the polyprotein to be used in these experiments. A: The control protein B: The protein containing a polyQ domain. Endonuclease restriction sites defining each cassette are shown (arrows). CC: double cysteine N-terminal motif. His: (His)6 affinity tag. ssrA: ssrA degradation tag.    
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4.3.1 DNA manipulation 
4.3.1.1 I27 trimer 
As there was no suitable protein available it was necessary to produce one. 
The strategy to create these constructs is summarised in Figure 4.2. First PCR 
was used to generate I27 domain 1 – an I27 domain, with a 5’ NdeI restriction 
endonuclease site and a 3’ multiple cloning site (MCS) encoding consecutive 
SpeI, BssHII and SacI restriction sites. After ligation into the plasmid 
containing the ssrA tag, domains 2 and 3 would be ligated in sequentially 
(Figure 4.2 D, E).  
The starting point for this construct was three plasmids:  two plasmids, each 
containing one copy of I27, one flanked by SpeI and BssHII restriction sites 
(suitable for use as domain 2) and the other suitable for use as domains 1 and 
3 after mutagenesis to insert the necessary restriction sites, and a pET23a 
plasmid containing an ssrA tag at the end of another protein (E2Lip3) which 
contained a 5’ NdeI restriction site, a SacI restriction site between E2Lip3 and 
the ssrA tag  and a 3’ XhoI restriction site (Figure 4.2A). E2Lip3 could be 
excised by restriction enzyme digest to allow ligation of the I27 sequences into 
the construct. PCR mutagenesis (Section 2.2.3) was used to produce domain 
1 (NdeI site 5’ to I27 and a 3’ MCS containing SpeI, BssHII and SacI) and 
domain 3 (SacI and BssHII sites 5’ and 3’ to I27 respectively). The E2Lip3 
gene was excised from the plasmid containing the ssrA tag with NdeI and 
SacI, dephosphorylated and purified on an agarose gel as described in 
Sections 2.2.8 and 2.2.9. The same restriction digest was performed on I27 
domain 1 and this was also gel purified. After gel extraction of the insert and 
vector, a ligation reaction was performed to produce a plasmid containing I27 
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domain 1 with a 3’ ssrA tag and containing the appropriate restriction sites to 
allow ligation of domains 2 and 3 by a similar method.  Restriction digests and 
DNA sequencing were carried out at each stage to confirm the insert was 
present and had the correct sequence. Figure 4.3 shows the results of a final 
restriction digest confirming the presence of 3 I27 genes. DNA sequencing 
confirmed that the correct sequence was present.  
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Figure 4.2: Summary of the required ligations to produce the (I27)3-ssrA control construct (domains not shown to scale). The construct is contained in a pET23 derived plasmid which is omitted for simplicity. T7+ is the T7 promoter sequence used to overexpress the protein. E2lip3 and I27 are the protein domains of the same name and ssrA is the ssrA degradation tag. A: The parent construct containing E2lip3 with a C-terminal ssrA tag. B: The same construct after digestion by NdeI and SacI. C: The  construct after ligation of I27 domain 1 containing the additional required restriction sites. D: The construct after the ligation of the second I27 domain. E. The construct after the ligation of the third I27 domain.    
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Figure 4.3: Agarose gel showing the results of a restriction digest confirming the presence of the required inserts. The bands labelled Uncut plasmid show a mixture of topological isomers such as supercoiled, linear and nicked DNA. The bands labelled Linear plasmid show the result of the circular plasmid after cutting by a restriction enzyme. 1, 2 and 3 are bands corresponding to the expected size of a DNA fragment with one, two or three I27 domains respectively.  
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4.3.1.2 Polyglutamine region 
Glutamine is encoded by only two codons: CAA and CAG. The resultant highly 
repetitive sequences pose problems for the construction of proteins containing 
pre-determined polyglutamine repeat lengths.  The method chosen to produce 
the different length polyQ sequences was based on that of Alexandrov et al. 
2008.155 This method was chosen because Alexanndrov et al. had 
successfully used it to produce polyQ sequences of varying lengths in the 
range we were interested in and it was straightforward to perform using 
commercially supplied DNA constructs. Three pairs of complementary DNA 
oligomers were designed (see Appendix – Section 7.2.1) to provide duplex 
DNA terminators and elongators. The terminators contained the necessary 
restriction site and had one overhanging end, the elongators had two 
overhanging ends compatible with each other and the terminators. After 
annealing of the oligomers to produce a duplex DNA fragment, the oligomers 
were mixed in a ratio of 1:10 terminators:elongators and ligated by T4 DNA 
ligase (Figure 4.4). 
The initial strategy was to design a 5’ terminator with both SpeI and BssHII 
restriction sites and two sets of 3’ terminators; one with a SpeI restriction site 
and one with a BssHII restriction site (Figure 4.5 A, B). These could be used 
to produce two polyQ sequences that could be inserted in between I27 
domains in the control protein. 
After ligation, a ladder of different length DNA products was obtained resolved 
using a 3% (w/v) agarose gel as in Figure 4.6. The ligated mixture was purified 
by use of a gel extraction kit (Qiagen) to remove proteins and small DNA 
fragments. After “A-tailing”, the ligation product was inserted into the 
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pre-cleaved T-tailed plasmid pGEM-T. The products of the second ligation 
step were transformed into E. coli SURE2. Blue/white screening 
(Section 2.2.7) was employed to select candidate colonies for growth and 
plasmid extraction. Restriction digests to determine the presence and 
estimated lengths of the inserted polyQ sequence in the plasmid were of mixed 
success. Sequencing showed that polyQ sequences of various lengths had 
been successfully created but that the restriction sites were no longer present. 
The terminators were redesigned minimising the amount of secondary 
structure that was likely to form using an online prediction tool156. The 
redesigned terminators (Appendix – Section 7.2.1) allowed the production of 
several successful polyQ sequences (15Q, 17Q, 30Q) flanked with SpeI 
restriction sites. The production of a construct which had a BssHII restriction 
site at both ends of the sequence was attempted (Figure 4.5 D), but this was 
not successful. 
It was decided to proceed with the 30Q sequence rather than the 15Q or 17Q 
sequences as it was long enough that a change in length could be easily 
detected using AFM and it was felt that a longer sequence would be more 
likely to exhibit unusual properties. This was ligated into the (I27)3-ssrA 
construct to produce I27-Q30-(I27)2-ssrA. Other ratios of elongators and 
terminators were assessed for their ability to produce polyQ sequences of 
differing lengths but none produced a result substantially different from that 
shown in Figure 4.6. 
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Figure 4.4: A schematic diagram of the process used to produce a polyQ sequence suitable for ligation into the control construct.  
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Figure 4.5: Summary of the design of polyQ regions for insertion into I27 trimer. A: initial design with 5’ BssHII and SpeI restriction sites and 3’ SpeI restriction site. B: initial design with 5’ BssHII and SpeI restriction sites and 3’ BssHII restriction site. C: final design with 5’ SpeI restriction site and 3’ SpeI restriction site. D: final design with 5’ BsshII restriction site and 3’ BsshII restriction site 
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Figure 4.6: Agarose gel showing the results of the ligation of a 1:10 mixture of terminators and elongators. Lanes containing DNA ligase show a ladder of different length ligation products. Lanes without DNA ligase show only the unligated elongators and terminators.   
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4.3.2 Protein production 
An expression trial of the control protein ((I27)3-ssrA) was carried out as shown 
in Figure 4.7. As this protein expressed well and was largely in the soluble 
fraction, a large scale overexpression was performed. The protein was purified 
by a three step protocol (nickel-affinity, followed by size-exclusion 
chromatography and ion exchange (Section 2.6.8)) as shown in Figure 4.8. 
The resultant protein (molecular mass = 32,990 Da (expected mass from the 
sequence)) was almost pure but contained a contaminant of a slightly lower 
molecular mass (molecular mass ≈ 31,000 Da (from electrophoretic mobility)). 
A similar contaminant has been observed in all of the ssrA-tagged proteins 
produced for this study which is believed to be a result of the protein 
undergoing  proteolytic cleavage to remove the ssrA tag. (Mass 
difference ≈ 2000), mass of residues 279-301 (KVKELLCGAQ 
AANDENYALAA= 2192)) Various strategies have been attempted to remove 
or reduce this contaminant but it was always present regardless of the 
presence of protease inhibitors or undertaking protein purification at low 
temperatures. While not ideal, the presence of this proteolytic product was 
tolerated for the following reasons: firstly, the presence of a C-terminally 
truncated protein would not affect AFM measurements as the cysteines used 
for immobilisation were N-terminal. Secondly, removal of the ssrA tag renders 
the protein “invisible” to ClpXP. While its presence would make the real 
substrate concentration difficult to quantify, these errors would be minimised 
by estimating the quantities of each species by densitometry and working at 
higher substrate concentrations.   
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The protein containing polyQ was produced using a protocol identical to that 
used for the control protein. Results of the expression trial (Figure 4.9) and 
purification (Figure 4.10) are shown below. 
Once the proteins required had been produced, it was necessary to 
characterise them to ensure that they were folded and that they were 
monomeric in solution. This is because the work by Dougan et al32 (which 
produced the initial result indicating that polyglutamine repeats had extreme 
mechanical stability) did not perform any controls to ensure the protein they 
used was monomeric. This may explain their surprising result, if the 
polyglutamine had begun to aggregate then the AFM experiments may not 
have been performed on monomeric polyglutamine. If the polyglutamine had 
begun to aggregate they may have been experimenting on a pre-fibrillar 
aggregate conformer of polyglutamine or even on polyglutamine amyloid-like 
fibrils. While the results they obtained (time-distance measurements showing 
distinct steps as expected for a monomeric I27 concatamer) mean that this is 
unlikely, it is important that this possibility be ruled out (section 1.6). 
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Figure 4.7: expression trial of (I27)3-ssrA. Cells were lysed then centrifuged to separate the soluble and insoluble fractions. Insoluble: re-suspended pellet.  Soluble: supernatant  
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Figure 4.8: SDS-PAGE composite summarising the purification of (I27)3-ssrA. Flow through: cell lysate which failed to bind to the nickel resin. Nickel Affinity: eluate from the nickel resin selected for further purification Size Exclusion: selected fraction after size-exclusion chromatography. Ion exchange: final fraction selected for use after ion exchange chromatography  
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Figure 4.9: expression trial of I27-Q30-(I27)2-ssrA. Insoluble: re-suspended pellet. Soluble: supernatant  
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Figure 4.10: SDS-PAGE composite summarising the purification of I27-Q30-(I27)2-ssrA. Nickel Affinity: eluate from nickel resin selected for further purification. Size Exclusion: selected fraction after size-exclusion chromatography. Ion Exchange: fraction selected for use after ion exchange chromatography 
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 Biophysical characterisation 
4.4.1 Circular dichroism spectroscopy 
CD is a valuable technique for examining the structure of proteins in solution 
based on the spectral properties of chiral molecules.  
When plane polarised light is separated into left and right circularly polarised 
components they are absorbed differently by chiral molecules. This results in 
the non-absorbed light being elliptically polarised157. The degree of 
polarisation can be measured at different wavelengths which gives insight into 
the three dimensional structure or environment of the molecule studied. While 
this does not give the same level of structural detail as nuclear magnetic 
resonance (NMR) or crystallographic techniques it is a relatively quick and 
easy technique that requires little sample.  When applied to biological 
molecules such as proteins near-ultraviolet (UV) CD gives insight into the 
tertiary structure of a protein due to the absorption, dipole orientation and the 
environment surrounding phenylalanine, tyrosine, cysteine and 
tryptophan amino acids. In this study far-UV CD was used, which can reveal 
important information about the secondary structure of proteins; allowing an 
assessment of the degree of alpha-helical, beta-sheet and random coil 
structure present in a sample157.  
Far-UV CD was used here to assess whether the I27 component of the protein 
had its expected predominantly beta-sheet structure42 and whether this was 
affected by the addition of the 30Q sequence which had been previously 
shown to have no regular secondary structure116,126,158. The experiment used 
30 mM protein (≈0.2 mg/ml) in a buffer that was 10 mM Tris-SO4, 1 mM EDTA, 
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42 mM K2SO4, 0.5 mM TCEP pH 7.6, known as characterisation buffer. This 
was chosen because it was as close as possible to the buffer used for the 
degradation experiments while still being compatible with the instruments 
used for characterisation. The results of the CD measurements are shown in 
Figure 4.11.    
The result for (I27)3-ssrA is similar to that found for (I27)5 and matches the 
expected result for a mostly beta-sheet protein157. By contrast, the spectrum 
for I27-Q30-(I27)2-ssrA was dominated by the unstructured polyQ region.  
Because the signal for the Q30 dominated the spectra it was not possible to 
categorically state that the I27 regions in I27-Q30-(I27)2-ssrA were correctly 
folded and a further technique was required to verify this. 
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Figure 4.11: Far-UV CD of the control protein (I27)3-ssrA (blue), the polyQ containing protein I27-Q30-(I27)2-ssrA (red) and the spectrum for Q30 calculated by subtracting the blue spectrum from the red spectrum (orange). Inset: Far-UV spectrum for (I27)5 (Toni Hoffman, personal communication).  
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4.4.2 Tryptophan fluorescence emission spectra 
A particularly straightforward method for probing the internal environment of a 
protein is the use of a fluorophore whose emission wavelength is sensitive to 
solvent polarity. Fluorescence from the amino acid tryptophan has long been 
known to be sensitive to the polarity of its local environment and has been 
used for many studies. Among the properties measured are changes in the 
fluorescence intensity, wavelength maximum (λmax), band shape, anisotropy, 
fluorescence lifetimes, and energy transfer. In this study an emission intensity 
wavelength scan was measured as Trp λmax, em is sensitive to its local 
environment, roughly correlating with the amount of solvent exposure of the 
fluorophore (i.e. whether buried in the hydrophobic core of a protein or not). 
Since each I27 domain in our protein contains a Trp residue while the polyQ 
region does not, it is possible to ascertain information about the folded state 
of the I27 domains by comparing the Trp emission spectra of the assumed 
folded state in characterisation buffer and the assumed unfolded state in the 
same buffer with the addition of a denaturant (8 M urea). The results of this 
experiment are shown in Figure 4.12.  
Both the proteins with and without poly Q show a similar shift in λmax and 
fluorescence intensity upon denaturation, this is a good indication that the Trp 
in the I27 in both proteins is in a similar state before and after denaturation; 
which in turn indicated that they both move from a similar folded to unfolded 
state upon the application of denaturant.  
After ascertaining that the I27 domains within the protein appeared to be 
folded under conditions close to the experimental conditions it was then 
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necessary to determine whether the sample was monomeric under these 
conditions.  
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Figure 4.12: Fluorescence emission spectra of the control ((I27)3-ssrA) and polyQ containing protein (I27-Q30-(I27)2-ssrA) in denaturing and non-denaturing conditions. Corrected absorbance is obtained by determining the maximum fluorescence value for the protein in urea then dividing all of the fluorescence values for that protein by the maximum value. This ensures that the maximum normalised fluorescence intensity for the unfolded protein is 1 and adjusts the folded protein’s fluorescence relative to the unfolded. The same is then done for the second protein.  
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4.4.3  Sedimentation velocity analytical ultracentrifugation 
In sedimentation velocity AUC analysis of proteins, a high centrifugation speed 
is used to cause sedimentation of particles over a number of hours. An optical 
system measures absorbance within the sample chamber and allows the 
sedimentation rate for the species in the sample to be measured by following 
the solvent-solute boundary. The control and polyQ containing proteins were 
analysed by AUC and the sedimentation rates for the various components of 
the solution were measured. The samples were prepared by dissolving them 
in characterisation buffer then dialysing them in the same buffer for 24 hours 
and filtering them before they were sent to the University of Leeds’ AUC 
service (Section 2.10). A summary of the results obtained are shown in Figure 
4.13. For both proteins there were some very small components present 
(<1 S), the bulk of the protein was in a monomeric state (around 2.5 S) and at 
higher concentrations there was a very small amount of higher order species 
(>3 S) and some very large species (25 S). However the majority of the protein 
at the 10 μM concentration used in the following experiments was monomeric. 
The fact that I27-Q30-(I27)2-ssrA was mostly monodisperse despite the 
presence of 30Q was not surprising as it is well known that the initial 
aggregation of polyglutamine repeat containing proteins is controlled by the 
flanking sequences. The absence of aggregated species also suggests that if 
mechanically resistant species are identified in AFM experiments that these 
cannot be due to extraction of the protein from stable fibres.    
198 
 
 
Figure 4.13: Sedimentation velocity AUC of: A - (I27)3-ssrA B - I27-Q30-(I27)2-ssrA. Insets show raw data for protein at 10 mM.  
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4.5 Dynamic force spectroscopy 
Dynamic force spectroscopy was performed on the polyQ construct designed 
and purified in this study to investigate whether this construct would show the 
high mechanical strength observed in previous studies32,33. 
4.5.1 Mechanical unfolding of the test protein (I27)5 
To validate the experimental protocol, constant velocity mechanical unfolding 
was first performed on the well characterised (I27)5 construct32,40 at retraction 
velocities of 200, 632 and 2000 nm.s-1.  
Approximately 1000 approach-retract cycles were made at each velocity, 
aiming to accumulate approximately 100 unfolding events per experiment 
(experiments with more than 100 good unfolding events had 100 events 
analysed, chosen at random) and each experiment was performed three 
times. A typical force-extension profile is shown in Figure 4.14. After filtering 
of the data to remove blank or unsuitable force-extension profiles (section 
2.7.4) force and unfolding distance histograms were generated. 
By fitting of a Gaussian distribution to the histograms (Figure 4.15) it was 
possible to obtain an estimate (from the location of the maxima, 0) of the most 
probable force required for unfolding and the difference in length between the 
folded and unfolded domain. Force-frequency histograms for (I27)5 unfolded 
at different retraction velocities are shown in Figure 4.15. They are presented 
in triplicate as each set of results is from a different experiment which will have 
a slightly different spring constant and will allow a better assessment of the 
errors in the experiments than plotting them on a single chart.  
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It can be seen that the force at which a protein unfolds is proportional to the 
log of the pulling speed (Figure 4.16) as expected and that the results agree 
with the previously published results.  
The frequency histogram for change of length upon unfolding (ΔLc) is shown 
in Figure 4.17. In order to obtain the data for this figure the contour length of 
each unfolding event was subtracted from the contour length of the 
subsequent unfolding event. For example it would be possible to obtain four 
I27 contour lengths from the data shown in Figure 4.14. The length for peak 1 
given by the fitting would be subtracted from the length for peak 2, the length 
for peak 2 subtracted from peak 3, 3 from 4 and 4 from 5. This data can then 
be plotted as a histogram and a Gaussian fit to the data used to obtain the 
most likely contour length. The change in contour length was found to be 28.4 
± 0.2nm which agrees well with the published value of 28.1 nm for this 
construct.138 The results obtained in this study agreed well with the previously 
published data especially considering that there is often a discrepancy of up 
to 20% between different group’s results25. 
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Figure 4.14: A typical force-extension profile for (I27)5 obtained at 632 nm.s-1 Peaks 1-5 are I27 domain unfolding events, peak 6 is the pull-off event. Each peak is labelled with the contour length (Lc) calculated by the fitting software. Persistence length was constrained to 400 pm for all events. Note: WLC fitting is only to the rising portion of each peak.  
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Figure 4.15: Force-frequency histograms generated from (I27)5 constant velocity mechanical unfolding. Top row (A-C)– red 200 nm.s-1 Middle row (D-F)– green 632 nm.s-1 Bottom row (G-I)– purple 2000 nm.s-1 Fits of a Gaussian distribution to each histogram are shown in black lines. Fitting parameters for the Gaussians are given in Table 4.1 
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Table 4.1: Fitting parameters for the Gaussian distributions shown in Figure 4.15.  
Experiment 0 /pN  2 Width 
(√૛ × ࢙࢚ࢇ࢔ࢊࢇ࢘ࢊ ࢊࢋ࢜࢏ࢇ࢚࢏࢕࢔) 
N 
200 nm/s (A) 139.4 ± 1.4 75.3 26.3 ± 2.0 100 
200 nm/s (B) 149.0 ± 0.7 20.6 26.1 ± 1.0 100 
200 nm/s (C) 156.3 ± 1.0 86.0 19.5 ± 1.4 100 
632 nm/s (D) 164.5 ± 1.5 69.5 27.6 ± 2.0 99 
632 nm/s (E) 173.1 ± 0.8 28.4 27.1 ± 1.2 100 
632 nm/s (F) 187.7 ± 1.0 22.7 33.0 ± 1.4 100 
2000 nm/s (G) 189.3 ± 0.8 34.8 24.1 ± 1.2 100 
2000 nm/s (H) 188.8 ± 0.9 37.6 25.7 ± 1.3 96 
2000 nm/s (I) 177.4 ± 0.8 10.7 37.5 ± 1.1 98 
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Figure 4.16: unfolding forces calculated from the mechanical unfolding of (I27)5 unfolding forces calculated from the mechanical unfolding of (I27)5. Red Squares: data obtained in this study. Blue Diamonds: data obtained in a previous study154 Purple +: data for (I27)3-ssrA obtained in section 4.5.2. Pink x: data for I27-Q30-(I27)2-ssrA obtained in section 4.5.2. 
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Figure 4.17: Length-frequency histogram generated from (I27)5 constant velocity mechanical unfolding. Fits of a Gaussian distribution to the histogram are shown as a black line. 2=1041.2 √2×standard deviation = 10.7 ± 0.3 nm 0=28.4 nm N=893 
206 
4.5.2 Mechanical unfolding of I(27)3-ssrA and I27-Q30-(I27)2-ssrA 
Having validated the experimental and data analysis protocols for the 
well-studied systems, a similar approach was taken for (I27)3-ssrA and 
I27-Q30-(I27)2-ssrA. Approximately 2000 approach-retract cycles were made 
at 1000 nm.s-1 and the experiment was repeated three times. This pulling 
speed was chosen because it provides a good balance between the speed at 
which data can be collected and the number of individual data points collected 
for each approach-retract cycle. Example force-extension profiles are shown 
in Figure 4.18. It can be seen that these profiles appear to have three unfolding 
events and a single unbinding event. There were no examples of force-
extension profiles observed that appeared to have a distinct 30Q unfolding 
event, indicating that either the 30Q was not unfolding or that it was unfolding 
at a force too low to be detected by the experiment. Since there were no 
apparent events visible for any 30Q unfolding events, the data needed to be 
analysed in a different way. It was decided to look only at the contour lengths 
of the initial unfolding event and final pull-off event for this set of data.  
Since this was a novel method of analysing this data it was not possible to 
directly compare the initial (Li) and final (Lf) contour lengths to known values 
to validate the experimental protocol. An initial analysis was carried out using 
just the unfolding forces and difference in contour lengths for the unfolding I27 
domains in the constructs. Since if these were consistent with previous results 
it would be a good indication that the AFM was set up correctly and providing 
accurate measurements. The results of this analysis are shown in Figure 4.19 
and Figure 4.20, and summarised in Table 4.2 and Table 4.3, the contour 
lengths obtained (27.3 nm and 26.7 nm) are in good agreement with the 
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published length of 28.1 nm138 and the most probable unfolding forces 
((I27)3-ssrA: 182.3 pN, I27-Q30-(I27)2-ssrA: 181.6 pN) are in good agreement 
with previously published data (182.6 pN154) and my own experiments (176.8 
pN) as shown in Figure 4.16 also agree well with the expected force at that 
unfolding velocity.  
For the mechanical unfolding of Q30 three scenarios were predicted, and are 
described in Figure 4.12. The data were analysed by looking only at the length 
of the initial unfolding event and the final extension at the pull-off event where 
the tip detached from the protein. This would  identify whether the Q30 was in 
a compact globular or expanded form without having to detect individual Q30 
unfolding events (see Figure 4.21). Three scenarios could be envisaged: (i) if 
the Q30 was in an expanded conformation, or too mechanically weak to resist 
mechanical unfolding it would be expected that the first and final events for 
I27-Q30-(I27)2-ssrA would be offset by approximately 10.8 nm (30 × 0.36 nm) 
from the surface in comparison to the control (I27)3-ssrA polyprotein. This is 
of course an approximation as polyglutamine is intrinsically disordered and 
has no fixed structure so it is not possible to calculate an exact value. (ii) the 
polyQ has a resistance to unfolding greater than the maximum force the AFM 
can apply before the pull-off event, in which case it would be expected that the 
initial and final unfolding events would close enough to the values for the 
control protein that the difference would not be detectable by this method. (iii) 
polyQ would unfold within the force-range of this experiment and a distinct 
peak for it would be visible in the force-extension profiles recorded. 
The experiments yielded much less data in comparison to the experiments 
described in section 4.5.1 as it was not possible to analyse partial traces. Only 
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traces which had three distinct unfolding events and a pull-off event were 
suitable for analysis. As can be seen from the data shown in Figure 4.22 and 
Figure 4.23 (and summarised in Figure 4.24) the data supports a model 
whereby polyQ unfolds at a force which is below the thermal noise of the AFM 
(~18 pN35). When comparing the most probable Li and Lf for the two proteins 
the values for I27-Q30-(I27)2-ssrA are 10.4 and 10.3 nm longer than those for 
(I27)3-ssrA respectively. This compares well to the estimated length increase 
of 10.8 nm.  
Although the experimental conditions may not have been ideal due to the low 
number of I27 domains in the concatamer, it is customary to use AFM to 
investigate homopolypeptides with five or more domains. An additional 
complication is the noise close to the surface where the Q30 domain would be 
observed if it unfolds at low force. It may be possible to overcome this problem 
by using the carrier-guest strategy developed by the Carrion-Vazquez group33 
(Section 1.6.1.2). To determine whether these results were statistically 
significant, Li and Lf values were compared between the two constructs, using 
a non-paired, two-tailed Student's t-test159 with equal variance. The t-test 
indicates the observed difference in length is significant (P<0.0001, P<0.0005 
respectively) which supports the model that the polyQ is unfolded or 
mechanically unstable under the experimental conditions employed here.  
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Figure 4.18: Examples of acceptable force-extension profiles obtained for (I27)3-ssrA (left) and I27-Q30-(I27)2-ssrA (right). Red: extension. Blue: retraction. The top row shows WLC fits to the first and last peaks (persistence length = 400 pm) and has the peaks labelled as either UF or UB representing the unfolding of I27 domains or the tip detaching from the polypeptide chain respectively. 
210 
 
Figure 4.19: Length-frequency histograms generated from (I27)3-ssrA (left) and I27-Q30-(I27)2-ssrA (right) constant velocity mechanical unfolding at 1000 pm/s. Fits of a Gaussian distribution to the histograms are shown as solid lines. Parameters of the fit are shown in Table 4.2. 
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Table 4.2: Fitting parameters for the Gaussian fits shown in Figure 4.19.  
Experiment 0 /pN 2 Width 
(√૛ ×࢙࢚ࢇ࢔ࢊࢇ࢘ࢊ ࢊࢋ࢜࢏ࢇ࢚࢏࢕࢔) 
N 
(I27)3-ssrA  27.3±1.0 116.0 14.2 ± 2.4 132 
I27-Q30-(I27)2-ssrA 26.7 ± 0.8 96.6 12.2 ± 1.6 136 
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Figure 4.20: Force-frequency histograms generated from (I27)3-ssrA (top row) and I27-Q30-(I27)2-ssrA (bottom row) constant velocity mechanical unfolding at 1000 nm.s-1 Fits of a Gaussian distribution to each histogram are shown as a solid line. Fitting parameters for the Gaussians are shown in Table 4.3. 
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Table 4.3: Fitting parameters for the Gaussians shown in Figure 4.20. 
Experiment 0 /pN 2 Width 
(√૛ ×࢙࢚ࢇ࢔ࢊࢇ࢘ࢊ ࢊࢋ࢜࢏ࢇ࢚࢏࢕࢔) 
N 
(I27)3-ssrA (A) 175.6 ± 3.0 61.0 39.2 ± 4.2 69 
(I27)3-ssrA (B) 178.2 ± 3.9 99.6 45.3 ± 5.5 81 
(I27)3-ssrA (C) 193.1 ± 2.9 39.0 32.5 ± 4.0 48 
I27-Q30-(I27)2-ssrA (D) 187.9 ± 6.5 59.2 65.3 ± 9.3 63 
I27-Q30-(I27)2-ssrA (E) 174.3 ± 4.0 46.9 54.6 ± 5.6 72 
I27-Q30-(I27)2-ssrA (F) 182.5 ± 4.3 55.2 52.6 ± 6.0 69 
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Figure 4.21: A: Expected force-extension profiles for the mechanical unfolding of (I27)3-ssrA. The profile shows three peaks indicating  the unfolding of I27 domains and a larger peak representing detachment of the tip from the polyprotein. B: Expected force-extension profiles for the three scenarios predicted for the mechanical unfolding of I27-Q30-(I27)2-ssrA. Each profile shows three peaks indicating  the unfolding of I27 domains and a larger peak representing detachment of the tip from the polyprotein. They represent the following possible hypotheses: Top - Q30 has extreme mechanical resistance, no peak is observed for its unfolding and the distance to the initial unfolding peak (Li) and final detachment peak (Lf) are short. Middle: Q30 is mechanically resistant; an additional peak is observed for poly Q unfolding, Li is short, and Lf is long. Bottom: Q30 is mechanically weak, no peak is observed for unfolding and Li is long as is Lf.  
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Figure 4.22: Length frequency histogram showing the length value obtained at the initial unfolding event and the final pull-off event for (I27)3-ssrA. Lines are a Gaussian fit to the data and the number shown above each peak is the mean length at  the centre of that peak.N=66  
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Figure 4.23: Length frequency histogram showing the length value obtained at the initial unfolding event and the final pull-off event for I27-Q30-(I27)2-ssrA. Lines are a Gaussian fit to the data and the number shown above each peak is the mean length at the centre of that peak. N=68 
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Figure 4.24: A box and whisker plot summarising the data shown in Figure 4.22 and Figure 4.23. For each column the central horizontal line represents the median, the interquartile range is contained within the box and the whiskers display the complete range of the data. * : P<0.0001, ** : P<0.0005.  
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 ΔNClpX6P Degradation of (I27)3-ssrA and 
I27-Q30-(I27)2-ssrA 
In order to further probe the mechanical stability of proteins containing polyQ 
repeats, they were degraded by the ClpXP system (ΔNClpX6 and ClpP) 
discussed in Chapter 3. As the rate-limiting step of the ClpXP degradation of 
a protein is the unfolding step (see introduction). It was hypothesised that if 
polyQ exhibited an enhanced mechanical stability then ΔNClpX6P would either 
fail to unfold and degrade it leaving a truncated intermediate (I27-Q30) or it 
would degrade these constructs more slowly than the control protein without 
polyQ. The results of these degradations are shown in Figure 4.25. Neither of 
the degradations had proceeded to completion over the duration of the 
experiment, longer time points were not recorded because the experimental 
procedure (described in section 2.8) involved taking samples from the 
reaction. Increasing the number of samples taken means that either the 
amount of material used for the experiment is increased, or the number of 
samples taken at shorter time-points, when the reaction is proceeding more 
quickly, has to be decreased. While it might have been interesting to see how 
the reaction progressed to completion, the data collected allowed the 
quantification of the reaction rates, which was the aim of the experiment. 
Therefore, expanding the duration of the experiment was not considered 
necessary. 
It can be seen from the SDS-PAGE that there is no detectable intermediate 
present in the reaction with the polyQ containing protein indicating that ClpXP 
can completely degrade it. Quantifying the degradation rates by densitometry 
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(Figure 4.26, Table 4.4) revealed that the polyglutamine containing protein is 
degraded more quickly than the one which does not contain polyglutamine. 
This result is difficult to explain in terms of the expected result: that either the 
degradation rates would be the same or that the polyglutamine containing 
protein would be degraded more slowly. There are two likely explanations, the 
first is experimental error. If the change in rate is less than the error involved 
in the experiment the rates could effectively be the same and the difference 
observed due to this error. The second is that the polyglutamine is having a 
destabilising effect on the I27 domains. While it was demonstrated that the I27 
domains appeared to be folded under experimental conditions (Section 4.4) 
they may not have been as stable as in the protein containing no polyQ. It has 
been suggested that the urea-like side chains of polyQ rich regions can act as 
a denaturant160 or it is possible that the importance of the flanking regions to 
polyQ structure and function are involved (Section 1.5.8). Despite this 
unexpected result it is clear that the biophysical characterisation together with 
the ClpXP degradation show that the polyQ containing protein analysed was 
monodisperse in solution and was not mechanically resistant to unfolding. 
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Figure 4.25: SDS-PAGE showing the results of ΔNClpX6P degradation of A: (I27)3-ssrA B: (I27-Q30-(I27)2-ssrA. i: full gels showing all bands ii-vi: repeat experiments showing just the substrate bands. Bands were quantified as described in Section 2.8.1and the results of the quantification are shown in Figure 4.26.  
221 
 
 
Figure 4.26: Densitometry of the ClpXP degradation of: Red squares: (I27)3-ssrA. Blue diamonds: I27-Q30-(I27)2-ssrA error bars show the standard error. N=6. Inset is the same data plotted as Ln [Substrate] vs Time. Lines are a straight line fit to the data to determine the degradation rate.  
Table 4.4: Quantification of degradation rates determined by fitting to Figure 4.26.  
 k /s-1 R2 for fit 
(I27)3-ssrA. 0.013 0.84 
I27-Q30-(I27)2-ssrA 0.023 0.97 
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5 Discussion 
 The use of ClpXP as a method of applying mechanical 
force 
It was demonstrated in Chapter 3 that it is possible to use ClpXP as a tool to 
investigate the mechanical resistance of a substrate peptide to degradation at 
biologically accessible force loading rates. The SDS-PAGE assay that was 
developed is robust and clearly shows the degradation of a protein substrate 
over the experimental time-course; coupled with densitometry performed on 
the SDS-PAGE gels the data can be analysed to obtain quantitative data for 
the degradation rates of different substrates. Table 5.1 shows the results of 
two such experiments, one to determine whether the presence of DTT affected 
the rate of ClpXP degradation of Im9-ssrA and one to determine whether a 
30Q sequence inserted into a protein affected its degradation rate. These 
results go some way towards showing the range of different rates which can 
be resolved as it was possible to measure rates that differed by an order of 
magnitude, although no attempt to determine the upper and lower rates which 
could be measured  was made. It is reasonable to assume that rates that 
differed more widely than these could be measured, the times at which 
samples were taken could easily be altered so that faster reactions could have 
samples taken at shorter time periods and slower reactions could have longer 
periods between samples.   
Proving that ClpX can operate in different redox environments is an important 
result because it further expands the range of protein substrates which can be 
investigated. Proteins with native disulphide bonds, the disruption of which 
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would take away the biological relevance of the degradation assay performed 
on them, can now have their mechanical properties investigated in a more 
native-like environment.  
We have also demonstrated that it is possible to fine-tune the substrate 
specificity of ClpX, while it was not possible to develop a robust assay for a 
degradation tag other than ssrA I am confident that with further research such 
an assay could be developed.  
It should also be possible to change the conditions under which experiments 
are performed in order to alter the rate of degradation of the protein substrate 
which will allow experiments to be fine-tuned to give a measurable change in 
substrate concentration over a convenient time-course.  
However there are some limitations to using ClpXP as a tool to measure 
mechanical resistance. The most obvious one being that it requires a tagged 
substrate, which in the most limiting case would allow only the investigation of 
the mechanical properties of protein expressed in E. coli and unfolded from 
the C-terminus. However many synthesis techniques can overcome this, such 
as recombinant protein expression in eukaryotic cells which would allow the 
study of proteins subjected to post-translational modification. The use of 
techniques such as sulfhydryl-reactive cross-linked chemistry161,162 or other 
techniques such as sortase modification163 could be used to add degradation 
tags in a site-specific manner. 
The major limitation if this technique is that experiments must be performed in 
conditions under which the ClpXP is stable and active. While the conditions 
are not particularly onerous for biological samples (200 mM KCl, 10% glycerol 
(v/v), pH 7.6, 30 °C), and it may be possible to vary them to some extent, they 
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still require consideration during experimental design and these 
considerations rule out the possibility of investigating identical proteins under 
different conditions (temperatures, salt concentrations, denaturant 
concentrations etc.). It will not be possible to differentiate between the effects 
of the changes on the mechanical properties of the protein substrate and the 
effects of changing conditions on the ClpXP unless we can discover a suitable 
control which could be used to determine the effect of the change in conditions 
on the ClpXP. For example since ClpXP can degrade a wide variety of 
substrates, even including ones with non-natural side chains or altered 
backbone bonds50,  it may be possible to discover a test substrate which had 
a mechanical stability (measured using an alternative technique such as AFM) 
that did not change over the range of assay conditions to be investigated, we 
would then know that any change in degradation rate was due to the effects 
of the different reaction conditions on the ClpXP. This would allow us to correct 
the data obtained for the protein we wanted to study by reference to the data 
obtained for the test protein. Alternatively it may be possible to compare the  
resting ATP hydrolysis rates of ClpXP under the different conditions and use 
these as a measure of ClpXP activity under those conditions, although further 
study would be required to determine whether the resting ATP hydrolysis rate 
changed proportionally to the degradation rate.  
The final limitation relates to batch-to-batch variations when producing ClpXP 
and the possibility of it becoming less active over time; this will mean that 
unless ClpXP activity can be normalised, by comparing the degradation of a 
reference protein perhaps, that it will be difficult to draw firm conclusions by 
comparing data obtained by different laboratories or over long time periods. 
To overcome this limitation, we performed experiments comparing different 
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protein substrates under identical conditions at the same time and using the 
same batch of ClpXP.  
It would be possible to compare the activity of different batches of ClpXP by 
comparing the degradation rates of a test protein. If several different batches 
were tested with a single test protein, either one produced in the laboratory 
and a single batch preparation used to quantify the activity of all further ClpXP 
produced or a high-quality commercially-available protein that would allow 
comparison over longer time periods and between different laboratories. This 
would mean that instead of having ClpXP of a known concentration but 
unknown activity it would be possible to use an amount of ClpXP known to 
provide a certain amount of activity. It would be possible to investigate the 
potential degradation over time of a single batch of ClpXP in the same way. 
By comparing its activity against a test protein any loss of activity could be 
detected and its effects accounted for in the experimental design.   
Overall the application of mechanical unfolding forces by ClpXP and their 
analysis using SDS-PAGE is a valuable addition to the toolkit of a scientist 
interested in the mechanical properties of proteins, particularly because it 
allows access to biologically relevant forces and loading rates, and replicates 
the geometry of force application found in chambered proteases in vivo, that 
cannot yet be achieved using other techniques, and makes an excellent 
complement to dynamic force spectroscopy.  
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Table 5.1: A summary of protein degradation rates obtained in this thesis. 
Substrate protein Degradation rate (k) /s-1 
Im9-ssrA with 2 mM DTT 0.28 
Im9-ssrA without DTT 0.15 
(I27)3-ssrA. 0.013 
I27-Q30-(I27)2-ssrA 0.023 
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 Mechanical unfolding of polyglutamine repeat containing 
proteins 
I was unable to replicate the work of Dougan et. al32. showing that polyQ had 
extreme mechanical stability, but it is unclear whether this was due to a lack 
of AFM data or because, as seems apparent from ClpXP degradation, that it 
did not have any unusual mechanical properties. It is possible that some 
hyperstable conformations as reported by Hérvas et al33. may have been 
present in our samples, but as they saw only 1% of such conformations at a 
similar (35Q) polyQ repeat length it is difficult to say whether they were not 
present or simply too rare to be observed here.  
The polyglutamine repeat-length studied (30Q) was degraded by ClpXP 
without an apparent reduction of the degradation rate compared to a control 
which did not contain a polyglutamine repeat. This is in contrast to the two 
DFS studies performed, one of which showed that polyglutamine was 
extremely mechanically resistant and one of which showed that it had access 
to a mechanically stable conformation.  
I have developed a hypothesis that when studying the force response of 
polyglutamine the loading rates and directionality of the applied force are very 
important. This can be thought of as being analogous to Velcro; when two 
pieces of Velcro are stuck together it is very difficult to separate them by pulling 
them apart from a direction perpendicular to the joined surfaces, but if they are 
peeled apart from the ends they can be easily separated. Applying force at a 
high loading rate by using AFM is analogous to the first situation, but rather 
than trying to separate Velcro’s hooks and eyes you are trying to separate a 
network of hydrogen bonds which may become locked in a rigid conformation 
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by the application of force meaning that they must all be broken at the same 
time in order to unfold the polyglutamine, unfolding with ClpX is analogous to 
the second situation where the hydrogen bond network is unravelled gradually 
from the end allowing the bonds to be broken individually as the polyglutamine 
is unfolded. Since polyglutamine is an intrinsically disordered peptide with no 
fixed secondary structure it is not possible to determine whether its structure 
supports such a hypothesis, however molecular dynamics simulations32, while 
giving no fixed structure, do support it containing a large number of hydrogen 
bonds which need to be disrupted in order for it to unfold.   
 Future work 
The obvious follow on from this work is to investigate polyglutamine repeats 
of different lengths. While the work by Dougan et al. found that the mechanical 
properties of polyglutamine repeats were length-independent, it is clear that 
the toxic effects and aggregation of polyglutamine are length-dependant and 
Hervás et al. saw an increase in hyperstable events with increasing 
polyglutamine length. As the repeat length investigated here (30Q) was under 
the disease length threshold (which varies but is generally considered to be 
approximately 36Q) it would be worthwhile to investigate longer sequences to 
determine whether a difference in mechanical strength was observed using 
the ClpXP assay.  
It would also be desirable to re-design the assay so that it could be monitored 
in a different way. While SDS-PAGE and densitometry is robust and 
inexpensive it can be seen from Section 3.4.2 that its accuracy is susceptible 
to loading errors and differences in staining. As mentioned above, it also does 
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not directly follow unfolding of the substrate. It is also a relatively low-
throughput assay, the number of time points which can be measured is limited 
by: the time taken to physically take samples and mix them with the quenching 
buffer, and by the desire to avoid differential staining between different 
SDS-PAGE gels which means all of the samples from one experiment must 
be analysed on the same gel. In addition removing the samples from the 
reaction mixture introduces a potential source of error and requires that if more 
data points are desired a larger reaction volume or an increase in 
concentration of the reaction components (so that smaller volumes can be 
removed) is required, this is not an insurmountable problem, but it does add 
to the complexity of the assay.  
To overcome these limitations an assay could be designed which measured 
the fluorescence of a sample. This would mean that once the substrate was 
added the reaction mixture would remain undisturbed and many more data 
points at closer time points could be collected. 
Three types of fluorescence assay could be used, illustrated in Figure 5.1, 
choosing the most appropriate one for the system under investigation: The 
first would be to use a fluorescent protein downstream of the protein under 
investigation, this would overcome the limitations of the SDS-PAGE assay but 
would still not provide a direct measurement of unfolding. The second would 
be to use an intrinsic fluorophore (such as tryptophan) within the protein under 
investigation that was known to change environment upon unfolding. This 
would allow unfolding to be measured directly as well as overcoming the 
limitations of the SDS-PAGE assay, but would obviously only be suitable for 
systems containing such an intrinsic fluorophore or to which one could be 
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added without altering the mechanical properties of the protein. The third 
would be to make use of fluorescent labelling techniques to add either a FRET 
pair or a self-quenching fluorophore at locations on the substrate protein 
where they would be disrupted by its unfolding, while not affecting its 
mechanical stability. 
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Figure 5.1: Cartoon representation of various methods of using fluorescence to follow a ClpXP (blue cylinder) degradation assay. A: A fluorescent protein (green) is added to the protein of interest (red) by a linker (blue line). The assay can be followed by monitoring the fluorescence emission which will end when the fluorescent protein is unfolded. B: An intrinsic fluorophore is used to detect unfolding of the protein of interest, the emitted fluorescence will change on unfolding. C: A FRET pair is used to detect unfolding, when the protein of interest is unfolded the FRET pair will be too far apart and fluorescence will cease.  
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7 Appendix 
 DNA and Amino Acid Sequences used in this work 
7.1.1 ClpX Variants 
7.1.1.1 Protein: ClpX 
Brief Description: Pseudo wild-type ClpX with N-terminal His tag 
Plasmid: pET23ClpX 
Antibiotic resistance encoded in plasmid: Ampicillin 
Number of amino acids: 431 
Protein Mass: 47310.0 Da 
Calculated extinction coefficient: 16765 M.cm-1 
DNA sequence: 
      1  ATGCATCATC ATCATCATCA TATGACCGAT AAACGTAAAG ATGGCAGCGG CAAACTGCTG       61  TATTGCAGCT TTTGCGGCAA AAGCCAGCAT GAAGTGCGTA AACTGATTGC GGGCCCGAGC      121  GTGTATATTT GCGATGAATG CGTGGATCTG TGCAACGATA TTATTCGTGA AGAAATTAAA      181  GAAGTGGCGC CGCATCGTGA ACGTAGCGCG CTGCCGACCC CGCATGAAAT TCGTAACCAT      241  CTGGATGATT ATGTGATTGG CCAGGAACAG GCGAAAAAAG TGCTGGCGGT GGCGGTGTAT      301  AACCATTATA AACGTCTGCG TAACGGCGAT ACCAGCAACG GCGTGGAACT GGGCAAAAGC      361  AACATTCTGC TGATTGGCCC GACCGGCAGC GGCAAAACCC TGCTGGCGGA AACCCTGGCG      421  CGTCTGCTGG ATGTGCCGTT TACCATGGCG GATGCGACCA CCCTGACCGA AGCGGGCTAT      481  GTGGGCGAAG ATGTGGAAAA CATTATTCAG AAACTGCTGC AGAAATGCGA TTATGATGTG      541  CAGAAAGCGC AGCGTGGCAT TGTGTATATT GATGAAATTG ATAAAATTAG CCGTAAAAGC      601  GATAACCCGA GCATTACCCG TGATGTGAGC GGCGAAGGCG TGCAGCAGGC GCTGCTGAAA      661  CTGATTGAAG GCACCGTGGC GGCGGTGCCG CCGCAGGGCG GCCGTAAACA TCCGCAGCAG      721  GAATTTCTGC AGGTGGATAC CAGCAAAATT CTGTTTATTT GCGGCGGCGC GTTTGCGGGC      781  CTGGATAAAG TGATTAGCCA TCGTGTGGAA ACCGGCAGCG GCATTGGCTT TGGCGCGACC      841  GTGAAAGCGA AAAGCGATAA AGCGAGCGAA GGCGAACTGC TGGCGCAGGT GGAACCGGAA      901  GATCTGATTA AATTTGGCCT GATTCCGGAA TTTATTGGCC GTCTGCCGGT GGTGGCGACC      961  CTGAACGAAC TGAGCGAAGA AGCGCTGATT CAGATTCTGA AAGAACCGAA AAACGCGCTG     1021  ACCAAACAGT ATCAGGCGCT GTTTAACCTG GAAGGCGTGG ATCTGGAATT TCGTGATGAA     1081  GCGCTGGATG CGATTGCGAA AAAAGCGATG GCGCGTAAAA CCGGCGCGCG TGGCCTGCGT     1141  AGCATTGTGG AAGCGGCGCT GCTGGATACC ATGTATGATC TGCCGAGCAT GGAAGATGTG     1201  GAAAAAGTGG TGATTGATGA AAGCGTGATT GATGGCCAGA GCAAACCGCT GCTGATTTAT     1261  GGCAAACCGG AAGCGCAGCA GGCGAGCGGC GAA  Protein sequence: 
     MHHHHHHMTD KRKDGSGKLL YCSFCGKSQH EVRKLIAGPS VYICDECVDL CNDIIREEIK      EVAPHRERSA LPTPHEIRNH LDDYVIGQEQ AKKVLAVAVY NHYKRLRNGD TSNGVELGKS      NILLIGPTGS GKTLLAETLA RLLDVPFTMA DATTLTEAGY VGEDVENIIQ KLLQKCDYDV      QKAQRGIVYI DEIDKISRKS DNPSITRDVS GEGVQQALLK LIEGTVAAVP PQGGRKHPQQ      EFLQVDTSKI LFICGGAFAG LDKVISHRVE TGSGIGFGAT VKAKSDKASE GELLAQVEPE      DLIKFGLIPE FIGRLPVVAT LNELSEEALI QILKEPKNAL TKQYQALFNL EGVDLEFRDE      ALDAIAKKAM ARKTGARGLR SIVEAALLDT MYDLPSMEDV EKVVIDESVI DGQSKPLLIY      GKPEAQQASG E  
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7.1.1.2 Protein: ΔNClpX6 
Brief Description: Pseudohexameric single-chain ClpX varaint 
Plasmid: pAYC ΔNClpX6 
Antibiotic resistance encoded in plasmid: Chloramphenicol 
Number of amino acids: 2305 
Protein Mass: 247192 Da 
Calculated extinction coefficient: 82700 M.cm-1 
DNA sequence: 
       1  TAATACGACT CACTATAGGG GAATTGTGAG CGGATAACAA TTCCCCTGTA GAAATAATTT       61  TGTTTAACTT TAATAAGGAG ATATACCATG GCCGATTACA AAGATGACGA TGACAAAAGC      121  TCTCATATGA GTGCGCTACC GACGCCGCAT GAAATTCGCA ACCACCTGGA CGATTACGTT      181  ATCGGCCAGG AACAGGCGAA AAAAGTGCTG GCGGTCGCGG TATACAACCA TTACAAACGT      241  CTGCGCAACG GCGATACCAG CAATGGCGTC GAGTTGGGCA AAAGTAACAT TCTGCTGATC      301  GGTCCGACCG GTTCCGGTAA AACGCTGCTG GCTGAAACGC TGGCGCGCCT GCTGGATGTT      361  CCGTTCACCA TGGCCGACGC GACTACACTG ACCGAAGCCG GTTATGTGGG TGAAGACGTT      421  GAAAACATCA TTCAGAAGCT GTTGCAGAAA TGCGACTACG ATGTCCAGAA AGCACAGCGT      481  GGTATTGTCT ACATCGATGA AATCGACAAG ATTTCTCGTA AGTCAGACAA CCCGTCCATT      541  ACCCGAGACG TTTCCGGTGA AGGCGTACAG CAGGCACTGT TGAAACTGAT CGAAGGTACG      601  GTAGCTGCTG TTCCACCGCA AGGTGGGCGT AAACATCCGC AGCAGGAATT CTTGCAGGTT      661  GATACCTCTA AGATCCTGTT TATTTGTGGC GGTGCGTTTG CCGGTCTGGA TAAAGTGATT      721  TCCCACCGTG TAGAAACCGG CTCCGGCATT GGTTTTGGCG CGACGGTAAA AGCGAAGTCC      781  GACAAAGCAA GCGAAGGCGA GCTGCTGGCG CAGGTTGAAC CGGAAGATCT GATCAAGTTT      841  GGTCTTATCC CTGAGTTTAT TGGTCGTCTG CCGGTTGTCG CAACGTTGAA TGAACTGAGC      901  GAAGAAGCTC TGATTCAGAT CCTCAAAGAG CCGAAAAACG CCCTGACCAA GCAGTATCAG      961  GCGCTGTTTA ATCTGGAAGG CGTGGATCTG GAATTCCGTG ACGAGGCGCT GGATGCTATC     1021  GCTAAGAAAG CGATGGCGCG TAAAACCGGT GCCCGTGGCC TGCGTTCCAT CGTAGAAGCC     1081  GCACTGCTCG ATACCATGTA CGATCTGCCG TCCATGGAAG ACGTCGAAAA AGTGGTTATC     1141  GACGAGTCGG TAATTGATGG TCAAAGCAAA CCGTTGCTGA TTTATGGCAA GCCGGAAGCG     1201  CAACAGGCAT CTGGTGAGGC CAGCGGGGCC GGCGGTTCTG AAGGTGGCGG CAGCGAAGGT     1261  GGTACCAGCG GGGCCACAAT GAGTGCGCTA CCGACGCCGC ATGAAATTCG CAACCACCTG     1321  GACGATTACG TTATCGGCCA GGAACAGGCG AAAAAAGTGC TGGCGGTCGC GGTATACAAC     1381  CATTACAAAC GTCTGCGCAA CGGCGATACC AGCAATGGCG TCGAGTTGGG CAAAAGTAAC     1441  ATTCTGCTGA TCGGTCCGAC CGGTTCCGGT AAAACGCTGC TGGCTGAAAC GCTGGCGCGC     1501  CTGCTGGATG TTCCGTTCAC CATGGCCGAC GCGACTACAC TGACCGAAGC CGGTTATGTG     1561  GGTGAAGACG TTGAAAACAT CATTCAGAAG CTGTTGCAGA AATGCGACTA CGATGTCCAG     1621  AAAGCACAGC GTGGTATTGT CTACATCGAT GAAATCGACA AGATTTCTCG TAAGTCAGAC     1681  AACCCGTCCA TTACCCGAGA CGTTTCCGGT GAAGGCGTAC AGCAGGCACT GTTGAAACTG     1741  ATCGAAGGTA CGGTAGCTGC TGTTCCACCG CAAGGTGGGC GTAAACATCC GCAGCAGGAA     1801  TTCTTGCAGG TTGATACCTC TAAGATCCTG TTTATTTGTG GCGGTGCGTT TGCCGGTCTG     1861  GATAAAGTGA TTTCCCACCG TGTAGAAACC GGCTCCGGCA TTGGTTTTGG CGCGACGGTA     1921  AAAGCGAAGT CCGACAAAGC AAGCGAAGGC GAGCTGCTGG CGCAGGTTGA ACCGGAAGAT     1981  CTGATCAAGT TTGGTCTTAT CCCTGAGTTT ATTGGTCGTC TGCCGGTTGT CGCAACGTTG     2041  AATGAACTGA GCGAAGAAGC TCTGATTCAG ATCCTCAAAG AGCCGAAAAA CGCCCTGACC     2101  AAGCAGTATC AGGCGCTGTT TAATCTGGAA GGCGTGGATC TGGAATTCCG TGACGAGGCG     2161  CTGGATGCTA TCGCTAAGAA AGCGATGGCG CGTAAAACCG GTGCCCGTGG CCTGCGTTCC     2221  ATCGTAGAAG CCGCACTGCT CGATACCATG TACGATCTGC CGTCCATGGA AGACGTCGAA     2281  AAAGTGGTTA TCGACGAGTC GGTAATTGAT GGTCAAAGCA AACCGTTGCT GATTTATGGC     2341  AAGCCGGAAG CGCAACAGGC ATCTGGTGAG GCCAGCGGGG CCGGCGGTTC TGAAGGTGGC     2401  GGCAGCGAAG GTGGCTCGAG CGGGGCCACA ATGAGTGCGC TACCGACGCC GCATGAAATT     2461  CGCAACCACC TGGACGATTA CGTTATCGGC CAGGAACAGG CGAAAAAAGT GCTGGCGGTC     2521  GCGGTATACA ACCATTACAA ACGTCTGCGC AACGGCGATA CCAGCAATGG CGTCGAGTTG     2581  GGCAAAAGTA ACATTCTGCT GATCGGTCCG ACCGGTTCCG GTAAAACGCT GCTGGCTGAA     2641  ACGCTGGCGC GCCTGCTGGA TGTTCCGTTC ACCATGGCCG ACGCGACTAC ACTGACCGAA     2701  GCCGGTTATG TGGGTGAAGA CGTTGAAAAC ATCATTCAGA AGCTGTTGCA GAAATGCGAC 
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    2761  TACGATGTCC AGAAAGCACA GCGTGGTATT GTCTACATCG ATGAAATCGA CAAGATTTCT     2821  CGTAAGTCAG ACAACCCGTC CATTACCCGA GACGTTTCCG GTGAAGGCGT ACAGCAGGCA     2881  CTGTTGAAAC TGATCGAAGG TACGGTAGCT GCTGTTCCAC CGCAAGGTGG GCGTAAACAT     2941  CCGCAGCAGG AATTCTTGCA GGTTGATACC TCTAAGATCC TGTTTATTTG TGGCGGTGCG     3001  TTTGCCGGTC TGGATAAAGT GATTTCCCAC CGTGTAGAAA CCGGCTCCGG CATTGGTTTT     3061  GGCGCGACGG TAAAAGCGAA GTCCGACAAA GCAAGCGAAG GCGAGCTGCT GGCGCAGGTT     3121  GAACCGGAAG ATCTGATCAA GTTTGGTCTT ATCCCTGAGT TTATTGGTCG TCTGCCGGTT     3181  GTCGCAACGT TGAATGAACT GAGCGAAGAA GCTCTGATTC AGATCCTCAA AGAGCCGAAA     3241  AACGCCCTGA CCAAGCAGTA TCAGGCGCTG TTTAATCTGG AAGGCGTGGA TCTGGAATTC     3301  CGTGACGAGG CGCTGGATGC TATCGCTAAG AAAGCGATGG CGCGTAAAAC CGGTGCCCGT     3361  GGCCTGCGTT CCATCGTAGA AGCCGCACTG CTCGATACCA TGTACGATCT GCCGTCCATG     3421  GAAGACGTCG AAAAAGTGGT TATCGACGAG TCGGTAATTG ATGGTCAAAG CAAACCGTTG     3481  CTGATTTATG GCAAGCCGGA AGCGCAACAG GCATCTGGTG AGGCCAGCGG GGCCGGCGGT     3541  TCTGAAGGTG GCGGCAGCGA AGGTGGGTCG ACCGGGGCCA CAATGAGTGC GCTACCGACG     3601  CCGCATGAAA TTCGCAACCA CCTGGACGAT TACGTTATCG GCCAGGAACA GGCGAAAAAA     3661  GTGCTGGCGG TCGCGGTATA CAACCATTAC AAACGTCTGC GCAACGGCGA TACCAGCAAT     3721  GGCGTCGAGT TGGGCAAAAG TAACATTCTG CTGATCGGTC CGACCGGTTC CGGTAAAACG     3781  CTGCTGGCTG AAACGCTGGC GCGCCTGCTG GATGTTCCGT TCACCATGGC CGACGCGACT     3841  ACACTGACCG AAGCCGGTTA TGTGGGTGAA GACGTTGAAA ACATCATTCA GAAGCTGTTG     3901  CAGAAATGCG ACTACGATGT CCAGAAAGCA CAGCGTGGTA TTGTCTACAT CGATGAAATC     3961  GACAAGATTT CTCGTAAGTC AGACAACCCG TCCATTACCC GAGACGTTTC CGGTGAAGGC     4021  GTACAGCAGG CACTGTTGAA ACTGATCGAA GGTACGGTAG CTGCTGTTCC ACCGCAAGGT     4081  GGGCGTAAAC ATCCGCAGCA GGAATTCTTG CAGGTTGATA CCTCTAAGAT CCTGTTTATT     4141  TGTGGCGGTG CGTTTGCCGG TCTGGATAAA GTGATTTCCC ACCGTGTAGA AACCGGCTCC     4201  GGCATTGGTT TTGGCGCGAC GGTAAAAGCG AAGTCCGACA AAGCAAGCGA AGGCGAGCTG     4261  CTGGCGCAGG TTGAACCGGA AGATCTGATC AAGTTTGGTC TTATCCCTGA GTTTATTGGT     4321  CGTCTGCCGG TTGTCGCAAC GTTGAATGAA CTGAGCGAAG AAGCTCTGAT TCAGATCCTC     4381  AAAGAGCCGA AAAACGCCCT GACCAAGCAG TATCAGGCGC TGTTTAATCT GGAAGGCGTG     4441  GATCTGGAAT TCCGTGACGA GGCGCTGGAT GCTATCGCTA AGAAAGCGAT GGCGCGTAAA     4501  ACCGGTGCCC GTGGCCTGCG TTCCATCGTA GAAGCCGCAC TGCTCGATAC CATGTACGAT     4561  CTGCCGTCCA TGGAAGACGT CGAAAAAGTG GTTATCGACG AGTCGGTAAT TGATGGTCAA     4621  AGCAAACCGT TGCTGATTTA TGGCAAGCCG GAAGCGCAAC AGGCATCTGG TGAGGCCAGC     4681  GGGGCCGGCG GTTCTGAAGG TGGCGGCAGC GAAGGTGGCA CCTCTGCAGG CACAATGAGT     4741  GCGCTACCGA CGCCGCATGA AATTCGCAAC CACCTGGACG ATTACGTTAT CGGCCAGGAA     4801  CAGGCGAAAA AAGTGCTGGC GGTCGCGGTA TACAACCATT ACAAACGTCT GCGCAACGGC     4861  GATACCAGCA ATGGCGTCGA GTTGGGCAAA AGTAACATTC TGCTGATCGG TCCGACCGGT     4921  TCCGGTAAAA CGCTGCTGGC TGAAACGCTG GCGCGCCTGC TGGATGTTCC GTTCACCATG     4981  GCCGACGCGA CTACACTGAC CGAAGCCGGT TATGTGGGTG AAGACGTTGA AAACATCATT     5041  CAGAAGCTGT TGCAGAAATG CGACTACGAT GTCCAGAAAG CACAGCGTGG TATTGTCTAC     5101  ATCGATGAAA TCGACAAGAT TTCTCGTAAG TCAGACAACC CGTCCATTAC CCGAGACGTT     5161  TCCGGTGAAG GCGTACAGCA GGCACTGTTG AAACTGATCG AAGGTACGGT AGCTGCTGTT     5221  CCACCGCAAG GTGGGCGTAA ACATCCGCAG CAGGAATTCT TGCAGGTTGA TACCTCTAAG     5281  ATCCTGTTTA TTTGTGGCGG TGCGTTTGCC GGTCTGGATA AAGTGATTTC CCACCGTGTA     5341  GAAACCGGCT CCGGCATTGG TTTTGGCGCG ACGGTAAAAG CGAAGTCCGA CAAAGCAAGC     5401  GAAGGCGAGC TGCTGGCGCA GGTTGAACCG GAAGATCTGA TCAAGTTTGG TCTTATCCCT     5461  GAGTTTATTG GTCGTCTGCC GGTTGTCGCA ACGTTGAATG AACTGAGCGA AGAAGCTCTG     5521  ATTCAGATCC TCAAAGAGCC GAAAAACGCC CTGACCAAGC AGTATCAGGC GCTGTTTAAT     5581  CTGGAAGGCG TGGATCTGGA ATTCCGTGAC GAGGCGCTGG ATGCTATCGC TAAGAAAGCG     5641  ATGGCGCGTA AAACCGGTGC CCGTGGCCTG CGTTCCATCG TAGAAGCCGC ACTGCTCGAT     5701  ACCATGTACG ATCTGCCGTC CATGGAAGAC GTCGAAAAAG TGGTTATCGA CGAGTCGGTA     5761  ATTGATGGTC AAAGCAAACC GTTGCTGATT TATGGCAAGC CGGAAGCGCA ACAGGCATCT     5821  GGTGAGGCCA GCGGGGCCGG CGGTTCTGAA GGTGGCGGCA GCGAAGGTGG ATCCAGCGGG     5881  GCCACAATGA GTGCGCTACC GACGCCGCAT GAAATTCGCA ACCACCTGGA CGATTACGTT     5941  ATCGGCCAGG AACAGGCGAA AAAAGTGCTG GCGGTCGCGG TATACAACCA TTACAAACGT     6001  CTGCGCAACG GCGATACCAG CAATGGCGTC GAGTTGGGCA AAAGTAACAT TCTGCTGATC     6061  GGTCCGACCG GTTCCGGTAA AACGCTGCTG GCTGAAACGC TGGCGCGCCT GCTGGATGTT     6121  CCGTTCACCA TGGCCGACGC GACTACACTG ACCGAAGCCG GTTATGTGGG TGAAGACGTT     6181  GAAAACATCA TTCAGAAGCT GTTGCAGAAA TGCGACTACG ATGTCCAGAA AGCACAGCGT     6241  GGTATTGTCT ACATCGATGA AATCGACAAG ATTTCTCGTA AGTCAGACAA CCCGTCCATT     6301  ACCCGAGACG TTTCCGGTGA AGGCGTACAG CAGGCACTGT TGAAACTGAT CGAAGGTACG     6361  GTAGCTGCTG TTCCACCGCA AGGTGGGCGT AAACATCCGC AGCAGGAATT CTTGCAGGTT     6421  GATACCTCTA AGATCCTGTT TATTTGTGGC GGTGCGTTTG CCGGTCTGGA TAAAGTGATT     6481  TCCCACCGTG TAGAAACCGG CTCCGGCATT GGTTTTGGCG CGACGGTAAA AGCGAAGTCC     6541  GACAAAGCAA GCGAAGGCGA GCTGCTGGCG CAGGTTGAAC CGGAAGATCT GATCAAGTTT     6601  GGTCTTATCC CTGAGTTTAT TGGTCGTCTG CCGGTTGTCG CAACGTTGAA TGAACTGAGC     6661  GAAGAAGCTC TGATTCAGAT CCTCAAAGAG CCGAAAAACG CCCTGACCAA GCAGTATCAG     6721  GCGCTGTTTA ATCTGGAAGG CGTGGATCTG GAATTCCGTG ACGAGGCGCT GGATGCTATC     6781  GCTAAGAAAG CGATGGCGCG TAAAACCGGT GCCCGTGGCC TGCGTTCCAT CGTAGAAGCC     6841  GCACTGCTCG ATACCATGTA CGATCTGCCG TCCATGGAAG ACGTCGAAAA AGTGGTTATC 
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    6901  GACGAGTCGG TAATTGATGG TCAAAGCAAA CCGTTGCTGA TTTATGGCAA GCCGGAAGCG     6961  CAACAGGCAT CTGGTGAATC TAGTCATCAC CATCATCACC ACTAAAAGCT TGCGGCCGCA     7021  CTCGAGTCTG GTAAAGAAAC CGCTGCTGCG AAATTTGAAC GCCAGCACAT GGACTCGTCT     7081  ACTAGCGCAG CTTAATTAAC CTAGGCTGCT GCCACCGCTG AGCAATAACT AGCATAACCC     7141  CTTGGGGCCT CTAAACGGGT CTTG  
Protein sequence: 
     MADYKDDDDK SSHMSALPTP HEIRNHLDDY VIGQEQAKKV LAVAVYNHYK RLRNGDTSNG      VELGKSNILL IGPTGSGKTL LAETLARLLD VPFTMADATT LTEAGYVGED VENIIQKLLQ      KCDYDVQKAQ RGIVYIDEID KISRKSDNPS ITRDVSGEGV QQALLKLIEG TVAAVPPQGG      RKHPQQEFLQ VDTSKILFIC GGAFAGLDKV ISHRVETGSG IGFGATVKAK SDKASEGELL      AQVEPEDLIK FGLIPEFIGR LPVVATLNEL SEEALIQILK EPKNALTKQY QALFNLEGVD      LEFRDEALDA IAKKAMARKT GARGLRSIVE AALLDTMYDL PSMEDVEKVV IDESVIDGQS      KPLLIYGKPE AQQASGEASG AGGSEGGGSE GGTSGATMSA LPTPHEIRNH LDDYVIGQEQ      AKKVLAVAVY NHYKRLRNGD TSNGVELGKS NILLIGPTGS GKTLLAETLA RLLDVPFTMA      DATTLTEAGY VGEDVENIIQ KLLQKCDYDV QKAQRGIVYI DEIDKISRKS DNPSITRDVS      GEGVQQALLK LIEGTVAAVP PQGGRKHPQQ EFLQVDTSKI LFICGGAFAG LDKVISHRVE      TGSGIGFGAT VKAKSDKASE GELLAQVEPE DLIKFGLIPE FIGRLPVVAT LNELSEEALI      QILKEPKNAL TKQYQALFNL EGVDLEFRDE ALDAIAKKAM ARKTGARGLR SIVEAALLDT      MYDLPSMEDV EKVVIDESVI DGQSKPLLIY GKPEAQQASG EASGAGGSEG GGSEGGSSGA      TMSALPTPHE IRNHLDDYVI GQEQAKKVLA VAVYNHYKRL RNGDTSNGVE LGKSNILLIG      PTGSGKTLLA ETLARLLDVP FTMADATTLT EAGYVGEDVE NIIQKLLQKC DYDVQKAQRG      IVYIDEIDKI SRKSDNPSIT RDVSGEGVQQ ALLKLIEGTV AAVPPQGGRK HPQQEFLQVD      TSKILFICGG AFAGLDKVIS HRVETGSGIG FGATVKAKSD KASEGELLAQ VEPEDLIKFG      LIPEFIGRLP VVATLNELSE EALIQILKEP KNALTKQYQA LFNLEGVDLE FRDEALDAIA      KKAMARKTGA RGLRSIVEAA LLDTMYDLPS MEDVEKVVID ESVIDGQSKP LLIYGKPEAQ      QASGEASGAG GSEGGGSEGG STGATMSALP TPHEIRNHLD DYVIGQEQAK KVLAVAVYNH      YKRLRNGDTS NGVELGKSNI LLIGPTGSGK TLLAETLARL LDVPFTMADA TTLTEAGYVG      EDVENIIQKL LQKCDYDVQK AQRGIVYIDE IDKISRKSDN PSITRDVSGE GVQQALLKLI      EGTVAAVPPQ GGRKHPQQEF LQVDTSKILF ICGGAFAGLD KVISHRVETG SGIGFGATVK      AKSDKASEGE LLAQVEPEDL IKFGLIPEFI GRLPVVATLN ELSEEALIQI LKEPKNALTK      QYQALFNLEG VDLEFRDEAL DAIAKKAMAR KTGARGLRSI VEAALLDTMY DLPSMEDVEK      VVIDESVIDG QSKPLLIYGK PEAQQASGEA SGAGGSEGGG SEGGTSAGTM SALPTPHEIR      NHLDDYVIGQ EQAKKVLAVA VYNHYKRLRN GDTSNGVELG KSNILLIGPT GSGKTLLAET      LARLLDVPFT MADATTLTEA GYVGEDVENI IQKLLQKCDY DVQKAQRGIV YIDEIDKISR      KSDNPSITRD VSGEGVQQAL LKLIEGTVAA VPPQGGRKHP QQEFLQVDTS KILFICGGAF      AGLDKVISHR VETGSGIGFG ATVKAKSDKA SEGELLAQVE PEDLIKFGLI PEFIGRLPVV      ATLNELSEEA LIQILKEPKN ALTKQYQALF NLEGVDLEFR DEALDAIAKK AMARKTGARG      LRSIVEAALL DTMYDLPSME DVEKVVIDES VIDGQSKPLL IYGKPEAQQA SGEASGAGGS      EGGGSEGGSS GATMSALPTP HEIRNHLDDY VIGQEQAKKV LAVAVYNHYK RLRNGDTSNG      VELGKSNILL IGPTGSGKTL LAETLARLLD VPFTMADATT LTEAGYVGED VENIIQKLLQ      KCDYDVQKAQ RGIVYIDEID KISRKSDNPS ITRDVSGEGV QQALLKLIEG TVAAVPPQGG      RKHPQQEFLQ VDTSKILFIC GGAFAGLDKV ISHRVETGSG IGFGATVKAK SDKASEGELL      AQVEPEDLIK FGLIPEFIGR LPVVATLNEL SEEALIQILK EPKNALTKQY QALFNLEGVD      LEFRDEALDA IAKKAMARKT GARGLRSIVE AALLDTMYDL PSMEDVEKVV IDESVIDGQS      KPLLIYGKPE AQQASGESSH HHHHH 
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7.1.1.3 Protein: ClpXΔRKH 
Brief Description: Pseudo wild-type ClpX with N-terminal His tag and R228A, 
K229A, H230A mutations.  
Plasmid: pET23ClpXRKH 
Antibiotic resistance encoded in plasmid: Ampicillin  
Number of amino acids: 431 
Protein Mass: 47101.7 Da 
Calculated extinction coefficient: 16765 M.cm-1 
DNA sequence: 
      1  ATGCATCATC ATCATCATCA TATGACCGAT AAACGTAAAG ATGGCAGCGG CAAACTGCTG       61  TATTGCAGCT TTTGCGGCAA AAGCCAGCAT GAAGTGCGTA AACTGATTGC GGGCCCGAGC      121  GTGTATATTT GCGATGAATG CGTGGATCTG TGCAACGATA TTATTCGTGA AGAAATTAAA      181  GAAGTGGCGC CGCATCGTGA ACGTAGCGCG CTGCCGACCC CGCATGAAAT TCGTAACCAT      241  CTGGATGATT ATGTGATTGG CCAGGAACAG GCGAAAAAAG TGCTGGCGGT GGCGGTGTAT      301  AACCATTATA AACGTCTGCG TAACGGCGAT ACCAGCAACG GCGTGGAACT GGGCAAAAGC      361  AACATTCTGC TGATTGGCCC GACCGGCAGC GGCAAAACCC TGCTGGCGGA AACCCTGGCG      421  CGTCTGCTGG ATGTGCCGTT TACCATGGCG GATGCGACCA CCCTGACCGA AGCGGGCTAT      481  GTGGGCGAAG ATGTGGAAAA CATTATTCAG AAACTGCTGC AGAAATGCGA TTATGATGTG      541  CAGAAAGCGC AGCGTGGCAT TGTGTATATT GATGAAATTG ATAAAATTAG CCGTAAAAGC      601  GATAACCCGA GCATTACCCG TGATGTGAGC GGCGAAGGCG TGCAGCAGGC GCTGCTGAAA      661  CTGATTGAAG GCACCGTGGC GGCGGTGCCG CCGCAGGGCG GCGCGGCGGC GCCGCAGCAG      721  GAATTTCTGC AGGTGGATAC CAGCAAAATT CTGTTTATTT GCGGCGGCGC GTTTGCGGGC      781  CTGGATAAAG TGATTAGCCA TCGTGTGGAA ACCGGCAGCG GCATTGGCTT TGGCGCGACC      841  GTGAAAGCGA AAAGCGATAA AGCGAGCGAA GGCGAACTGC TGGCGCAGGT GGAACCGGAA      901  GATCTGATTA AATTTGGCCT GATTCCGGAA TTTATTGGCC GTCTGCCGGT GGTGGCGACC      961  CTGAACGAAC TGAGCGAAGA AGCGCTGATT CAGATTCTGA AAGAACCGAA AAACGCGCTG     1021  ACCAAACAGT ATCAGGCGCT GTTTAACCTG GAAGGCGTGG ATCTGGAATT TCGTGATGAA     1081  GCGCTGGATG CGATTGCGAA AAAAGCGATG GCGCGTAAAA CCGGCGCGCG TGGCCTGCGT     1141  AGCATTGTGG AAGCGGCGCT GCTGGATACC ATGTATGATC TGCCGAGCAT GGAAGATGTG     1201  GAAAAAGTGG TGATTGATGA AAGCGTGATT GATGGCCAGA GCAAACCGCT GCTGATTTAT     1261  GGCAAACCGG AAGCGCAGCA GGCGAGCGGC GAA Protein sequence: 
     MHHHHHHMTD KRKDGSGKLL YCSFCGKSQH EVRKLIAGPS VYICDECVDL CNDIIREEIK      EVAPHRERSA LPTPHEIRNH LDDYVIGQEQ AKKVLAVAVY NHYKRLRNGD TSNGVELGKS      NILLIGPTGS GKTLLAETLA RLLDVPFTMA DATTLTEAGY VGEDVENIIQ KLLQKCDYDV      QKAQRGIVYI DEIDKISRKS DNPSITRDVS GEGVQQALLK LIEGTVAAVP PQGGAAAPQQ      EFLQVDTSKI LFICGGAFAG LDKVISHRVE TGSGIGFGAT VKAKSDKASE GELLAQVEPE      DLIKFGLIPE FIGRLPVVAT LNELSEEALI QILKEPKNAL TKQYQALFNL EGVDLEFRDE      ALDAIAKKAM ARKTGARGLR SIVEAALLDT MYDLPSMEDV EKVVIDESVI DGQSKPLLIY      GKPEAQQASG E  
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Figure 7.1: Plasmid map of pET23ClpXΔRKH. 
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7.1.1.4 Protein: ClpXΔRKH-TC 
Brief Description: Pseudo wild-type ClpX with N-terminal His-tag upstream of 
a thrombin cleavage site and R228A, K229A, H230A mutations. 
Plasmid: pET23 ClpXΔRKH-TC 
Antibiotic resistance encoded in plasmid: Ampicillin  
Number of amino acids: 444 
Protein Mass: 48311.0 Da 
Calculated extinction coefficient: 16765 M.cm-1 
DNA sequence: 
  1  ATGGGCAGCA GCCATCATCA TCATCATCAT AGCAGCGGCC TGGTGCCGCG CGGCAGCCAT  61  GGCTCAGGCA AATTGCTGTA TTGCTCTTTT TGCGGCAAAA GCCAGCATGA AGTGCGCAA    121  CTGATTGCCG GTCCATCCGT GTATATCTGC GACGAATGTG TTGATTTATG TAACGACATC 181  ATTCGCGAAG AGATTAAAGA AGTTGCACCG CATCGTGAAC GCAGTGCGCT ACCGACGCCG 241  CATGAAATTC GCAACCACCT GGACGATTAC GTTATCGGCC AGGAACAGGC GAAAAAAGTG 301  CTGGCGGTCG CGGTATACAA CCATTACAAA CGTCTGCGCA ACGGCGATAC CAGCAATGGC 361  GTCGAGTTGG GCAAAAGTAA CATTCTGCTG ATCGGTCCGA CCGGTTCCGG TAAAACGCTG 421  CTGGCTGAAA CGCTGGCGCG CCTGCTGGAT GTTCCGTTCA CCATGGCCGA CGCGACTACA 481  CTGACCGAAG CCGGTTATGT GGGTGAAGAC GTTGAAAACA TCATTCAGAA GCTGTTGCAG 541  AAATGCGACT ACGATGTCCA GAAAGCACAG CGTGGTATTG TCTACATCGA TGAAATCGAC 601  AAGATTTCTC GTAAGTCAGA CAACCCGTCC ATTACCCGAG ACGTTTCCGG TGAAGGCGTA 661  CAGCAGGCAC TGTTGAAACT GATCGAAGGT ACGGTAGCTG CTGTTCCACC GCAAGGTGGG 721  CGTAAACATC CGCAGCAGGA ATTCTTGCAG GTTGATACCT CTAAGATCCT GTTTATTTGT 781  GGCGGTGCGT TTGCCGGTCT GGATAAAGTG ATTTCCCACC GTGTAGAAAC CGGCTCCGGC 841  ATTGGTTTTG GCGCGACGGT AAAAGCGAAG TCCGACAAAG CAAGCGAAGG CGAGCTGCTG 901  GCGCAGGTTG AACCGGAAGA TCTGATCAAG TTTGGTCTTA TCCCTGAGTT TATTGGTCGT 961  CTGCCGGTTG TCGCAACGTT GAATGAACTG AGCGAAGAAG CTCTGATTCA GATCCTCAAA 1021  GAGCCGAAAA ACGCCCTGAC CAAGCAGTAT CAGGCGCTGT TTAATCTGGA AGGCGTGGAT 1081  CTGGAATTCC GTGACGAGGC GCTGGATGCT ATCGCTAAGA AAGCGATGGC GCGTAAAACC 1141  GGTGCCCGTG GCCTGCGTTC CATCGTAGAA GCCGCACTGC TCGATACCAT GTACGATCTG 1201  CCGTCCATGG AAGACGTCGA AAAAGTGGTT ATCGACGAGT CGGTAATTGA TGGTCAAAGC 1261  AAACCGTTGC TGATTTATGG CAAGCCGGAA GCGCAACAGG CATCTGGTGA ATAAGGATCC 1321  CATCACCA  Protein sequence: 
     MGSSHHHHHH SSGLVPRGSH MTDKRKDGSG KLLYCSFCGK SQHEVRKLIA GPSVYICDEC      VDLCNDIIRE EIKEVAPHRE RSALPTPHEI RNHLDDYVIG QEQAKKVLAV AVYNHYKRLR      NGDTSNGVEL GKSNILLIGP TGSGKTLLAE TLARLLDVPF TMADATTLTE AGYVGEDVEN      IIQKLLQKCD YDVQKAQRGI VYIDEIDKIS RKSDNPSITR DVSGEGVQQA LLKLIEGTVA      AVPPQGGAAA PQQEFLQVDT SKILFICGGA FAGLDKVISH RVETGSGIGF GATVKAKSDK      ASEGELLAQV EPEDLIKFGL IPEFIGRLPV VATLNELSEE ALIQILKEPK NALTKQYQAL      FNLEGVDLEF RDEALDAIAK KAMARKTGAR GLRSIVEAAL LDTMYDLPSM EDVEKVVIDE      SVIDGQSKPL LIYGKPEAQQ ASGE  
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Figure 7.2: Plasmid map of pET23ClpXΔRKH-TC 
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7.1.2 ClpP 
7.1.2.1 Protein: ClpP 
Brief Description: Pseudo wild-type ClpP with C-terminal His tag 
Plasmid: pET23ClpP 
Antibiotic resistance encoded in plasmid: Ampicillin  
Number of amino acids: 202 
Protein Mass: 22760.1 Da 
Calculated extinction coefficient: 9065 M.cm-1 
DNA sequence: 
       1  ATATGGCGCT GGTGCCGATG GTCATTGAAC AGACCTCACG CGGTGAGCGC TCTTTTGATA       61  TCTATTCTCG TCTACTTAAG GAACGCGTCA TTTTTCTGAC TGGCCAGGTT GAAGACCACA      121  TGGCTAACCT GATTGTGGCG CAGATGCTGT TCCTGGAAGC GGAAAACCCA GAAAAAGATA      181  TCTATCTGTA CATTAACTCC CCAGGCGGGG TGATCACTGC CGGGATGTCT ATCTATGACA      241  CCATGCAGTT TATCAAGCCT GATGTCAGCA CCATCTGTAT GGGCCAGGCG GCCTCGATGG      301  GCGCTTTCTT GCTGACCGCA GGGGCAAAAG GTAAACGTTT TTGCCTGCCG AATTCGCGCG      361  TGATGATTCA CCAACCGTTG GGCGGCTACC AGGGCCAGGC GACCGATATC GAAATTCATG      421  CCCGTGAAAT TCTGAAAGTT AAAGGGCGCA TGAATGAACT TATGGCGCTT CATACGGGTC      481  AATCATTAGA ACAGATTGAA CGTGATACCG AGCGCGATCG CTTCCTTTCC GCCCCTGAAG      541  CGGTGGAATA CGGTCTGGTC GATTCGATTC TGACCCATCG TAATTCGCGA CACCATCACC      601  ATCACCATTA ACTCGAG  
Protein sequence: 
     MALVPMVIEQ TSRGERSFDI YSRLLKERVI FLTGQVEDHM ANLIVAQMLF LEAENPEKDI      YLYINSPGGV ITAGMSIYDT MQFIKPDVST ICMGQAASMG AFLLTAGAKG KRFCLPNSRV      MIHQPLGGYQ GQATDIEIHA REILKVKGRM NELMALHTGQ SLEQIERDTE RDRFLSAPEA      VEYGLVDSIL THRNSRHHHH HH  
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7.1.3 Substrates 
7.1.3.1 Protein: Im9-ssrA 
Brief Description: E. coli immunity protein Im9 with N-terminal His-tag and 
C-terminal ssrA tag.  
Number of amino acids: 107 
Protein Mass: 12012.1 Da 
Calculated extinction coefficient: 11460 M.cm-1 
Protein sequence: 
     MEHHHHHHME LKHSISDYTE AEFLQLVTTI CNADTSSEEE LVKLVTHFEE MTEHPSGSDL      IYYPKEGDDD SPSGIVNTVK QWRAANGKSG FKQGLEAAND ENYALAA 
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7.1.3.2 Protein: λO-Arc-His6 
Brief Description: E. coli 
Plasmid:pET23λOArc-His6 
Antibiotic resistance encoded in plasmid: Ampicillin 
Number of amino acids: 73 
Protein Mass: 8555.8 Da 
Calculated extinction coefficient: 6990 M.cm-1 
DNA sequence: 
       1  ATGACCAACA CCGCGAAAAT TCTGAACTTT GGCCGCGCGA GCATGAAAGG CATGAGCAAA       61  ATGCCGCAGT TTAACCTGCG CTGGCCGCGC GAAGTGCTGG ATCTGGTGCG CAAAGTGGCG      121  GAAGAAAACG GCCGCAGCGT GAACAGCGAA ATTTATCAGC GCGTGATGGA AAGCTTTAAA      181  AAAGAAGGCC GCATTGGCGC GCATCATCAT CATCATCAT Protein sequence: 
 MTNTAKILNF GRASMKGMSK MPQFNLRWPR EVLDLVRKVA EENGRSVNSE IYQRVMESFK  KEGRIGAHHH HHH 
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Figure 7.3: Plasmid map of pET23λOARC-His6. 
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7.1.3.3 Protein: λO-(T 1-16)-TEV-E9 
Brief Description: E. coli E9 colicin with N-terminal λO-tag and residues 1-16 
of the translocation domain located upstream of a Tobacco etch virus (TEV) 
cleavage site.  
Plasmid: pET23λO(T1-16)TEVE9 
Antibiotic resistance encoded in plasmid: Ampicillin 
Number of amino acids: 170 
Protein Mass: 18882.1 Da 
Calculated extinction coefficient: 1690 M.cm-1 
DNA sequence: 
       1  ATATGACCAA TACCGCGAAA ATTCTGAATT TTGGCCGCAT GAGCGGTGGA GATGGACGCG       61  GCCATAACAC GGGCGCGCAT AGCACAGAAA ACCTGTATTT CCAGGGCGCC ATGGAGAGTA      121  AACGGAATAA GCCAGGGAAG GCGACAGGTA AAGGTAAACC AGTTGGTGAT AAATGGCTGG      181  ATGATGCAGG TAAAGATTCA GGAGCGCCAA TTCCAGATCG CATTGCTGAT AAGTTGCGTG      241  ATAAAGAATT TAAAAGCTTC GACGATTTTC GGAAGGCTGT ATGGGAAGAG GTGTCGAAAG      301  ATCCTGAGCT TAGTAAAAAT TTAAACCCAA GCAATAAGTC TAGTGTTTCA AAAGGTTATT      361  CTCCGTTTAC TCCAAAGAAT CAACAGGTCG GAGGGAGAAA AGTCTATGAA CTTCATCATG      421  ACAAGCCAAT TAGTCAAGGT GGTGAGGTTT ATGACATGGA TAATATCCGA GTGACTACAC      481  CTAAGCGACA TATCGATATT CACCGAGGTA AGTAAAATGG AACTGAAGCA TAGCATTAGT      541  GATTATACAG AAGCTGAATT TTTACAGCTT GTAACAACAA TTTGTAATGC GGACACTTCC      601  AGTGAAGAAG AACTGGTTAA ATTGGTTACA CACTTTGAGG AAATGACTGA GCACCCTAGT      661  GGTAGTGATT TAATATATTA CCCAAAAGAA GGTGATGATG ACTCACCTTC AGGTATTGTA      721  AACACAGTAA AACAATGGCG AGCCGCTAAC GGTAAGTCAG GATTTAAACA GGGCCTCGAG      781  CACCACCACC ACCACCACTG Protein sequence: 
     MTNTAKILNF GRMSGGDGRG HNTGAHSTEN LYFQGAMESK RNKPGKATGK GKPVGDKWLD      DAGKDSGAPI PDRIADKLRD KEFKSFDDFR KAVWEEVSKD PELSKNLNPS NKSSVSKGYS      PFTPKNQQVG GRKVYELHHD KPISQGGEVY DMDNIRVTTP KRHIDIHRGK This is co-expressed with Im9 from the same plasmid: 
     MELKHSISDY TEAEFLQLVT TICNADTSSE EELVKLVTHF EEMTEHPSGS DLIYYPKEGD      DDSPSGIVNT VKQWRAANGK SGFKQGLEHH HHHH  
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Figure 7.4: Plasmid map of pET23λO-(T1-16)-E9. 
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7.1.3.4 Protein: (I27)3-ssrA 
Brief description: Titin I27 concatamer for use in AFM and ClpXP degradation 
experiments. With an N-terminal hexahistidine sequence and a C-terminal 
ssrA tag.  
cleavage site.  
Plasmid: pET23His6-I27-ssrA 
Antibiotic resistance encoded in plasmid: Ampicillin 
Number of amino acids: 293 
Protein Mass: 31960.3 Da 
Calculated extinction coefficient: 22460 M.cm-1 
DNA sequence: 
      1  ATGCTAATAG AAGTGGAAAA GCCTCTGTAC GGAGTAGAGG TGTTTGTTGG TGAAACAGCC       61  CACTTTGAAA TTGAACTTTC TGAACCTGAT GTTCACGGCC AGTGGAAGCT GAAAGGACAG      121  CCTTTGACAG CTTCCCCTGA CTCTGAAATC ATTGAGGATG GAAAGAAGCA TATTCTGATC      181  CTTCATAACT CTCAGCTGGG TATGACAGGA GAGGTTTCCT TCCAGGCTGC TAATGCCAAA      241  TCTGCAGCCA ATCTGAAAGT GAAAGAACTA GTAGAGGCTC GACTAATAGA AGTGGAAAAG      301  CCTCTGTACG GAGTAGAGGT GTTTGTTGGT GAAACAGCCC ACTTTGAAAT TGAACTTTCT      361  GAACCTGATG TTCACGGCCA GTGGAAGCTG AAAGGACAGC CTTTGACAGC TTCCCCTGAC      421  TCTGAAATCA TTGAGGATGG AAAGAAGCAT ATTCTGATCC TTCATAACTC TCAGCTGGGT      481  ATGACAGGAG AGGTTTCCTT CCAGGCTGCT AATGCCAAAT CTGCAGCCAA TCTGAAAGTG      541  AAAGAATTGC TTATCGAAGC GCGCCTAATA GAAGTGGAAA AGCCTCTGTA CGGAGTAGAG      601  GTGTTTGTTG GTGAAACAGC CCACTTTGAA ATTGAACTTT CTGAACCTGA TGTTCACGGC      661  CAGTGGAAGC TGAAAGGACA GCCTTTGACA GCTTCCCCTG ACTCTGAAAT CATTGAGGAT      721  GGAAAGAAGC ATATTCTGAT CCTTCATAAC TCTCAGCTGG GTATGACAGG AGAGGTTTCC      781  TTCCAGGCTG CTAATGCCAA ATCTGCAGCC AATCTGAAAG TGAAAGAATT GCTGTGTGGA      841  GCTCAGGCGG CTAACGACGA AAACTACGCG CTGGCGGCTT AA  Protein sequence: 
     MLIEVEKPLY GVEVFVGETA HFEIELSEPD VHGQWKLKGQ PLTASPDSEI IEDGKKHILI      LHNSQLGMTG EVSFQAANAK SAANLKVKEL VEARLIEVEK PLYGVEVFVG ETAHFEIELS      EPDVHGQWKL KGQPLTASPD SEIIEDGKKH ILILHNSQLG MTGEVSFQAA NAKSAANLKV      KELLIEARLI EVEKPLYGVE VFVGETAHFE IELSEPDVHG QWKLKGQPLT ASPDSEIIED      GKKHILILHN SQLGMTGEVS FQAANAKSAA NLKVKELLCG AQAANDENYA LAA  
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Figure 7.5: Plasmid map of pET23His6-I27-ssrA. 
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7.1.3.5 Protein: I27-Q30-(I27)2-ssrA 
Brief description: Titin I27 concatamer for use in AFM and ClpXP degradation 
experiments with a Q30 section inserted between the second and third I27 
domain. With an N-terminal hexahistidine sequence and a C-terminal ssrA tag.  
cleavage site.  
Plasmid: pET23His6-Q30-ssrA 
Antibiotic resistance encoded in plasmid: Ampicillin 
Number of amino acids: 326 
Protein Mass: 36145.7 Da 
Calculated extinction coefficient: 22460  M.cm-1 
DNA sequence: 
       1  ATGCTAATAG AAGTGGAAAA GCCTCTGTAC GGAGTAGAGG TGTTTGTTGG TGAAACAGCC       61  CACTTTGAAA TTGAACTTTC TGAACCTGAT GTTCACGGCC AGTGGAAGCT GAAAGGACAG      121  CCTTTGACAG CTTCCCCTGA CTCTGAAATC ATTGAGGATG GAAAGAAGCA TATTCTGATC      181  CTTCATAACT CTCAGCTGGG TATGACAGGA GAGGTTTCCT TCCAGGCTGC TAATGCCAAA      241  TCTGCAGCCA ATCTGAAAGT GAAAGAACTA GTAGAACAGC AACAGCAACA ACAGCAACAG      301  CAACAACAGC AACAGCAACA ACAGCAACAG CAACAACAGC AACAGCAACA ACAGCAACAG      361  CAACAACTAG TAGAGGCTCG ACTAATAGAA GTGGAAAAGC CTCTGTACGG AGTAGAGGTG      421  TTTGTTGGTG AAACAGCCCA CTTTGAAATT GAACTTTCTG AACCTGATGT TCACGGCCAG      481  TGGAAGCTGA AAGGACAGCC TTTGACAGCT TCCCCTGACT CTGAAATCAT TGAGGATGGA      541  AAGAAGCATA TTCTGATCCT TCATAACTCT CAGCTGGGTA TGACAGGAGA GGTTTCCTTC      601  CAGGCTGCTA ATGCCAAATC TGCAGCCAAT CTGAAAGTGA AAGAATTGCT TATCGAAGCG      661  CGCCTAATAG AAGTGGAAAA GCCTCTGTAC GGAGTAGAGG TGTTTGTTGG TGAAACAGCC      721  CACTTTGAAA TTGAACTTTC TGAACCTGAT GTTCACGGCC AGTGGAAGCT GAAAGGACAG      781  CCTTTGACAG CTTCCCCTGA CTCTGAAATC ATTGAGGATG GAAAGAAGCA TATTCTGATC      841  CTTCATAACT CTCAGCTGGG TATGACAGGA GAGGTTTCCT TCCAGGCTGC TAATGCCAAA      901  TCTGCAGCCA ATCTGAAAGT GAAAGAATTG CTGTGTGGAG CTCAGGCGGC TAACGACGAA      961  AACTACGCGC TGGCGGCTTA A  Protein sequence: 
     MLIEVEKPLY GVEVFVGETA HFEIELSEPD VHGQWKLKGQ PLTASPDSEI IEDGKKHILI      LHNSQLGMTG EVSFQAANAK SAANLKVKEL VEQQQQQQQQ QQQQQQQQQQ QQQQQQQQQQ      QQLVEARLIE VEKPLYGVEV FVGETAHFEI ELSEPDVHGQ WKLKGQPLTA SPDSEIIEDG      KKHILILHNS QLGMTGEVSF QAANAKSAAN LKVKELLIEA RLIEVEKPLY GVEVFVGETA      HFEIELSEPD VHGQWKLKGQ PLTASPDSEI IEDGKKHILI LHNSQLGMTG EVSFQAANAK      SAANLKVKEL LCGAQAANDE NYALAA  
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Figure 7.6: Plasmid map of pET23His6-Q30-ssrA. 
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 PCR and Quikchange Primers 
Table 7.1: List of mutagenic PCR primers used in the creation of the I27 concatamer and their 
purpose. 
Primer Sequence Purpose 
5’ ATCCTATGCCATATGCTAATAGAAGTGGAAA
AGCCTCT 3’ 
 
Add NdeI restriction site to 
I27 cassette 2 5’ end to 
produce cassette 1 
5’ ATCGTAGCAGAGCTCGCGCGCACTAGTTCTTTCACTTT
CAGATTGGCTGC 3’ 
  
Add MCS (SpeI, BssHII and 
SacI) to 3’ end of cassette 
2 to produce cassette 1 
5’ GCTACTCATGGCGCGCCTAATAGAAGTGGAAAAGCCTC
T 3’ 
 
Add BssHII restriction site to 
5’ end of cassette 2 to 
produce cassette 3 
5’ TGATGCTAGTGAGCTCCACACAGCAATTCTTTCACTTT
CAGATTGGC 3’ 
 
Add SacI to 3’ end of cassette 
2 to produce cassette 3 
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Table 7.2: List of mutagenic PCR primers used in the addition of λO-tag to (T1-16)-TEV-E9 
 
Primer sequence Purpose 
5’-
ATCGCATCACATATGACCAATACCGCGAA
AATTCTGAATTTTGGCCGCATGAGCGGTG
GAGATGGACG-3’ 
 
Forward primer to add λO-tag to 
(T1-16)-TEV-E9 
5’-CCGGATCTCAGTGGTGGTGG-3’  Reverse primer to  add λO-tag to (T1-16)-TEV-E9 
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7.2.1 Elongators and Terminators for PolyQ production 
Table 7.3: Oligomer sequences for polyQ elongators and terminators. Restriction sites are underlined and complementary overhangs are highlighted in red.  
Oligomer Sequence Purpose 
5’-TCAATCAACTAGTAG-3’ 
 
5’ terminator coding strand, with 
SpeI restriction site 
5’-TTCTACTAGTTGATTGA-3’ 
 
5’ terminator non-coding strand, 
with SpeI restriction site 
5’-AACTAGTTAGGTAAGTT-3’ 
 
3’ terminator coding strand, with 
SpeI restriction site 
5’-AACTTACCTAACTAG-3’ 3’ terminator non-coding strand, 
with SpeI restriction site 
5’-AACAGCAACAGCAAC-3’ Elongator coding strand 
5’-TTGTTGCTGTTGCTG-3’ Elongator non-coding strand 
 
